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tetradeceneyloxy)-1-propanaminium bromide 
GAU Glutamic acid unit 
GFP Green fluorescent protein 
GL67A-DOPE 1,2-Dimyristoyl-sn-glycero-3-phosphoetanolamine 
Glu Glutamic acid 
GO Glycolate oxidase 
Hb Haemoglobin 
HEPES 4-(2-Hydroxyethyl)-1-piperazineethane-sulfonic 
acid  
HGH Human growth hormone 
Hist Histidine  
HIV-1 Human immunodeficiency virus type 1 
HMW High molecular weight 
HMWC HMW conjugates 
HOBt 1-Hydroxybenzotriazole 
HPLC High performance liquid chromatography 
HPMA N-(2-Hydroxypropyl)methacrylamide 
hrGCSF Human recombinant granulocyte-colony stimulating 
factor 
HSV Herpes virus protein 
I Observed intensity 
I(Q) Scattering intensity 
I0 Reference intensity 
IFM Immunofluorescence microscopy 
IM Intramuscular 
IR Infrared spectroscopy 
ITC Isothermal titration calorimetry 
IV Intravenous 
k Wave vector of the incident radiation 
k’ Wave vector of the scattered radiation 
kDa Kilodalton 
LDL Low-density lipoprotein 
LMW Low molecular weight 
LNP Lipid-based nanoparticle 
LPEI Linear PEI 
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MDR Multidrug resistance 
MeOD Deuterated methanol 
MeOH Methanol 
Met Methionine 
Mn Number average MW 
mol% Mol percent 
Morph Morpholine 
mRNA Messenger RNA 
MTBE Tert-butyl methyl ether 
MTS 3- (4,5-dimethylthiazol-2-yl)-5- (3-
carboxymethoxyphenyl)-2- (4- sulfophenyl)-2H-
tetrazolium 
MW Molecular weight 
MWCO Molecular weight cut-off 
n.s. Non-significant 
N/P ratio Nitrogen to phosphate ratio 
nanoDDS Nanoscale drug delivery systems 
NCE New chemical entity 
Nf Scale (Dozier model) 
NMR Nuclear magnetic resonance 
NOESY NMR Nuclear overhauser effect spectroscopy NMR 
NSCLC Non-small cell lung cancer 
NTA Nanoparticle tracking analysis 
P(Orn) Poly-L-ornithine 
P(Q) Form factor 
P(r) Pair-distribution function 
PAGE Polyacrylamide gel electrophoresis 
PAMAM Polyamidoamine 
PArg Poly-L-arginine 
PBLG Poly-(ɣ-benzyl-L-glutamate) 
PBS Phosphate buffer saline 
PCB Polycarboxybetaine 
PD Pyridyl dithiol 
PDEPT Polymer-directed enzyme produg therapy 
PdI Polydispersity index 
pDNA Plasmid DNA 
PEG Polyethyleneglycol 
PEI Polyethylenimine 
PELT Polymer enzyme liposome therapy 
PGA Poly-L-glutamic acid 
P-gp P-glycoprotein 
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PGSE NMR Pulsed-gradient spin-echo NMR 
PH1 Primary hyperoxaluria type I 
PLK1 Polo-like kinase 1 
PLL Poly-L-lysine 
PLP pyridoxal 5’-phosphate 
PMS Phenazinemethosulfate 
pSar Polysarcosine 
PSB Polysulfobetaine 
PT Polymer Therapeutics 
PT Potentiometric titration 
PTS Peroxisomal targeting sequence 
PTS1 Type 1 PTS 
PTX Paclitaxel 
PyBOP (Benzotriazol-1-yl)oxy-tris-pyrrolidino-phosphonium 
hexafluorophosphate 
Q Scattering vector 
RAFT Reversible addition-fragmentation chain transfer 
RBC Red blood cell 
RES Reticulo-endothelial system 
Rg Radius of gyration 
Rh Hydrodynamic radius 
RISC RNA-induced silencing complex 
RLU  Relative light units  
RNAi RNA interference 
ROS Reactive oxygen species 
RRM2 Ribonucleotide reductase M2 
RS Raman spectroscopy 
RT Room temperature 
S(Q) Structure factor 
SANS Small angle neutron scattering 
SAR Structure-activity relationship 
SAS Small angle scattering 
SAXS Small angle X-ray scattering 
SC Subcutaneous 
SD Standard deviation 
SDS Sodium dodecyl sulphate 
SEC Size exclusion chromatography 
SEM Standard error mean 
Ser Serinol 
siRNA Small interfering RNA 
SLS Small angle light scattering 
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SMANCS Styrene maleic anhydride neocarzinostatin 
SNALP Stale nucleic acid-lipid particle 
SPPS Solid phase peptide synthesis 
SPR Surface plasmon resonance 
ssDNA Single stranded DNA 
SSE Sum of square errors 
STD NMR Saturation transfer difference NMR 
Stp Succinyl tetraethylene pentamine 
Stp5 Pentameric Stp 
Tat Transactivating transcriptional activator 
Tat-AGT AGT-cell-penetrating Tat-peptide fusion protein 
tBoc Tert-butoxycarbonyl 
TCEP tris(2-carboxyethyl)phosphine 
TEM Transmission electron microscopy 
TFA Trifluoroacetic acid 
Tfn Transferrin 
TIS Triisopropylsilane 
TNF Tumor necrosis factor 
TTR Transthyretin 
Tyr Tyrosine 
UV-Vis Ultraviolet-visible spectroscopy 
VEGFR Vascular endothelial growth factor receptor 
Vp Volume of a single particle 
wt% Weight percent 
x Percentage of modification 
α/Nf Relative scale of the fractal term (Dozier model) 
γ Gyromagnetic ratio 
δ Length of the gradient 
Δ Diffusion time 
Δρ Contrast term 
ζ-potential Zeta-potential 
λem Emission wavelength 
λex Excitation wavelength 
ξ Exponential damping length (Dozier model) 
ρpolymer Polymer scattering length density 
ρsolvent Solvent scattering length density  
χ Flory-Huggins interaction parameters 
ф Polymer volume fraction 
 Flory exponent (Dozier model) 
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A convenient cytosolic drug delivery constitutes a very powerful 
tool for the treatment and/or prevention of several relevant human 
diseases. Along with recent advances in therapeutic technologies based 
on biomacromolecules (e.g. oligonucleotides or proteins), we also 
require the development of technologies which improve the transport 
of therapeutic molecules to the cell of choice. This has led to the 
emergence of a variety of promising methods over the last 20 years. 
Despite significant progress, these methods still suffer from several 
shortcomings including low/variable delivery efficiency, high 
cytotoxicity, and perhaps most importantly, ineffective 
endosomal/lysosomal escape. In this context, Polymer Therapeutics 
(PT) have emerged as an exciting alternative to overcome such 
limitations. Specifically, well defined polypeptide-based therapeutics 
could be considered excellent candidates for drug delivery due to their 
suitable biodegradability, versatility, multivalence and high drug loading 
capacity. On the other hand, a comprehensive understanding of 
therapeutic molecules is also required for the rational selection and 
design of an appropriate intracellular delivery carrier.  
The application of new, robust, and sophisticated characterisation 
techniques has complemented existing techniques to meet the 
challenge of working under physiological or near-physiological 
conditions.  The remarkable development in the design of drug delivery 
systems has forced the establishment of design guidelines to achieve 
the specific therapeutic effect. The importance of an exhaustive 
physicochemical characterisation has given rise to more efficient 
therapeutic strategies via better control of the pharmacokinetics and 
biodistribution of such nanomedicines. 
On this basis, the main aim of this thesis is focused on two main 
topics: (i) the design, development, and validation of nanosized 
polypeptide-based carriers capable of facilitating the cytosolic transport 
of bioactive agents which are not able to cross biological membranes by 
themselves or exhibit low lysosomal stability, such as plasmid DNA 
(pDNA), small interfering RNA (siRNA), or proteins, and (ii) the 
exhaustive physicochemical characterisation of polymeric drug delivery 
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systems to determine their solution conformation and its correlation 
with their therapeutic output.  
In order to accomplish the above-mentioned goals and based on 
well-established properties of poly-L-glutamic acid (PGA) as a polymer 
carrier, firstly, we synthesised and evaluated different conjugates of 
PGA with succinyl tetraethylene pentamine (Stp) oligoaminoamides as 
non-viral carriers for pDNA or siRNA delivery. We hypothesised that 
these zwitterionic bioresponsive and biodegradable carriers may 
achieve similar transfection efficiencies as those achieved for analogous 
polycations, but with greater safety in biological scenarios by avoiding 
polycation-triggered side effects. After physicochemical 
characterisation of the obtained conjugates, we evaluated cytotoxicity 
in both N2a and 4T1 cell lines to assess cell viability. We also performed 
transfection and cell internalisation assays to assess conjugate 
functionality. 
We also continued exploring different alternatives within the field 
of polypeptides.  We synthesised and characterised multifunctional 
polymeric platforms based on natural or synthetic polyaminoacids, such 
as PGA, poly-L-arginine (PArg), poly-L-ornithine (P(Orn)), and their 
derivatives to find an encouraging vehicle for effective siRNA delivery as 
anticancer treatment. We obtained several oligonucleotide conjugates 
and complexes and performed preliminary in vitro studies in B16F10-
luc-G5 cell line. Upon comparing the obtained results of silencing, we 
established that P(Orn)-based systems offered the most promising 
results. 
Additionally, the feasibility of the delivery of a protein, 
alanine:glyoxylate aminotransferase (AGT), in order to promote 
enzyme-replacement therapy in a rare disease Hyperoxaluria Type I by 
conjugating the enzyme with a polyethyleneglycol (PEG)-PGA block-co-
polymer based nanocarrier was also evaluated. This conjugation 
strategy does not significantly alter the functional properties of AGT and 
endows the protein with the ability to cross the plasma membrane and 
localise in the cytosol of a cellular model of PH1. Engineering AGT by the 
insertion of a stronger peroxisomal targeting sequence (PTS) and the 
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mutation of one of the polymer anchoring points located on the 
“extended PTS1” partly decreases the conjugation efficiency. However, 
this allows peroxisomal targeting of the conjugates, resulting in the 
enhanced ability to detoxify intraperoxisomal glyoxylate with respect to 
the wild-type protein. 
We obtained all mentioned systems from polymers with very low 
polydispersity (Ɖ~1.2) and, therefore, precise and well-defined 
structures, so allowing reproducibility and the determination of a clear 
structure-activity relationship (SAR). We also exhaustively investigated 
physicochemical properties of all obtained polypeptides in terms of size 
and solution conformation. 
Finally, in order to deeply understand the importance of solution 
conformation in conjugate therapeutic output, highly advanced 
physicochemical techniques such as small angle neutron scattering 
(SANS) or small angle X-ray scattering (SAXS) were used always trying to 
mimic physiological conditions. A rigorous and detailed structural 
investigation of polymeric nanosystems already classified as successful 
drug delivery nanocarriers were performed.  
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The present thesis dissertation aims to discuss the design and 
development of nanosized polypeptide-based carriers for cytosolic 
delivery of biomacromolecules such as plasmid DNA (pDNA), small 
interfering RNA (siRNA), and proteins. Likewise, this thesis is also 
focused on the exhaustive physicochemical characterisation in solution 
of several polymer therapeutics containing similar polymeric base in 
order to elucidate structure-activity relationships between conjugate 
solution conformation and their therapeutic output. These principal 
objectives can be summarised in the following specific tasks: 
(i) Design of poly-L-glutamate (PGA)-based complexes for gene-
based therapy. Chapter II aims include the design, synthesis, 
physicochemical characterisation, and in vitro biological evaluation of 
PGA-based systems functionalised with linear synthetic 
polyamidoamines to be used as oligonucleotide intracellular delivery 
systems. 
(ii) Development of non-viral polypeptide-based carriers for 
siRNA delivery. Chapter III aims involve the development and biological 
evaluation of a versatile methodology for the modification of 
polyaminoacids, both synthetic and natural, in order to obtain 
appropriate carriers for cytosolic siRNA delivery. 
(iii) Development of PGA-based conjugates for intracellular 
protein delivery. As an example, intraperoxisomal delivery of 
engineered human alanine:glyoxylate aminotransferase (AGT). 
Chapter IV aims to the delivery of AGT to liver peroxisomes by 
conjugating the enzyme with a polyethyleneglycol (PEG)-PGA block-co-
polymer based nanocarrier. 
(iv) Use of Small Angle Neutron Scattering (SANS) and Small Angle 
X-Ray Scattering (SAXS) to study solution conformation of Polymer 
Therapeutics.  Chapter V aims to elucidate, by means of scattering 
techniques, the solution conformation of complex nanosystems in 
order to better correlate size and shape with their biological output.  
The exhaustive physicochemical characterisation of different 
nanosystems in solution through advanced techniques such as SANS or 
SAXS mimicking physiological conditions will be performed. 
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I.1. POLYMER THERAPEUTICS (PT) 
I.1.1. Introduction and Background 
Biopharmaceuticals such as proteins, peptides or nucleic acids are 
eminent candidates in the development of macromolecular drugs for 
the treatment of several diseases. They generally offer the advantage 
of biocompatibility and biodegradability since many are naturally 
produced by the human body and hence are well tolerated and 
excreted. Nevertheless, one of the most important rate-limiting steps 
of their efficiency relates to the successful delivery to the desired site of 
action and subsequent release inside the target cell [1]. Therefore, the 
development of an appropriate delivery vehicle that combines high 
specificity for the target cell, high therapeutic payload, relatively low 
toxicity, and stability during passage through the body still represents 
an important challenge. A variety of promising methods have emerged 
in the last 20 years including, for example, the use of cell-penetrating 
peptides (CPPs), liposomes, or polymers (further explained in Section 
I.2.2). Despite significant progress, these examples still present with 
several shortcomings including low/variable delivery efficiency, high 
cytotoxicity, and perhaps most importantly, ineffective 
endosomal/lysosomal escape.  
In order to further enhance the pharmacological behaviour and 
stability of these macromolecules, polymers have played an essential 
role.  
I.1.2. Definition and Classification 
The descriptor “Polymer Therapeutics”(PT), firstly introduced by 
Ruth Duncan [2], encompasses a variety of rationally designed polymer-
based constructs: polymeric drugs, polymers with inherent activity [3], 
polymer conjugates of proteins, drugs and aptamers [4-7], polymeric 
micelles containing covalently bound drug [8-10], and multicomponent 
polyplexes that are being developed as non-viral vectors [2, 11, 12] 
(Figure I.1). All of these examples are amongst the most successful first-
generation nanomedicines, with 16 products already in routine clinical 
use [13]. Furthermore, two polymer therapeutics are within the US Top 
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10 selling drugs: the polymeric drug Glatiramer acetate for the 
treatment of multiple sclerosis (Copaxone®, Teva Pharm) and the 
polymer conjugate polyethyleneglycol (PEG)-filgrastim for the 
treatment of neutropenia (Neulasta®, Amgen) [14].  These subclasses 
use specific water-soluble polymers, either as the bioactive agent itself 
or as an inert functional part of a multifaceted construct for improved 
drug, protein, or gene delivery [15]. 
 
Figure I.1. Schematic representation of Polymer Therapeutics. Redrawn from 
Duncan [11]. 
After more than two decades, development of PT has resulted in 
several products entering the market (Table I.1) and a growing number 
of as new chemical entities (NCEs) in clinical development (Table I.2). 
Through the knowledge and understanding acquired regarding 
biodistribution, clearance, mechanism of action, and stability of first 
generation PT, a second generation is now being designed with 
improved and promising features. 
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Table I.1. First generation marketed polymer therapeutics. Adapted and update from refs [16-18]. IV=intravenous, IM=intramuscular, 
SC=subcutaneous. 
Product name Technology Indication Route  Information source 
Polymer-protein conjugates 
Zinostatin stimaler® Styrene maleic anhydride 
neocarzinostatin (SMANCS) 
Cancer-hepatocellular 
carcinoma 
Local via hepatic 
artery infusion 
Yamanouchi Japan 
Oncaspar® PEG-asparaginase Cancer-acute 
lymphocytic leukaemia  
(ALL) 
IV/IM Enzon 
Peg-intron® PEG-interferon alpha 2b Hepatitis C SC Schering-Plough 
Pegasys® PEG-interferon alpha 2a Hepatitis C SC Roche 
NeulastaTM PEG-hrGCSF (human 
recombinant granulocyte-
colony stimulating factor) 
Chemotherapy-induced 
neutropenia 
SC Amgen 
Andagen® PEG-adenosine deaminase Severe combined 
immune deficiency 
syndrome 
IM Enzon 
Somavert® PEG-HGH (human growth 
hormone) antagonist 
Acromegalia SC Pfizer 
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Mircera® PEG-EPO (epoetin beta) Treatment of anaemia 
associated with chronic 
kidney disease 
IV/SC Roche 
Cimzia® 
(certolizumab pegol) 
PEG-anti-TNF Fab (tumor 
necrosis factor fragment 
antigen-binding)  
Rheumatoid arthritis, 
Crohn´s disease  
SC UCB 
KrystexxaTM 
pegloticase 
PEG-uricase  Chronic gout IV Savient 
Pharmaceuticals 
ADYNOVATE Antihemophilic 
Factor(recombinant), PEGYlated 
Hemophilia A IV Nektar and Baxalta 
Polymer-aptamer conjugate 
Macugen® PEG-aptamer (apatinib) Age-related macular 
degeneration (AMD) 
Local 
intravitreal 
OSI-Eyetech 
Polymer-drug conjugate 
MovantikTM/Movent
ig® (NKTR-118) 
PEG-naxolol Opioid-induced 
constipation 
Oral AstraZeneca/Daiichi 
Sankyo Co, Ltd. 
Polymeric drugs 
Copaxone® Glutamic acid (Glu), Alanine 
(Ala), Tyrosine (Tyr) copolymer 
Multiple sclerosis SC Teva 
Renagel® Phosphate binding polymer End stage renal failure Oral Genzyme (Daiichi Co, 
LTD. Licensed) 
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Welchol® Cholesterol binding polymer Type 2 diabetes Oral Genzyme 
 
Table I.2. Examples of polymer therapeutics in clinical development. Adapted and updated form refs [16-18]. IV=intravenous. 
Product name Technology Indication Route Stage Information source 
Polymer-protein conjugates 
ADI-PEG 20 PEG-arginine 
deaminase 
Cancer-
hepatocellular 
carcinoma, 
melanoma 
IV Phase III Polaris Group 
Hemospan® MP40X PEG-Haemoglobin Delivery of O2 in 
post-surgery and 
trauma patients 
IV Phase III Sangart 
CDP 791 PEG anti vascular 
endothelial growth 
factor receptor 
(VEGFR)-2-Fab 
Cancer-non-small 
cell lung cancer 
(NSCLC) 
IV Phase II UCB Pharma 
 
Polymer-aptamer conjugate 
ARC1779 PEG-anti-platelet-
binding function of 
von Eillebrand Factor 
Thrombotic 
microangiopathies 
IV Phase II Archemix 
E10030 PEG-anti-platelet 
derived growth factor 
AMD Local intravitreal Phase III Ophthotech 
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(PDGF) aptamer 
combination with 
Lucentis® 
Polymeric drugs 
AMG 223 Phosphate binding 
polymer 
 
Hyperphosphatemi
a in chronic kidney 
disease (CKD) 
patients on 
haemodialysis  
Oral Phase II Amgem 
VivaGel® Lysime-based 
dendrimer 
Microbiocide Topical Phase III Starpharma 
Polymer-drug conjugates 
CT2103; Xyotax; 
OpaxioTM 
PGA-paclitaxel Ovarian, Stomach IV Phase III Cell Therapeutics Inc 
Prolindac® N-(2-
Hydroxypropyl)metha
crylamide (HPMA)-
copolymer-1,2-
diaminocyclohexane 
(DACH) platinate 
Cancer-melanoma, 
ovarian 
IV Phase III Acces Pharmaceuticals 
FCE 28068 (PK1) HPMA-copolymer-
doxorubicin (DOX) 
Breast, lung and 
colon cancer 
IV Phase II Pfizer 
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FCE 28069 (PK2) HPMA-copolymer-
DOX 
Hepatocellular 
carcinoma 
IV Phase I/II Pfizer 
PEG-SN38  Multiarm PEG-
camptothecin 
Cancer-various IV Phase 
II/III 
Enzon Inc 
CRLX101 Cyclodextrin (CD)-
PEG-Camptothecin 
Cancer-various only 
in combinations 
IV Phase II  Cerulean Pharma 
CRLX301 CD-PEG-Docetaxel Solid tumours IV Phase I Cerulean Pharma 
DEPTM Docetaxel Docetaxel Solid tumours IV Phase I Starpharma/AstraZene
ca 
CriPECTM Docetaxel Docetaxel Solid tumours IV Phase I Cristal Therapeutics 
NKTR-181 PEG-naloxone Chronic pain Oral Phase III Nektar 
NKTR-171  PEG-Na+ channel 
blocker 
Neuropathic pain Oral  Phase I Nektar 
NKTR-102 PEG-Irinotecan Advanced breast 
cancer and brain 
metastases 
IV Phase III Nektar 
XMT-1001 (Fleximer® 
based) 
Polyacetal-
camptothecin 
Cancer-various IV Phase II Mersana 
XMT-1107 Polyacetal-fumagillin Solid tumours IV Phase I Mersana/Teva 
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Polymeric Micelles 
SP1049C 
BiotransportTM 
Pluronic® based 
formulation of DOX 
Cancer-Upper GI, 
NSCLC colorectal 
IV Phase III Supratek Pharma Inc 
NK 105 (Nanocarrier 
® technology) 
Paclitaxel block 
copolymer micelle 
Breast cancer, 
Stomach cancer 
IV Phase III Nippon Kayaku Co 
 
NC-6004, 
NanoplatinTM 
Cisplatin block 
copolymer micelle 
Cancer-various  IV Phase III NanoCarrier Co./Orient 
Neuropharma 
NC-4016 
(Nanocarrier® 
technology) 
Oxaliplatin block 
copolymer micelle 
 
Solid tumours IV Phase I NanoCarrier Co 
NC-6300 (K-912) Epirubicin block 
copolymer micelle 
Solid tutors IV Phase I NanoCarrier Co/Kowa 
NanoxelTM Paclitaxel Advanced Breast 
cancer 
IV Phase I Samyang 
Biopharmaceuticals 
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As mentioned previously, the main objectives of any drug delivery 
system (DDS), and therefore of polymer therapeutics, are the release of 
the active agent at the correct location of action (targeting) and the 
maintenance of the bioactive drug concentration within a therapeutic 
window for an adequate duration (controlled drug release) [19]. The 
examples given in the previous tables demonstrate that the preferred 
administration route for intracellular delivery is via intravenous 
injection. This allows rapid bioavailability in the bloodstream when 
compared to other parenteral routes explored. Therefore, this 
enhances the benefits of intrinsic targeting mechanisms, such as the 
EPR (Enhanced Permeability and Retention) effect [20-24], and 
bypasses specific biological barriers. 
I.1.3. Passive Targeting: Enhanced Permeability and Retention 
(EPR) Effect 
Since the mid-80s, the design of nanosized therapeutic agents, 
such as polymer therapeutics, has been inspired by the EPR effect, a 
passive tumour targeting phenomenon which considerably increases 
therapeutic effect. This evolving theory, firstly described by Matsumura 
& Maeda [23], is based on the unique pathophysiological features of 
most solid tumours, such as extensive angiogenesis (hyper-
vasculature), defective vascular architecture, and impaired lymphatic 
drainage. Once a given macromolecule is in the bloodstream, it will 
extravasate more selectively at tumour tissues due to the enhanced 
permeability of the angiogenic tumour vasculature. Furthermore, the 
macromolecule will be retained and accumulate at the tumour site 
assisted by the lack of an effective lymphatic drainage (Figure I.2).  The 
EPR effect is also an important factor in inflammatory tissues, thereby 
justifying the development and use of these nanodrugs in infectious and 
inflammatory conditions [25].  
The EPR effect is ultimately driven by the circulating plasma 
concentration of the polymer therapeutic [26, 27], but it is also highly 
dependent on tumour vascularisation, which may change between 
different tumour regions as well as from patient to patient [28]. 
Typically, the peripheral area of damaged tissues is well-vascularised, 
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the core is semi-necrotic, and the central region is vascularly necrotic. 
Poor-vascularised damaged tissues are less susceptible to therapies 
based on nanosystems. Therefore, simply utilising the 
hyperpermeability of this vasculature alone may not provide equal 
treatment throughout the entire tumour [29]. Reports suggest that the 
ideal molecular size needed to take full advantage of the EPR effect is 
larger than 40 kDa [30, 31].  
There are other characteristics and limitations that have to be 
taking into account when discussing the EPR effect [21]. These include 
(i) the fact that the macromolecule may not be able to interact with 
blood components or blood vessels; (ii) the total surface charges have 
to be weakly negative to near neutral; (ii) and EPR requires systemic 
circulation times of several hours. These reasons highlight the need to 
also employ active targeting strategies to improve disease-to-normal 
tissue ratios. 
 
Figure I.2. Schematic representation of the enhanced permeability and 
retention (EPR) effect. 
The EPR effect had been thought of as a universal approach to 
direct nanoparticles to tumours, and so drug have been designed in a 
manner that exploits this effect. However, this topic has come under 
discussion in more recent times. Tumours in vivo manifest great 
diversity and some demonstrate a poor EPR effect. The effect varies 
depending on a patient's pathological and physiological characteristics 
and clinical condition. Due to the fact that cancer is highly diverse and 
heterogeneous, there will be also heterogeneity associated with the 
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EPR effect [32-34]. This heterogeneity has provoked a debate regarding 
the real value of this effect, and has led to differing opinions. Some 
studies support EPR-mediated accumulation of nanomedicines within 
tumours, while others show that the EPR effect is highly dependent on 
the tumour model and suggest that the EPR alone may not provide the 
entire solution. Dr. Maeda himself recognizes such heterogeneity and 
has developed methods to enhance the EPR effect in order to overcome 
the heterogeneity and improve drug delivery to tumours [34]. 
I.2. CYTOSOLIC DELIVERY 
 Some drugs are large hydrophilic and/or charged molecules and 
this represents a major obstacle to their intracellular delivery through 
the lipidic environment of biological membranes.  Additionally, after 
endocytosis (if it has taken place), lysosomal enzymatic degradation 
must be avoided. Therefore, a comprehensive understanding of the 
therapeutic in question is required to rationally design an appropriate 
intracellular drug delivery carrier. As a result, several strategies to 
promote the cytosolic delivery of macromolecular therapeutics have 
been developed over recent years. These strategies include the use of 
CPPs, pH sensitive and cationic liposomes, and cationic lipids and 
polymers, among others. Different strategies can be classified into 
those that exploit the biochemical aspects of the endosomal cavity to 
promote endosome-to-cytosol transfer (e.g. pH-responsive carriers or 
endosome disrupting agents) and those approaches that bypass the 
endocytic pathway by facilitating direct transport of macromolecules 
across the plasma membrane (e.g. some CPPs) [35]. Additionally, for 
more efficient/specific delivery, various targeting moieties can be 
attached to the surface of the delivery system, e.g. folate and 
transferrin (Tfn) for tumour cells [36], and polysaccharides for 
hepatoma cells [37].  
I.2.1. Pathways for Intracellular Drug Delivery 
All eukaryotic cells exhibit one or more forms of endocytosis. 
Endocytosis encompasses multiple mechanisms by which the 
internalisation of the plasma membrane takes place with the 
simultaneous dipping of extracellular molecules or fluid into small 
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membrane-bounded vesicles effectively reducing the extracellular 
volume that the cell must process. Traditionally, endocytosis is 
subdivided into two main types: phagocytosis (uptake of large particles 
or “cell eating”) and pinocytosis (uptake of fluid and solutes or “cell 
drinking”). The former is typically carried out by phagocytes, i.e. 
macrophages, neutrophils and dendritic cells, responsible for clearing 
large pathogens such as bacteria or yeast as well as large debris such as 
the remnants of dead cells, arterial deposits of fat, etc. [38, 39]. 
Pinocytosis is utilised by essentially all nucleated cell types and occurs 
by multiple pathways including clathrin-mediated endocytosis, 
caveolae-mediated endocytosis, clathrin and caveolae-independent 
endocytosis, and macropinocytosis. The last three pathways are 
collectively referred to as non-clathrin dependent endocytosis (Figure 
I.3) [40].  
 
Figure I.3. Multiple portals of entry into the cell. Adapted from [40]. 
Conventional small molecule drugs, such as amino acids, sugars, 
and ions, generally enter cells via transmembrane diffusive transport or 
non-specific adsorptive pinocytosis. Cellular uptake of macromolecules, 
due to their polarity and large hydrodynamic diameter, is mostly 
restricted to receptor-mediated endocytosis. When transported by 
diffusion, the drug will reach the cytoplasm of the cell, whereas all 
pinocytic processes are lysosomotropic. 
Clathrin-mediated endocytosis, an energy-dependent process, is 
the best characterised mode of cellular internalisation [41]. Clathrin-
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coated pits have been proposed as molecular “filters” and are 100-150 
nm in size. Clathrin-mediated endocytosis is used for the uptake of 
specific ligands such as transferrin (Tfn) and low-density lipoproteins 
(LDLs) [40, 42, 43]. Initial uptake of ligands into coated vesicles, 
encapsulated by a polygonal clathrin coat, is followed by fusion with 
early tubule-vesicular endosomes near the plasma membrane.  
There are also clathrin-independent mechanisms for endocytosis 
for which caveolae-mediated endocytosis has been widely investigated. 
Caveolae are small caveolin-coated invaginations of the plasma 
membrane that are rich in cholesterol and glycosphingolipids. Caveolae 
are present in many cell types and are primarily involved in transcytosis 
in blood vessels wall endothelial cells. Caveolae are smaller in size (50-
80 nm) and differ in receptor disposition from clathrin-coated vesicles 
in that they do not separate from the plasma membrane while 
unloading their cargo. This pathway is advantageous for drug delivery 
because it avoids acidic compartments (endosomal/lysosomal 
pathways) [44]. However, some of these uncoated vesicles deliver their 
contents to endosomes and lysosomes. The process has been termed 
potocytosis, being exemplified by folate, which is the best characterised 
cargo molecule undergoing potocytosis [45].  
Macropinocytosis is another type of actin-dependent endocytotic 
pathway in which irregular sized and shaped vesicles are formed. The 
macropinocytosis process can be stimulated by growth factors, such as 
epithelial growth factor (EGF). Large endocytic vesicles 
(macropinosomes, generally 0.5-2.5 µm in diameter) formed after 
stimulation have no coat and do not concentrate receptors [46] and 
represent a non-selective phenomenon for the uptake of large volumes 
of fluid. In macropinocytosis, the macropinosomes do not fuse with 
endosomes or lysosomes despite fusing with each other, although 
macromolecules internalised in macropinosomes can be delivered to 
lysosomes.  
I.2.2. Intracellular Targeted Drug Carriers 
Many nanosized drug delivery carriers are intended to deliver the 
drug to a specific intracellular compartment, such as the cytosol. The 
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time taken to internalise the therapeutic agent and deliver it to the 
cytosol, as well as the steady-state level of the nanoparticle and its 
cargo, influenced by degradation and dose, will ultimately determine 
the overall efficacy of the drug delivery system. Nanopharmaceuticals 
are able to enter cells via multiple endocytic pathways or even using 
non-endocytic pathways. Although targeting to lysosomal pathways is 
generally undesirable and actively avoided in drug delivery due to the 
possible enzymatic degradation, some DDS take advantage of this 
pathway in order to improve their efficiency. In this section, various 
examples of drug delivery carriers currently under investigation will be 
discussed together with their different internalisation mechanisms. 
I.2.2.1. Polymer Conjugates 
Increased understanding on the mechanisms of action of polymer 
conjugates is aiding the design of the next generation of conjugates and 
the optimisation of clinical protocols for their evaluation.  Rapid blood 
clearance after intravenous administration needs to be avoided to 
maintain the high plasma concentration essential for EPR-mediated 
targeting. Once accumulated in the tumour or target tissue, the 
conjugates are generally internalised into cells by endocytic 
mechanisms driven by interactions with proteins and receptors on the 
cell surface. Drug conjugation to a water-soluble polymer restricts 
cellular uptake to the endocytic pathway and, therefore, bypasses 
mechanisms of resistance such as MDR (multidrug resistance) induced 
by P-gp (P-glycoprotein) overexpression in the plasma membrane [47]. 
As previously mentioned, macromolecules are captured by 
invaginations of the cell plasma membrane forming vesicles named 
endosomes. Such vesicles undergo a complex sequence of fusion events 
directing the substances to the correct compartment. In this process, 
the endosomal compartment pH drops from the early to late endosome 
to values around 5.5. At the end of the fusion process, the formed 
lysosomes contain a battery of enzyme machinery utilised to degrade 
complex molecules such as lipids or proteins. Most polymer conjugates 
rely on the lysosomotropic drug delivery pathway, where either 
proteolytic enzymes or acidic pH triggers drug release. However, the 
hostile environment of lysosomes must be avoided if the presence of 
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hydrolytic enzymes and acidic pH drives the inactivation/degradation of 
the bioactive agent. This issue is particularly important in 
peptide/protein and nucleic acid delivery. To circumvent this problem, 
pH-responsive endosomolytic carriers are being developed to promote 
endosomal escape upon pH stimuli [48]. 
I.2.2.2. Lipoplexes/Polyplexes  
Complexes between cationic lipids (such as Lipofectin®) and 
oligonucleotides (lipoplexes) [49] and complexes between cationic 
polymers (such as polyethylenimine, PEI) [50] and oligonucleotides 
(polyplexes) are mediated by strong electrostatic interactions between 
the positively charged carrier and negatively charged nucleic acid. The 
slight net positive charge of the resulting lipoplexes and polyplexes 
facilitates their interaction with negatively charged cells, so improving 
transfection efficiency.  
Endocytosis (including receptor-mediated endocytosis) has been 
repeatedly confirmed as the main mechanism of lipoplex/polyplex 
internalisation by cells [51]. Despite endocytosis-mediated uptake, 
oligonucleotides do not accumulate in lysosomes, but instead are 
released into the cytoplasm due to the destabilisation of the endosomal 
membrane provoked by the lipid or polymeric component of the 
complexes. In particular, lipoplexes fuse with the endosomal membrane 
when they contain a fusogenic lipid such as L-dioleoyl 
phosphatidylethanolamine (DOPE) [52], which easily undergoes the 
transition from bilayer to hexagonal phase, facilitating the fusion.  
In the case of polyplexes, which cannot directly destabilise the 
endosomal membrane, the mechanism of oligonucleotide escape from 
endosomes is still not completely understood. However, the “proton 
sponge hypothesis”, first proposed by Boussif et al. [53], may explain 
oligonucleotide escape. In this hypothesis, the substantial buffering 
capacity of polycations (dependent on their pKa) raises intra-vesicle pH, 
induces chloride influx, causes vesicle swelling, and leads to membrane 
destabilisation.  
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However, the proton sponge mechanism is still debated due to 
several different aspects [54]. For example, there is a requirement for 
transporters (and channels) for ions and aquaporins for water during 
normal cellular homeostasis as neither water nor ions move readily over 
membranes of their own volition. Moreover, the osmotic pressure 
required for the rupture of endosomes has been calculated to be 
greater than that generated by internalised PEI, the gold standard [55]. 
Given that different cell types exhibit different trafficking pathways, and 
may well also exhibit different pHs, the proton-sponge effect may 
contribute differently according to the vector tested and cellular model. 
Other mechanisms to explain polycation-induced membrane 
permeabilisation include direct membrane interaction, induction of 
pore formation, and colloidal osmotic effects.  
I.2.2.3. Cell Penetrating Peptides (CPPs) 
CPPs are short peptides with the ability to transport molecules or 
colloidal drug carriers systems across the cell membrane to the cell 
interior [56].  The most extensively studied CPPs are derived from the 
human immunodeficiency virus type 1 (HIV-1) encoded Tat 
(transactivating transcriptional activator)-peptide [57, 58], HSV (herpes 
virus protein)-VP22 [59], and Antennapedia (Antp, transcription factor 
of Drosophila) [60]. These peptides are water-soluble, partly 
hydrophobic, and structurally similar in that they all contain a short 
sequence of less than 30-35 amino acids with positively charged 
arginine and/or lysine residues giving them a net positive charge at 
physiological pH. These peptides have been used for intracellular 
delivery of various cargoes with molecular weights several times greater 
than their own. The main feature of these CPPs is their ability to 
penetrate cell membranes at low micromolar concentrations in vitro 
and in vivo without using chiral receptors and without causing 
significant membrane damage. Moreover, they are efficient over a 
range of cell types and hold great potential for therapeutic application. 
The mechanism of internalisation of CPPs is not completely 
understood. Recent studies point to more than one mechanism, 
depending on the experimental conditions, but endocytosis and direct 
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penetration have been suggested as the two major uptake forms [61]. 
CPP-mediated intracellular delivery of large molecules and 
nanoparticles proceed via energy-dependent macropinocytosis, with 
subsequent enhanced escape from endosome into the cell cytoplasm. 
Individual CPPs or CPP-conjugated small molecules penetrate cells via 
electrostatic interactions and hydrogen bonding and do not seem to 
depend on energy. Direct contact between the translocating moiety and 
cell membrane or cell-membrane-interacting proteoglycans is required 
for successful intracellular delivery. 
I.2.2.4. Liposomes 
Liposomes are artificial vesicular nanosystems (50-1000 nm) 
consisting of a hydrophilic core surrounded by a lipid bilayer. Liposomes 
have been extensively investigated as potential carriers for the cytosolic 
delivery of substances such as drugs, proteins, and oligonucleotides. 
They are biologically inert and completely biocompatible, they cause 
practically no toxicity or antigenic reactions, and drugs packaged into 
liposomes are protected from the destructive action of the external 
environment. Packaged elements can be water-soluble drugs (loaded 
into their inner aqueous compartment) and sometimes even water-
insoluble drugs (loaded into the hydrophobic compartment of the 
phospholipid bilayer). Alteration of the lipid composition (sometimes 
using cationic or anionic lipids) and/or the cholesterol:lipid ratio has 
been used to modulate liposomal properties. For example, cationic 
liposomes have been used to complex DNA and oligonucleotides on 
their surface [62].  
Association of drugs with liposomes has pronounced effects on the 
pharmacokinetic profile of the drug, resulting in delayed drug 
absorption, restricted drug biodistribution, decreased volume of drug 
biodistribution, delayed drug clearance, and retarded drug metabolism. 
Non-stealth liposomes are rapidly eliminated from the blood and 
captured by the cells of the reticulo-endothelial system (RES), primarily 
in the liver and spleen, as the result of rapid opsonisation of the 
liposomes. Although liposomes can be internalised by endocytosis, 
studies suggest that delivery of entrapped anti-tumour agents is largely 
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due to diffusion of the drug from the liposomes into tumour cells. The 
use of targeted liposomes may increase the efficacy of the liposomal 
drug and decrease the loss of liposomes and their contents in the RES.  
Different formulation strategies have been developed to increase 
the ability of liposomes to mediate cytosolic delivery of therapeutics. 
These include the development of “fusogenic” and “pH-sensitive” 
liposomes. Fusogenic lipids, such as unsaturated DOPE, contain weak 
acids as head groups. These lipids, when incorporated into liposomes, 
facilitate an interaction and fusion or destabilisation of liposomes with 
the endosomal membranes, resulting in the release of the encapsulated 
therapeutic agent in the cytoplasm. pH-sensitive liposomes are stable 
at physiological pH but undergo destabilisation and acquire fusogenic 
properties under acidic conditions. Different hypothetical mechanisms 
have been proposed for the endosomal escape of pH-sensitive 
liposomes: (i) Destabilisation of pH-sensitive liposomes destabilises the 
endosomal membrane possibly through pore formation, (ii) 
destabilisation of pH-sensitive liposomes allows cargo to diffuse 
through the endosomal membrane, and (iii) liposomal membrane 
fusion with the endosomal membrane. 
I.3. PHYSICOCHEMICAL CHARACTERISATION 
Molecular weight, polydispersity, purity, identity, drug content, 
free drug content, and quantification of targeting units are some of the 
intrinsic quality characteristics of a given therapeutic agent that need to 
be controlled during the manufacturing process in order to enter clinical 
development. Many drug delivery systems fail in this purpose due to 
impractical scale-up production and manufacturing processes that do 
not meet the required criteria. Other systems have not progressed 
because of problems related to toxicity, other undesirable side effects, 
low correlation of performance from in vitro to in vivo in animal models 
to humans, or an imbalance in the safety-efficacy relationship [63-66]. 
The design of drug delivery systems is hampered both by their 
intrinsic complexity and the multiple complex interactions with the 
multiple biological environments encountered following delivery to a 
biological system [67].  
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The selection of a nanosized carrier for a given pathology must take 
into account considerations such as the route of administration, site of 
action, and therapeutic window of the bioactive species. This will 
describe the pathway taken by the therapeutic as it passes through the 
different biological barriers and physiological environments to reach 
the site of action and, therefore, will define the restrictions and rules in 
the design of the therapeutic. Therefore, there is a general agreement 
for the need of characterisation methodologies that, beyond quality 
control parameters, would allow for the identification and study of 
representative physicochemical descriptors [11]. These findings will be 
useful for structure-activity relationships which themselves will enable 
the rational design of nanomedicines towards improved biological 
performance. Altogether, such a strategy requires a deeper and more 
comprehensive approach to the study of conformation, dimensions, 
dynamics, and interactions with the biological environment to provide 
robust tools towards rational design of DDS to overcome biological 
barriers. 
I.3.1. Rational Design of Drug Delivery Systems (DDS) 
The therapeutic efficacy of conventional drugs is usually limited by 
their low bioavailability, low stability in physiological media, fast 
clearance, and unspecific or ineffective pharmacokinetic profile. In 
order to overcome these issues, the nanoscale manipulation of drugs 
can facilitate the modulation of their physicochemical properties and so 
enhance their biological output. In this regard, a multitude of strategies 
have been described, encompassing the use of various colloidal, 
polymeric, and supramolecular systems (e.g. liposomes, polymeric 
micelles, polymer conjugates, and polyplexes). These have provided a 
myriad of nano drug delivery systems (nanoDDS) with differential 
structural, compositional, responsive, and conformational properties. 
Additionally, cargos may be incorporated into these nanoDDS through 
physical entrapment (encapsulation), non-covalent interactions (e.g. 
siRNA polyplexes), or relying on responsive covalent linkages, allowing 
for the stimuli controlled release of the therapeutic agent (e.g. polymer 
conjugates). The degree of complexity can be increased if an active 
targeting strategy is required using selected targeting moieties (e.g. 
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antibody, peptide, or glyco-compounds) towards specific receptors. 
This toolbox of nanosized carriers provides scientists with multiple 
solutions towards the design of nanomedicines to treat a given 
pathology. Therefore, any accurate design must include the 
consideration of several parameters, including the pathology to treat, 
the biological target, the therapeutic strategy (chemotherapy, gene 
therapy, photodynamic therapies or their combinations, etc.), the 
associated pharmacokinetic requirements for effective therapeutic 
output, and the route of administration. 
I.3.2. Physicochemical Descriptors 
Any attempt to carry out an exhaustive physicochemical 
characterisation of a given therapeutic agent must be driven towards 
the establishment of structure-activity relationships. This fact allows 
the prior prediction of biological outputs enabling an improved rational 
design [68-70]. Given the heterogeneity and complexity in the chemical 
structural and conformational nature of nanomedicines, general 
descriptions of physicochemical parameters covering all the involved 
features would not be accurate and each nanocarrier family should be 
studied individually. The same line of reasoning applies to the 
biomedical application pursued in terms of pathology, biological target, 
site of action, route of administration, and pharmacokinetic 
requirements for an effective therapeutic outcome of the active species 
with minimal or no associated toxicity. The experimental design 
strategies for the precise characterisation of both physicochemical 
descriptors and the biological activities must be built from a step-wise 
and holistic perspective [71]. 
The choice of an appropriate drug carrier, based on the pathway 
transited through the body to reach the site of action, will significantly 
reduce the number of feedback design cycles required. This choice 
should also account for the variable environmental conditions that the 
nanosized medicine will encounter, as these conditions will affect the 
physicochemical properties of the soft nanomaterial. Indeed, 
interactions at the bio-nano interface comprise reciprocal multiple, 
complex and dynamic interactions, producing responses at the 
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biological and nanomedicinal interface, involving multiple colloidal 
forces [72]. Recorded changes to the physicochemical parameters in 
response to the environmental changes experienced along the route 
through the body and the study of interactions with biological 
macromolecules in relevant physiological conditions will allow for a 
better understanding and enhanced candidate selection towards the 
successful progression into biological in vitro and in vivo 
experimentation. 
I.3.3. Techniques to Study DDS in Biological Relevant Media 
As nanomedicine characterisation in terms of identity, molecular 
weight, composition, purity, solubility, and stability have been 
successfully achieved, DDS performance in relevant physicochemical 
environments must now be addressed. A progressive increase in media 
complexity would allow a more complete understanding of DDS 
performance based on the physicochemical descriptors extracted in 
solvated states. Characterisation in hydrated states and relevant 
physiological media is accessible through a battery of complementary 
techniques entailing a multitude of different principles. Table I.3 
summarises several of the most important techniques used in 
physicochemical characterisation of the different nanosystems, some of 
which will be explained in detail in the following chapters.
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Table I.3. Summary of the most relevant techniques used to elucidate physicochemical descriptors in physiological media. Adapted from ref 
[73].  
Technique Strengths Descriptor Measured Drawbacks 
UV-Vis 
(Ultraviolet Visible 
Spectroscopy) 
Quantitative, non-destructive, fast 
measurements, time-course studies, 
physiological conditions (aqueous, pH, ionic 
strength) 
Composition, conformation, 
non-covalent interactions 
Necessity of chromophores, 
signal overlapping 
DR  
(Differential 
Refractometry) 
Quantitative, non-destructive, fast 
measurements, time-course studies, 
physiological conditions (aqueous, pH ionic 
strength), universal 
Concentration Reference cell, not specific 
FS  
(Fluorescence 
Spectroscopy) 
Quantitative, selective, time-course studies, 
non-destructive, physiological conditions 
(aqueous, pH, ionic strength) 
 
Concentration, composition, 
Critical micellar 
concentration (CMC), 
stability 
Necessity of fluorophores, 
fluorescence quenching 
FRET  
(Fluorescence 
Resonance Energy 
Transfer) 
Quantitative, selective, low sample 
concentration, physiological conditions 
(aqueous, pH, ionic strength) 
 
Structure, binding affinities, 
stability, conformational 
change 
Insufficient spectral 
separation (false negatives), 
donor reabsorbs emission, 
high background noise 
 
FCS  Sensitive to single-entities, very small 
sample volumes, fast measurement, in vivo 
measurement 
Size (Rh), size distribution 
 
Dimerization not observable, 
high preparation time, 
requires fluorophores 
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(Fluorescence 
Correlation 
Spectroscopy) 
IR  
(Infrared Spectroscopy) 
Fast measurement, small sample volumes, 
time-course studies 
Composition, conformation, 
non-covalent interactions 
Water mask part of the 
spectra, signal overlap 
ATR-FTIR  
(Attenuated Total 
Reflection Fourier 
Transform Infrared 
Spectroscopy) 
Fat measurement, small sample volumes, 
null sample preparation, aqueous samples, 
time-course studies 
 
Composition, conformation, 
interactions 
Needs ATR correction 
software, signal overlap 
RS 
(Raman Spectroscopy)
  
Quantitative, minimal sample preparation, 
relative fast measurements, physiological 
conditions (pH, ionic strength, biological 
fluids), mapping of biological tissues 
Composition, conformation, 
interaction with biological 
environment 
Auto-fluorescence, signal 
overlap 
CD  
(Circular Dichroism) 
Quantitative, non-destructive, fast 
measurement, minimal sample preparation, 
time-course studies, physiological conditions 
(aqueous, pH ionic strength) 
Conformation, non-covalent 
interactions, binding 
affinities 
Signal overlap 
1D-NMR 
1H NMR 
19F NMR  
(Nuclear Magnetic 
Resonance) 
Non-destructive, minimal sample 
preparation, semi-quantitative, time-course 
studies, physiological conditions (aqueous, 
pH, ionic strength), highly selective, water 
Composition, binding 
affinities, interactions, 
quantification in tissues 
Relatively long measurements, 
expertise required, relatively 
large concentration required, 
signal overlapping, biological 
sample preparation 
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signals can be eliminated, biological 
samples, tissues 
NOESY NMR 
(Nuclear Overhauser 
Effect Spectroscopy 
NMR)  
Non-destructive, minimal sample 
preparation, semi-quantitative, physiological 
conditions (aqueous, pH, ionic strength), 
highly selective, water signals can be 
eliminated 
Conformation at the 
molecular level, non-
covalent interactions, 
epitope mapping, dynamics 
Very long measurements 
times, expertise required, 
relatively large concentration 
required, signal overlap 
PGSE NMR 
(Pulsed-gradient Spin-
echo NMR) 
Non-destructive, minimal sample 
preparation, semi-quantitative, complex 
mixtures, physiological conditions (aqueous, 
pH, ionic strength), highly selective, water 
signals can be eliminated, biological fluids 
Size (Rh), conformation, 
non-covalent interactions, 
co-assembling systems, fast 
screening of interacting 
components within complex 
mixtures, dynamics 
Relatively long measurement 
times, expertise required, 
relatively large concentration 
required, signal overlap 
STD NMR 
(Saturation Transfer 
Difference NMR) 
Non-destructive, minimal sample 
preparation, semi-quantitative, physiological 
conditions (aqueous, pH, ionic strength), 
highly selective, water signals can be 
eliminated 
Binding affinities, epitope 
mapping, screening of 
interacting components 
within complex mixtures, 
dynamics 
Long measurement times, 
expertise required, relatively 
large concentration required, 
signal overlap 
NMR Relaxometry Non-destructive, minimal sample 
preparation, semi-quantitative, physiological 
conditions (aqueous, pH, ionic strength), 
highly selective, water signals can be 
eliminated 
Conformation, mobility, 
flexibility (or rigidity), 
structure topology, 
dynamics 
Long measurement times, 
expertise required, relatively 
large concentration required, 
signal overlap 
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SANS 
(Small Angle Neutron 
Scattering) 
Non-destructive, minimal sample 
preparation, semi-quantitative, physiological 
conditions (aqueous, pH, ionic strength), 
possibility of contrast variation scattering 
studies 
Size, conformation, 
flexibility (or rigidity), 3D 
shape 
Long measurements, expertise 
required, relatively large 
concentration required 
SAXS 
(Small Angle X-ray 
Scattering) 
Non-destructive, minimal sample 
preparation, physiological conditions 
(aqueous, pH ionic strength) 
Size, conformation, 
flexibility (or rigidity), 3D 
shape 
Expertise required, relatively 
large concentration required, 
heavier elements mask the 
scattering from lighter 
elements 
SLS 
(Static Light Scattering) 
Non-destructive, small sample volumes, 
physiological conditions (aqueous, pH, ionic 
strength) 
Size (Rh, Rg), size 
distribution, form factor (ρ), 
molecular weight 
Requires sample preparation, 
interference (dust, 
aggregation) 
DLS 
(Dynamic Light 
Scattering) 
Non-destructive, small sample volumes, 
physiological conditions (aqueous, pH, ionic 
strength), biological fluids 
Size (Rh), size distribution Requires sample preparation, 
interference (dust, 
aggregation), can´t 
differentiate similar sized 
populations 
ITC 
(Isothermal Titration 
Calorimetry) 
 
Quantitative, aqueous samples Non-covalent interactions, 
binding affinities and 
associated thermodynamic 
data 
High preparation time, high 
precision in sample 
preparation 
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ESEM 
(Environmental 
Scanning Electron 
Microscopy) 
Non-destructive, 3D mapping, physiological 
conditions 
 
Size, size distribution, 
surface morphology, shape 
Expertise required 
Cryo-TEM 
(Cryogenic Transmission 
Electron Microscopy) 
Physiological conditions, 3D mapping Size, size distribution, 
surface morphology, shape 
 
Expertise required 
AFM 
(Atomic Force 
Microscopy) 
Non-destructive, 3D mapping, minimal 
sample preparation 
 
Size, size distribution, 
surface, morphology, shape 
Overestimation of 
measurements 
PT 
(Potentiometric 
Titration) 
Non-destructive, aqueous sample 
 
Salt ration, ionisation state, 
pKa 
Salts and pH might interfere 
the measurements 
 
ζ-potential 
(Zeta Potential) 
Non-destructive, physiological conditions 
(aqueous, pH, ionic strength) 
Surface charge, stability, 
binding affinities 
Salts and pH might interfere 
the measurements 
NTA  
(Nanoparticle Tracking 
Analysis) 
Small sample volumes, minimal sample 
preparation, physiological conditions 
(aqueous, pH, ionic strength), selective 
measurement through fluorescent labelling 
Size (Rh), size distribution, 
particle size, concentration, 
selective filtering through 
fluorescence 
Interferences (dust, 
aggregation), limited particle 
concentration range 
SPR 
(Surface Plasmon 
Resonance) 
Quantitative, small sample volumes, 
physiological conditions 
 
Interactions, binding rates Artefacts 
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The work presented in this thesis chapter was made possible by a 
collaboration between the Polymer Therapeutics lab at the Centro de 
Investigación Príncipe Felipe, in Valencia and The Pharmaceutical 
Biotechnology Department from Ludwig-Maximilians-Universität 
(LMU), in Munich in Prof Wagner’s group. A publication entitled “Design 
of Poly-L-glutamate based Complexes for pDNA delivery” in the journal 
Macromolecular Bioscience has been the result of this collaborative 
work. 
II.1. INTRODUCTION AND BACKGROUND 
Gene therapy is an experimental technique that offers a wide 
spectrum of applications including regulation, repair, and replacement 
of the genes which affect genetic disease. The ability to influence 
change at the genetic level is a promising and encouraging strategy for 
several diseases. Such diseases include cancer which can be promoted 
by complex genetic alterations and still represents an often incurable 
disease and one of the main causes of mortality in humans.  
Gene therapy is designed to introduce genetic material (nucleic 
acids) into cells to compensate for an abnormal gene or to promote the 
production of a protein required by the cell for proper function. For 
example, if a mutated gene causes a necessary protein to be faulty or 
missing, gene therapy may be able to introduce a normal copy of the 
gene to restore the function of the protein. While this concept appears 
simple, the reality is much more problematic given the difficulty of 
correctly and efficiently introducing a genetic sequence into a cell of 
choice. This strategy usually employs genetically engineered carriers, 
so-called “vectors”, to deliver the genetic material. Such vectors can be 
categorized as viral or non-viral, although, despite their high efficiency, 
viral vectors exhibit significant disadvantages. These include 
immunogenicity, limited cargo loading, high production costs, and the 
risk of promoting cancer by insertional mutagenesis. 
Over recent decades, the field of gene therapy has evolved 
tremendously with regard to both employed nucleic acid and vector 
diversity [1]. However, numerous technical barriers have limited the 
success of gene therapy in clinical trials [2].  
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Lipid-based vectors are amongst the most widely used non-viral 
gene carriers. Various liposomal formulations continue to be developed 
clinically, even though Allovectin-7, a locally administered formulation 
comprising a cationic lipid (N-[1-(2,3-dimyristyloxy)propyl]-N,N-
dimethyl-N-(2-hydroxyethyl)ammonium bromide, DMRIE), a neutral 
phospholipid (dioleoyl phosphatidylethanolamine, DOPE), and a 
plasmid DNA (pDNA), recently failed to meet its efficacy endpoints in a 
Phase III clinical trial for the treatment of advanced metastatic 
melanoma [3]. Other examples include DOTAP (dioleoyl-
trimethylammonium propane)-cholesterol, GAP-DMORIE [(±)-N-(3-
aminopropyl)-N,N-dimethyl-2,3-bis(syn-9-tetradeceneyloxy)-1-
propanaminium bromide]-DPyPE (1,2-diphytanoyl-sn-glycero-3-
phosphoethanolamine), and GL67A-DOPE (1,2-dimyristoyl-sn-glycero-
3-phosphoetanolamine)-DMPE (1,2-dimyristoyl-sn-glycero-3-
phosphoethanolamine)-PEG (polyethylene glycol) (Table II.1).  
Small interfering RNA (siRNA) species have been combined with a 
lipid-based nanoparticle (LNP) family known as stable nucleic acid-lipid 
particles (SNALP) for clinical applications [4] (Table II.2). Such 
combinations have been used in the treatment of 
hypercholesterolemia. PRO-040201 (TKM-ApoB, Tekmira 
Pharmaceuticals Corporation) and ALNPCS02 (Alnylam 
Pharmaceuticals) [4, 5] have been reported to substantially reduce 
expression of their target genes (ApoB and ALN) and subsequently of 
low-density lipoprotein (LDL) cholesterol in Phase I trials. Also, two 
separate clinical trials are currently assessing the effects of SNALP-
based siRNA delivery in patients with hepatocellular carcinoma; 
TKM080301 (Tekmira Pharmaceuticals Corporation) suppresses polo-
like kinase 1 (PLK1) and ALN-VSP02 (Alnylam Pharmaceuticals) 
simultaneously targets KIF11 and VEGF. A second generation 
SNALP:siRNA formulation called ALNTTR02 (also known as Patisiran, 
Alnylam Pharmaceuticals) aims to suppress mutant transthyretin (TTR) 
in TTR-mediated amyloidosis. This formulation features a 1,2-
dilinoleyloxy-N,N-dimethylaminopropane (DLinDMA) analogue that has 
allowed a tenfold increase in efficacy in preclinical studies [6].  
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There are also two clinical trials that feature LNP formulations 
other than SNALP. AtuPLEX (Silence Therapeutics) becomes internalised 
by mouse vascular endothelium after intravenous injection [7, 8]. The 
AtuPLEX-based formulation Atu027 is also under evaluation for the 
treatment of patients with advanced solid cancer (Table II.2) [9].  
Finally, the MD Anderson Cancer Center has also initiated a clinical 
trial for their siRNA-EphA2-DOPC (1,2-dioleoyl-sn-glycero-3-
phosphocholine) formulation in patients with advanced cancers. In this 
case, the siRNA is incorporated into neutral liposomes composed of 
DOPC (Table II.2) [10]. 
Cationic carriers [11, 12], capable of condensing large nucleic acids 
into smaller structures and masking negative DNA or RNA charges, are 
also an attractive alternative class of non-viral vectors due to their 
immense chemical diversity and their potential for functionalisation. 
The clinical potential of the PEGylated poly-L-lysine (PLL) vector has 
been investigated in the treatment of cystic fibrosis; a Phase I clinical 
trial supports the safety and tolerability of these DNA nanoparticles and 
provides some evidence for vector gene transfer [13]. Polyethylenimine 
(PEI) and its variants are also amongst the most studied polymeric 
materials for gene delivery and have been applied widely in local gene 
therapy of various cancers (Table II.1). However, cationic carriers can be 
targets of the innate immune system [14, 15]. These and numerous 
other challenges may be met by new design processes that also must 
take into account the requirement for dynamic responsiveness during 
the delivery process [16]. Thus, instead of taking a static stable form, 
polymers need to change their properties with time and position in 
order to protect the nucleic acid outside the cell, facilitate the transfer 
across the endosomal barrier triggered by acidification, and support 
intracellular release and bioavailability of the nucleic acid in the 
required cellular compartment. The sum of all these factors points to 
the implementation of an intricate design strategy [17]. 
Naturally occurring biodegradable cationic polymers such as 
chitosan derivatives [18, 19], cationic cyclodextrin polymers (CDPs) [20, 
21], or cationised collagens [22] have been also assessed as pDNA 
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carriers to solve biocompatibility issues. A CDP-siRNA formulation has 
been evaluated in several therapeutically relevant animal models of 
cancer [23, 24] and in Phase I clinical trials. A CDP-based RNA 
interference (RNAi) delivery system has also been successfully applied 
in a Phase I clinical trial (Table II.2). In this case, targeting ribonucleotide 
reductase M2 (RRM2) messenger RNA (mRNA) in patients with solid 
cancers. This trial noted a reduction in target mRNA levels and the 
presence of the specific mRNA cleavage product, supporting a RNA 
interference (RNAi) mechanism of action [25]. However, while these 
carriers do present certain advantages, it is important to be aware of 
their limitations. These include an inherent heterogeneity 
(polydispersity >1.6) which masks precise structure-activity 
relationships (SARs) [26, 27]. It is extremely important to use controlled 
polymerisation techniques to diminish the variability of these dynamic 
vehicles looking towards an efficient clinical translation.  
Numerous other polymers are currently being preclinically 
evaluated for DNA delivery to address issues of efficacy and toxicity 
associated with commonly used cationic polymers. This includes the 
evaluation of a non-ionic poloxamer (CRL1005) and cationic surfactant 
benzalkonium chloride formulation in a Phase II/III study as a genetic 
vaccine to prevent cytomegalovirus (CMV) infection in patients 
undergoing allogeneic haematopoietic stem cell transplantation (Table 
II.1). 
Several promising delivery systems have been developed through 
covalent attachment of delivery ligands to a siRNA cargo. This strategy 
yields precisely defined single-component systems that require minimal 
delivery material. The most clinically advanced conjugate platforms are 
dynamic polyconjugates (DPCs) and carbohydrate N-acetyl 
galactosamine (GalNAc) conjugates. siRNA-GalNAc conjugates under 
development by Alnylam Pharmaceuticals contain a highly modified 
siRNA stably conjugated to a multivalent targeting ligand. 
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Table II.1. Non-viral DNA vectors under clinical evaluation. Adapted from reference [28] and updated from [29]. 
Delivery System Gene Therapy Drug Sponsor Indications Phase Status 
DOTAP-
cholesterol 
DOTAP-Chol-fus 1 MD Anderson Cancer 
Center 
Non-small-cell 
lung cancer 
 I Completed 
 I/II Recruiting 
GAP-DMORIE-
DPyPE 
Tetravalent dengue 
vaccine 
US Army Medical 
Research and 
Materiel Command 
Dengue disease 
vaccine 
I Completed 
GL97A-DOPE-
DMPE-PEG 
pGM169/GL67A Imperial College 
London 
Cystic fibrosis II Completed 
PEI 
 
BC-819/PEI BioCancell Ltd. Bladder cancer II Unknown 
BC-819 BioCancell Ltd. Ovarian cancer I/II Completed 
DTA-H19 BioCancell Ltd. Pancreatic cancer I/II Completed 
SNS01-T Senesco 
Technologies, Inc. 
Multiple myeloma 
and B cell 
lymphoma 
I/II Unknown 
CYL-02 University Hospital 
Toulouse 
Pancreatic ductal 
adenocarcinoma 
I Completed 
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PEG-PEI 
cholesterol 
EGEN-001 Gynecologic 
Oncology Group 
Ovarian, tubal and 
peritoneal 
cancers 
I Unknown 
II Active, not 
recruiting 
EGEN-001-301 EGEN Inc. Colorectal 
peritoneal cancer 
I/II Terminated 
PEI-mannose-
dextrose 
DermaVir/LC002 Genetic Immunity HIV vaccine II Unknown 
Poloxamer CR 
L005-
benzakonium 
chloride 
ASP0113 Astellas Pharma Inc. CMV vaccine III Active, not 
recruiting 
II Completed 
VCL-CB01 Astellas Pharma Inc. CMV vaccine II Completed 
 
Table II.2. Non-viral siRNA vectors under clinical evaluation. Adapted from reference [28] and updated from [29]. 
Delivery System Drug Sponsor Target gene Disease Phase Status 
Naked siRNA ALN-RSV01 Alnylam 
Pharmaceuticals  
Nucleocaspid 
gene of RSV 
RSV Infections II Completed 
Chapter II 
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TD101 Pachyonychia 
Congenita Project 
KRT6A (N171 
mutation) 
Pachyonychia 
congenital 
I Completed 
AGN211745 Allergan FLT1 Age-related macular 
degeneration and 
choroidal 
neovascularisation 
II Completed 
QPI-1007 Quark 
Pharmaceuticals 
CASP2 Optic atrophy and 
non-arteritic anterior 
ischemic optic 
neuropathy 
I Completed 
Acute primary angle-
closure glaucoma 
II Completed 
ISNP Quark 
Pharmaceuticals 
TP53 Kidney injury and 
acute renal failure 
I Completed 
Delayed graft function 
and complications of 
kidney transplant 
I/II Completed 
PF-655 (PF-
04523655) 
Quark 
Pharmaceuticals 
DDIT4 Choroidal 
neovascularisation, 
diabetic retinopathy 
II Completed 
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and diabetic macular 
oedema 
Age-related macular 
degeneration 
II Completed 
Bevasiranib OPKO Health, Inc. VEGFA Diabetic macular 
oedema 
II Completed 
Macular degeneration II Completed 
SYL1001 Sylentis S.A. TRPV1 Ocular pain and dry 
eye syndrome 
I/II Completed 
SYL040012 Sylentis S.A. ADRB2 Ocular hypertension 
and open angle 
glaucoma 
II Completed 
RXI-109 RXi 
Pharmaceuticals 
CTGF Cicatrix and scar 
prevention 
I Completed 
Hypertrophic scar II Completed 
Keloid II Completed 
Lipid-based 
nanoparticles 
ALN-VSP02 Alnylam 
Pharmaceuticals 
KIF11 and 
VEGF 
Solid tumours I Completed 
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sRNA-
EphA2-DOPC 
MD Anderson 
Cancer Center 
EPHA2 Advanced cancers I Recruiting 
Atu027 Silence 
Therapeutics 
PKN3 Advanced solid 
cancers  
I/II Completed 
TKM-080301 Tekmira 
Pharmaceuticals 
Corporation 
PLK1 Cancer I/II Completed 
TKM-100201 Tekmira 
Pharmaceuticals 
Corporation 
VP24, VP35 
and Zaire 
Ebola L-
polymerase 
gene 
Ebola virus Infection I Terminated 
PRO-040201 Tekmira 
Pharmaceuticals 
Corporation 
APOB Hypercholesterolemia I Terminated 
ALN-PCS02 Alnylam 
Pharmaceuticals 
PCSK9 Hypercholesterolemia I  Completed 
ALN-TTR02 Alnylam 
Pharmaceuticals 
TTR TTR-mediated 
amyloidosis 
III Active, not 
recruiting 
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ND-L02-
s0201 
Nitto Denko 
Corporation 
SERPINH1 Fibrosis I Completed 
CDP-based 
nanoparticle 
CALAA-01 Calando 
Pharmaceuticals 
RRM2 Solid tumours I Terminated 
Dynamic Poly-
Conjugate 
ARC-520 Arrowhead 
Research 
Corporation 
Two 
conserved 
regions of HBV 
transcripts 
Hepatitis B I Completed 
II Recruiting 
siRNA-GaINAc 
conjugate 
ALN-TTRsc Alnylam 
Pharmaceuticals 
TTR TTR-mediated 
amyloidosis 
I Completed 
II Completed 
LODER polymer siG12D 
LODER 
Silenseed Ltd. KRAS Pancreatic cancer II Not yet 
recruiting 
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Synthetic peptide-based polymers represent a simpler, cost-
effective, and potentially less immunogenic classes of gene delivery 
agents as compared to viruses [30]. As stated before, PLL has been 
frequently explored due to its cationic character [31], although only a 
few studies with well-controlled systems have been published. Using 
reversible addition-fragmentation chain transfer polymerisation (RAFT-
polymerisation) Zentel and co-workers [32, 33] generated cationic PLL-
poly[2-(hydroxypropyl methacrylamide)] (p[HPMA]) block copolymers 
which display transfection activity at minimal cytotoxicity in cell models. 
Barz and colleagues synthesised a series of well-defined polypeptide-
polypeptoid block copolymers (PLL-block-polysarcosine (pSar)) by ring 
opening polymerisation for pDNA polyplex formation (renamed as 
PeptoPlexes) [34]. Polyplexes consisting of a cationic block for pDNA 
complexation and a non-ionic hydrophilic block for shielding of the 
cargo were also studied by Kataoka and co-workers [35, 36] and Martin 
et al. [37]. The hydrophilic polymer corona of these systems can 
reduce/suppress unspecific interactions with serum proteins caused by 
hydrophobic or electrostatic interactions. Thereby, circulation times are 
elongated and inadvertent effects such as coagulation or complement 
activation are reduced.  
Several studies have attempted to eliminate in vivo cytotoxicity of 
polyplexes by masking their high cationic surface charge with PEG [38] 
or proteins such as albumin or transferrin in DNA complexes [39-41]. 
However, conjugating hydrophilic PEG segments into delivery systems 
markedly reduced gene transfection efficiency as the inserted PEG 
segments reduced polyplex association with cells. As an alternative, 
shielding of positive charges of cationic polymers with polyanions has 
been extensively studied [42]. These polyanions are able to stabilise the 
complexes, minimise nonspecific interactions, and prolong in vivo 
circulation times. However, there has been little development in 
polyplex design with regard to the use of polymer conjugates containing 
both cationic and anionic domains. One of the few examples following 
a zwitterionic strategy are polycarboxybetaine (PCB) or 
polysulfobetaine (PSB), which have shown promising properties for 
gene delivery (such as appreciable transfection efficiency and relatively 
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low cytotoxicity) [43]. These encouraging characteristics are due to their 
ability to resist non-specific adsorption of proteins caused by 
electrostatically induced hydration. 
Poly-L-glutamic acid (PGA) is a negatively charged, multifunctional, 
biodegradable polymer already tested in Phase III trials [44, 45].  PGA 
can markedly improve the cytocompatibility and reduce the cytotoxicity 
of carriers in gene delivery [46] and several examples in the literature 
have explored the use of PGA as a vector for effective and safe gene 
delivery. Some of these examples studied neutral or cationic PGA 
derivatives such as poly-(ɣ-benzyl-L-glutamate) (PBLG) functionalised 
with different amines with the ability to be protonated under 
physiological conditions [46-48]. After aminolysis, PBLG can be 
converted into polyglutamine and can be used as a potential gene 
delivery vector. However, suitable aminolysis agents are vitals factor in 
preparing an efficient gene vector [49]. Further research lines have 
focused on the use of the anionic PGA chain to shield non-viral vectors 
for effective and safe gene delivery [50-52].  
The current study addresses the fundamental question of whether 
negatively charged well-defined PGA polymers functionalised with 
positively charged oligomer domains can be used as oligonucleotide 
delivery systems. Succinyl tetraethylene pentamine (Stp)-based 
oligomers were selected for PGA derivatisation [53]. The artificial oligo-
amino acid Stp has been prepared in a properly protected form as a 
building block for standard solid-phase peptide synthesis (SPPS) [54-56]. 
SPPS can be defined as a process in which a peptide attached by its 
C-terminus to an insoluble polymer is assembled by the successive 
addition of protected amino acids constituting its sequence (Figure II.1). 
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Figure II.1. General scheme of SPPS. 
 SPPS, first introduced for peptide synthesis [57] and peptidic 
nucleic acid carriers [54-56], is a widely studied method that provides 
defined monodisperse products by the control of position and structure 
of every unit in a polymer. Hartmann et al. [58-61] adopted standard 
Fmoc- (9-fluorenylmethoxycarbonyl) protective group-based SPPS to 
build up a small library of monodisperse, sequence-defined 
polyamidoamine polymers. An extension of this strategy permitted the 
generation of artificial oligo-amino acids such as Stp (Figure II.2) [53] in 
tBoc- (tert-butoxycarbonyl)/Fmoc-protected form, containing the 
diaminoethane motif (three protonatable secondary amino nitrogen 
atoms per unit), also present in the gold standard PEI [62-67].  
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Figure II.2. Schematic representation for the synthetic amino acid Stp 
(succinimidyl tetraethylene pentamine: protected (up) and deprotected 
(down) forms) and for the polycationic transfection agent linear 
polyethyleneimine (LPEI).  
Schaffert et al. [68] demonstrated that this protonatable Stp repeat 
unit is responsible for favourable transfection properties by mediating 
electrostatic binding with oligonucleotides. Furthermore, Stp provides 
the additional protonation capacity upon cell entry to endolysosomal 
compartments giving rise to the hypothesized proton sponge effect [63, 
69, 70]. This effect allows residual unprotonated nitrogens with lower 
basicity to become cationised within the endolysosomal pH range (from 
pH 7.4 to pH < 5.0) and thus may trigger vesicular escape. Other than 
osmotic pressure triggered by chloride and water influx, alternative 
mechanisms such as direct membrane destabilisation by the 
protonated polycation may also account for endosomal escape [36, 71, 
72]. 
A recently published study [73] synthesised linear sequences of the 
Stp building block in order to investigate the effect of increasing 
molecular weight (MW) of linear oligo(ethanamino) amides in 
nanosized pDNA particle formation. These Stp-based oligomers differ 
from standard linear PEI (LPEI) by an amide-bonded succinic acid linker 
every fifth ethanamino unit, which contributes favourably to 
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biocompatibility. The study revealed that only above a certain length 
threshold (more than 10 Stp units), DNA polyplex formation and gene 
transfer occurred [73]. Moreover, at an optimum length of 30 Stp units 
(8.4 kDa, 90 protonatable nitrogens), the study observed a six-fold 
higher transfection efficiency compared with LPEI (22 kDa, 500 ± 200 
protonatable nitrogens). Importantly, oligomers with 30 Stp units 
displayed a ten-fold lower level of toxicity when compared with LPEI. 
Further studies also demonstrated that a simple linear sequence of 5 
Stp units did not trigger gene transfer due to the small number of 
protonatable nitrogens present (16) compared to standard LPEI [68, 73, 
74]. The small, precise oligomer could not form stable complexes with 
nucleic acids. Importantly, as outlined in previous studies [73], the 
development of effective transfection carriers required the addition of 
additional moieties such as cysteines (stabilisation of polyplexes by 
disulphide formation between oligomers) [74, 75], tyrosine trimmers 
[76], or fatty acids (hydrophobic stabilisation of formed particles) [68, 
74, 77].  
On this basis, different conjugates of PGA with Stp 
oligoaminoamides (PGA-Stp) were synthesised and evaluated as non-
viral carriers for pDNA delivery. (i) System 1: PGA-based polymers 
modified through amide bond formation with oligoaminoamide S, 
which is a Stp-based oligomer containing 5 Stp units with a C-terminal 
tryptophan (Figure II.3). (ii) System 2: PGA-based polymers modified 
through amide bond formation with oligoaminoamide SH (bearing 
additional histidines), or SC (additional cysteine), or SHC (additional 
histidines and cysteine). (iii) System 3: PGA-based polymers modified 
with oligomer SHC via disulphide bond formation. (iv) System 4: In 
addition, pDNA polyplexes were formed with oligomer SHC and 
subsequently coated with different PGA-based structures (PGA50, 
PGA100 and PEG5000-PGA88 (DB88)). 
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Figure II.3. Schematic representation of the used defined oligomers: S, SH 
(containing histidines), SC (containing cysteine), and SHC (containing histidines 
and cysteine). 
 The first three systems are based on PGA polymers 
(homopolymers or block-copolymers) modified with a monodisperse 
Stp-based polyamidoamine (Figure II.4).  
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Figure II.4. Schematic representation of the synthetic process for Systems 1-3: 
(A) PGA-Stp5 synthesis; (B) PGA-Stp5/pDNA polyplex formation. 
System 4 differs from the previous three systems in several ways. 
Firstly, we generated a polyplex between pDNA and SHC 
polyamidoamine, and subsequently coated the positively charged pDNA 
complex with a negatively charged PGA-polymer in an attempt to 
improve the pharmacokinetics and biodistribution of SHC (Figure II.5). 
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We employed two different lengths of PGA and diblock PEG-PGA as 
coating agents.  
 
Figure II.5. Schematic representation for System 4. 
We hypothesised that the zwitterionic bioresponsive and 
biodegradable carriers designed in the current study may achieve 
similar transfection efficiencies as those achieved for analogous 
polycations, but with greater safety in biological scenarios by avoiding 
polycation-triggered side effects. 
II.2. RESULTS AND DISCUSSION 
II.2.1. Synthesis of Sequence-Defined Oligomers 
SPPS of cationic oligomers using artificial oligo-amino acids has 
been previously used to establish polymer libraries which included 
effective carriers for gene delivery [68, 74, 75]. In the current work, we 
applied Fmoc-based SPPS to generate a small library of linear 
oligo(ethanamino)amides containing 5 Stp units (25 nitrogens), 
optionally bearing histidines as protonatable buffering units [78] and 
cysteines as disulphide-forming polyplex stabilising units or disulphide-
forming PGA-based-conjugates (Table II.3, Figure II.3) [68, 77]. A C-
terminal tryptophan was also included for better analytical 
characterisation.  
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Table II.3. Sequences of oligomer structures written from the C- terminus to 
the N- and the corresponding calculated molecular weights. 
Compound Id Sequence 
Molecular 
formula 
[M-H]-a 
(Da) 
[M-H]-b 
(Da) 
S W-Stp5 C71H137N27O12 1559.1 1558.2 
SH W-(StpH)5 C74H142N28O13S 2244.4 2243.4 
SC W-Stp5-C C101H172N42O17 1662.1 1661.3 
SHC W-(StpH)5-C C104H177N43O18S 2347.4 2346.9 
a Calculated; b Determined by MALDI-TOF mass analysis. 
II.2.2. System 1: PGA Chain Modified with S via Amide Bond 
Formation 
Three different designs were considered within System 1: i) PGA 
homopolymers of different MW, as starting carriers; ii) PEG-co-PGA 
block-co-polymers, to explore both altered cell trafficking; and iii) 
histidine methyl ester (Hist) as an extra moiety conjugated to PEG-co-
PGA side-chains, aiming for an enhancement in endosomolytic capacity 
[79] and thus ensure the release of the nucleic acid into the cytosol.  
We obtained a family of defined PGA-based conjugates of different 
net charges (Table II.4) by means of DMTMM·Cl (4-(4,6-Dimethoxy-
1,3,5-triazin-2-yl)-4-methylmorpholinium chloride) coupling chemistry 
[80], keeping oligoaminoamide S content between 13 to 26 mol% as 
determined by 1H NMR (Figure II.6A) in the hope of facilitating a 
comparison between the different conjugates. At the same time, 
adequate reaction conditions (concentration, timings, etc.) were 
implemented in order to minimise possible side reactions due to the 
presence of carboxylates in the oligoaminoamides. 
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Table II.4. System 1 conjugates tested as possible non-viral vectors. 
Conjugate Polymer Id GAU 
S loading a 
(mol%) 
MW b 
(g/mol) 
Positiveb 
Charges 
Dc 
(m2/s) 
Rhc 
(nm) 
W-Stp5 S - - - 16 1.40e-11 14.35 
PGA50-S17% PS2 50 17 25073 86 ND ND 
PGA50-S20% PS3 50 20 28165 110 7.20e-12 27.86 
PGA50-S21% PS4 50 21 29196 110 ND ND 
PGA100-S14% PS5 100 14 43961 124 ND ND 
PEG5000-PGA40-S20% PPS1 40 20 27532 88 ND ND 
PEG5000-PGA40-Hist12%-S26% PPHS1 40 26 33099 131 ND ND 
PEG2000-PGA80-Hist35%-S13% PPHS2 80 13 40434 114 ND ND 
PEG2000-PGA80-Hist35%-S19% PPHS3 80 19 51953 191 ND ND 
a Determined by 1H NMR; b Estimated after 1H NMR analysis; c Diffusion coefficient (D) and hydrodynamic radius (Rh) determined 
by fitting the intensities of the arrayed DOSY NMR spectra into Stejskal-Tanner equation. GAU= glutamic acid units. ND= not 
determined. 
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Figure II.6. Example of (A) 1H NMR spectrum and (B) DOSY NMR for PS 
conjugates in D2O. 
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DMTMM·Cl is a common coupling reagent that facilitates an 
efficient one-step condensation of both small molecules and polymers 
and provides high reaction yields [81]. DMTMM·Cl is relative 
inexpensive and can be easily synthesised (Figure II.7) [82]. An easily 
isolatable white solid appears within several minutes. 
 
 
Figure II.7. DMTMM·Cl synthesis according to Kunishima et al. [82]. 
Concerning the synthesis of PGA-WStp5 conjugates, the 
mechanism of action of DMTMM·Cl consists of the formation of the 
corresponding activated ester with the release of 4-methylmorpholine 
in a first step (Figure II.8). This activated ester then reacts with the 
terminal amino group in W-Stp5 at pH 8 to favour its nucleophilic 
character.  
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Figure II.8. General scheme of PS synthesis via DMTMM·Cl activation. 
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II.2.2.1. pDNA and siRNA Binding Assay by Electrophoresis 
The ability of synthetic carriers to condense pDNA or siRNA 
represents a crucial requirement for successful gene delivery. For this 
reason, after the synthesis process, we carried out agarose gel 
electrophoresis for every polyplex obtained to evaluate the strength of 
the electrostatic interaction between the polymers and negatively 
charged pDNA (Figure II.9) as well as siRNA (Figure II.10). Free nucleic 
acid migrates in the gel due to its negative charge, whereas polyplexes 
are retained and can even remain in the loading pockets of the agarose 
gel. 
 
Figure II.9. pDNA binding ability of System 1 family determined by agarose gel 
shift assay at different charge-ratios (+/-).  
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Figure II.10. siRNA binding ability of System 1 family determined by agarose gel 
shift assay at different +/- ratios.  
These gels provide an idea of how binding strength correlates to 
the amount of polymer needed for complete oligonucleotide 
retardation. Evaluation of pDNA binding capability demonstrated that 
only homopolymers with shorter PGA chain (PS2-PS4) at high charge-
ratios (Figure II.9) possessed adequate pDNA binding properties. We 
verified this binding ability via an ethidium bromide (EtBr) exclusion 
assay (Section II.2.2.2, Figure II.11) finding that neither the PEG-PGA 
block-co-polymers (PPS1-PPHS3) nor the longer polyglutamate (PS5) 
demonstrated any pDNA condensation ability. Concerning siRNA 
(Figure II.10), no compound inhibited siRNA migration at the tested 
concentrations. Moreover, the presence of histidine moieties did not 
affect the complex formation for any of the nucleotides. 
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II.2.2.2. Ethidium Bromide (EtBr) Exclusion Assay 
In order to investigate the influence of the +/- ratio on the binding 
capability in more detail, we evaluated all the PGA-based systems 
presented in Table II.4 via EtBr exclusion assay using both pDNA and 
siRNA. LPEI was used as a positive control, displaying the fastest and the 
greatest decrease in the intercalated fluorescence and the highest 
compaction ability already at low +/- ratios. We measured the effect of 
stepwise addition of oligomer solution to pDNA or siRNA in HEPES (4-
(2-hydroxyethyl)-1-piperazineethane-sulfonic acid) containing EtBr at 
increasing +/- ratios. We set the maximal fluorescence intensity at 100% 
for the EtBr solution containing free nucleic acid, and the measured 
fluorescence decrease after each addition of oligomer aliquot. 
In the case of pDNA (Figure II.11A), the structures composed of 
homopolymers demonstrated improved pDNA condensation ability 
compared to the diblock structures with the exception of P5 polyplex, 
which presented similar behaviour to the PEG-PGA block-co-polymers. 
These results are in agreement with the gel shift assay data reported 
above. Surprisingly, when siRNA was used as oligonucleotide (Figure 
II.11B), the P5 polyplex offered better results followed by the PPH3 
polyplex.  
At this stage, the results indicated that the PGA-homopolymers 
formed more stable complexes with pDNA as compared to siRNA. 
However, the results obtained with the block-co-polymers were not 
conclusive and require further analysis. 
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Figure II.11. Nucleic acid binding ability of System 1 polymers determined by 
EtBr assay at different +/- ratios. (A) pDNA; (B) siRNA. 
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II.2.2.3. Dynamic Light Scattering (DLS) Measurements - Particle 
Size and Zeta (ζ)-Potential  
The determination of polyplex sizes and Zeta (ζ)-potential by 
dynamic light scattering (DLS) of selected homopolymers (PS2- PS4) 
indicated a particle size between 150 and 190 nm diameter. Moreover, 
small differences in the content of oligomer S resulted in significant 
differences in terms of ζ-potential, presumably caused by 
conformational changes (see PS3 vs. PS4, Table II.5). 
Table II.5. Physicochemical characterisation of System1/pDNA polyplexes. 
Conjugate  
Polymer 
pDNA 
polyplex 
Id 
Sizea 
(d. nm) 
ζ-potentiala 
(mV) 
PdIa 
PGA50-S17% PS2 polyplex 166.9 ± 7.2 1.1 ± 0.3 0.233 ± 0.011 
PGA50-S20% PS3 polyplex 151.9 ± 9.3 17.8 ± 0.8 0.287 ± 0.033 
PGA50-S21% PS4 polyplex 188.9 ± 81.7 8.3 ± 0.4 0.224 ± 0.015 
a As determined by DLS at +/- 12 in 20 mM HEPES buffer at 25˚C. Polyplexes 
were diluted 1:20 before measurement. Size values are expressed in terms of 
number. d.= diameter. PdI= polydispersity index. Variations refer to the median 
of three measurements of the sample. 
Regarding siRNA complexation, we analysed the same conjugates 
by DLS and obtained very different results, as presented in Table II.6. 
We did not identify any stable species with siRNA for PS3 and only less 
compact polyplexes with PS2 and PS4. This fact indicates weaker 
interactions than that observed for pDNA or more heterogeneous 
aggregates. 
Table II.6. Physicochemical characterisation of System1/siRNA polyplexes.  
Conjugate  
Polymer 
siRNA 
polyplex 
Id 
Sizea 
(d., nm) 
ζ-potentiala 
(mV) 
PdIa 
PGA50-S17% PS2 polyplex 357.1 ± 50.6 3.6 ± 0.2 0.529 ± 0.085 
PGA50-S21% PS4 polyplex 259.3 ± 5.6 10.1 ± 0.5 0.304 ± 0.025 
a As determined by DLS at +/- 12 in 20 mM HEPES buffer at 25˚C. Polyplexes 
were diluted 1:20 before measurement. Size values are expressed in terms of 
number. Variations refer to the median of three measurements of the sample. 
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II.2.2.4. Biological Evaluation: Gene Transfer, Gene Silencing and 
Cell Viability In Vitro 
We then examined transfection efficiency by luciferase pDNA gene 
transfer to N2a neuroblastoma cells. The presence of oligomer S in PGA 
homopolymers (Figure II.12A) had a positive impact (better efficiency 
than PEI at nitrogen to phosphate ratio (N/P) 6), except for the PS5 
polyplex which was used as negative control due to absence of pDNA 
binding ability. This clearly demonstrated that a greater S mol% 
modification correlated with improved efficiency (PS3-PS4). PGA-S17% 
(PS2) also demonstrated robust transfection results, but did not exceed 
the efficacy of PEI. However, polyplexes formed by PEG-PGA block-co-
polymers did not transfect pDNA, supporting the results obtained by 
previous assays (Figure II.12B).  
                                                                                                               
 
Figure II.12. Gene transfer in System 1 homopolymers (A) and diblocks (B) in 
N2a neuroblastoma cell line. Luciferase activity was normalised to HEPES 
(control) luciferase activity. Data expressed as mean ± SD, n≥3. Statistical 
significance between polyplexes and PEI (n.s. = p > 0.05; *p < 0.01), determined 
using one-sided ANOVA. 
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We also tested the synthesised polymers for siRNA-mediated gene 
silencing, with results confirming the data obtained by gel 
electrophoresis and EtBr assays. Neither homopolymers (Figure II.13) 
nor block-co-polymers (Figure II.14) formed stable complexes with 
siRNA. 
 
Figure II.13. Gene silencing data from PS2, PS4 and PS5 in N2a EGFPLuc cells. 
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Figure II.14. Gene silencing data from PPS1 and PPHS1-3 in N2a EGFPLuc cells. 
A possible reason for the absence of activity could be poor 
endosomolytic character of the tested polymers. In an attempt to 
surpass this limitation, we covalently conjugated INF-7, a lytic peptide 
known to promote endosomal escape [83, 84], to siRNA and complexed 
the resulting INF-7-siRNA to PS5 polymer. 
Unlike previous cases, we used the defined polycationic carrier 386 
(Figure II.15) [85] as a positive control to avoid the toxic effects arising 
from PEI use. 
 
Figure II.15. Defined polycationic carrier 386 [85] used as positive control. 
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Figure II.16. Gene silencing using PS5/INF-7-siRNA in N2a EGFPLuc cells. 
Unfortunately, the inclusion of the INF-7 residue did not provide 
any improvements to gene silencing (Figure II.16), perhaps due to the 
poor availability of the INF-7 moiety and, therefore, diminished lytic 
effect. 
It is important to note the absence of cytotoxicity in N2a cells for 
all of the studied polyplexes at any optimum +/- ratio and 
concentrations tested, as determined by the MTS assay (Figure II.17).  
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Figure II.17. Cell viability of PEI (N/P 6) and pDNA polyplexes at different +/- 
ratios developed in N2a cells, determined MTS assay 24 h post-incubation. Data 
expressed as mean ± SD, n≥4. 
II.2.3. System 2: PGA Chain Modified with Oligomers SH, SHC or 
SC, Bearing Histidine and/or Cysteine via Amide Bond Formation 
In an attempt to improve the transfection efficiency of System 1, 
we introduced N-terminal cysteine and histidines in the S 
polyamidoamine structure with the aim of increasing polyplex 
stabilisation by internal disulphide linkages [68, 77] and also improving 
endosomal protonation and escape [78]. 
By using SH, SC, and SHC polyamidoamines (Figure II.3), we 
obtained three different PGA-based (50 glutamic acid units, GAU) 
conjugates following the synthetic approach reported above (Table II.7).  
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Table II.7. System 2 conjugates tested as possible non-viral vectors. 
Conjugate 
Polymer 
Id GAU 
S loadinga 
(mol%) 
MWb 
(g/mol) 
Positive 
Chargesb 
Dc 
(m2/s) 
Rhc 
(nm) 
PGA50-SH40% PSH 50 40 62458 270 5.65e-12 35.52 
PGA50-SC30% PSC 50 30 39980 190 1.56e-11 12.84 
PGA50-SHC40% PSHC 50 40 64510 270 1.25e-11 16.05 
a Determined by 1H NMR; b Estimated after 1H NMR analysis; c Diffusion coefficient (D) and 
hydrodynamic radius (Rh) determined by fitting the intensities of the arrayed DOSY NMR spectra 
into Stejskal-Tanner equation.    
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II.2.3.1. pDNA Binding Assay by Electrophoresis 
As in the case of System 1, we evaluated the ability of synthetic 
gene carriers to condense oligonucleotides by agarose gel 
electrophoresis (Figure II.18).  
 
Figure II.18. pDNA binding ability of System 2 family determined by agarose gel 
shift assay at different +/- ratios.  
As shown in Figure II.18, all compounds formed complexes at high 
+/- ratios, but insertion of a histidine motif (PSH and PSHC) led to better 
complexation capabilities. 
II.2.3.2. Biological Evaluation: Gene Transfer and Cell Viability In 
Vitro 
In agreement with gel shift assay findings, at high +/- ratios, results 
in the N2a cell line demonstrated a positive impact of histidine motif on 
transfection efficiency (Figure II.19).  
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Figure II.19. Normalised transfection efficiency of carriers with (PSCH and PSH 
polyplexes) and without histidine (PSC polyplex) in the N2a cell line. PEI data is 
representative of two different experiments. Luciferase activity was 
normalised to HEPES (control) luciferase activity. Data expressed as mean ± SD, 
n≥3. Statistical significance between polyplexes and PEI (*p < 0.01, **p < 
0.001), determined using one-sided ANOVA. 
Although the addition of a greater number of histidine residues led 
to a slight reduction in cell viability, no compound displayed significant 
cytotoxicity even at high +/- ratios (Figure II.20). 
 
Figure II.20. Cell viability of the polyplexes developed in the N2a cell line by 
MTS assay at 24 h post-incubation and different +/- ratios. Data expressed as 
mean ± SD, n≥4. 
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We confirmed results in the 4T1 cell line with the selected highest 
+/- ratio for each compound showing similar trends as those observed 
in N2a cells regarding transfection efficiency (Figure II.21) as well as cell 
viability (Figure II.22).  
 
Figure II.21. Transfection efficiency of carriers with (PSCH and PSH polyplexes) 
and without histidine (PSC polyplex) in the 4T1 cell line. Luciferase activity was 
normalised to HEPES (control) luciferase activity. Data expressed as mean ± SD, 
n≥3. 
 
Figure II.22. Cell viability of the polyplexes in the 4T1 cell line by MTS assay at 
different +/- ratios and 24 h post-incubation. Data expressed as mean ± SD, 
n≥4. 
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Whereas the overall data supports the beneficial effect of 
additional histidine residues on the polyglutamates, the effect of 
cysteine residues was not fully conclusive (Figure II.23). 
 
Figure II.23. Comparison between System 1 and System 2 in N2a cells. 
Luciferase activity was normalised to HEPES (control) luciferase activity. Data 
expressed as mean ± SD, n≥3. 
II.2.3.3. DLS Measurements- ζ-Potential  
DLS measurements determined the ζ-potential of System 2 
polyplexes (Table II.8). As expected for a non-viral vector, we identified 
a correlation between ζ-potential and transfection efficiency, with the 
positively charged polyplexes presenting the highest activity. 
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Table II.8. Physicochemical characterisation of System 2/pDNA polyplexes. 
Conjugate  
Polymer 
Id +/- 
ζ –potentiala 
 (mV) 
PdIa 
PGA50-SH40% PSH polyplex 6 -5.2 ± 0.7 0.392 ± 0.007 
  12 -1.4 ± 0.6 0.459 ± 0.031 
  24 3.7 ± 0.5 0.544 ± 0.127 
  36 6.0 ± 0.2 0.700 ± 0.130 
  48 7.7 ±0.3 0.741 ± 0.060 
PGA50-SC30% PSC polyplex 6 -1.1 ± 0.4 0.429 ± 0.057 
  12 -0.6 ± 1.9 0.518 ± 0.090 
  24 -1.6 ± 2.6 0.488 ± 0.052 
  36 4.6 ± 0.3 0.966 ± 0.032 
  48 6.1 ± 0.2 0.675 ± 0.063 
PGA50-SHC40% PSHC polyplex 6 -1.1 ± 0.2 0.399 ± 0.023 
  12 -1.5 ± 0.3 0.416 ± 0.047 
  24 1.6 ± 0.3 0.499 ± 0.040 
  36 3.1 ± 0.2 0.645 ± 0.040 
  48 5.7 ± 0.2 0.891 ± 0.102 
a As determined by DLS in 20 mM HEPES buffer at 25˚C. Polyplexes were diluted 
1:20 before measurement. PdI= polydispersity index. Variations refer to the 
median of three measurements of the sample. 
II.2.3.4. Transmission Electron Microscopy (TEM) 
As we observed heterogeneity in size distribution, indicating the 
formation of large aggregates, we performed transmission electron 
microscopy (TEM) measurements to gain a better idea of size 
distribution. We recorded TEM images at different pDNA 
concentrations: from 10 µg/mL pDNA (equivalent to those in DLS 
measurements, i.e. polyplex formation concentration, Figure II.24A) to 
2 µg/mL pDNA (Figure II.24C) and observed a main polyplex population 
of around 30-40 nm. However, at higher concentrations large 
aggregates (> 500 nm) could also be found, demonstrating an important 
dependence of size on concentration (Figure II.24). 
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Figure II.24. TEM images of PSHC polyplex at +/- 48 measured at different 
pDNA concentrations: (A) 10 µg/mL pDNA; (B) 4 µg/mL pDNA; (C) 2 µg/mL 
pDNA. 
II.2.4. System 3: PGA-Based Conjugates Obtained via Disulphide 
Bond Formation 
System 3 was developed to attach the oligomer SHC by 
bioreducible disulphide linkage and to avoid possible side-chain 
crosslinking reactions hoping for a more controlled polymer structure. 
For this purpose, we employed a pyridyl disulphide modified PGA (PGA-
PD) as the starting material, obtained as previously reported (Figure 
II.25) [80]. 
 
Figure II.25. Modification of PGA chain with pyridyl dithiol ethylamine via 
DMTMM·Cl activation. 
 
We determined the modification degree by 1H NMR and UV-Vis 
(ultraviolet-visible spectroscopy), using the average of both results 
(Figure II.26, Table II.9). 
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Table II.9. Characteristics of obtained PGA-PD. 
Conjugate Polymer 
PD loading 
(%mol)a 
PD loading 
(%mol)b 
MW 
(g/mol)c 
PGA50-PD 22 24 9170 
a Determined by 1H NMR; b Determined by UV-Vis; c Estimated after 1H 
NMR and UV-Vis assays.  
 
Figure II.26. 1H NMR spectrum in D2O of PGA-PD. 
We conjugated SHC (Figure II.3) to PGA-PD through disulphide 
bonds yielding a new family of polyglutamates (Table II.10). 1H NMR and 
DOSY NMR in D2O verified SHC content and purity of the obtained 
conjugated polymers (Figure II.27). 
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Table II.10. System 3 conjugates tested as possible non-viral vectors. 
Conjugate Polymer Id GAU 
S loading a 
(mol%) 
MW b 
(g/mol) 
Positive 
Chargesb 
Dc 
(m2/s) 
Rhc 
(nm) 
PGA50-PCSH21% PCSH1 50 21 32849 129 ND ND 
PGA50 PCSH10% PCSH2 50 10 19565 35 ND ND 
PGA50-PCSH22% PCSH3 50 22 33983 137 1.27e-11 15.70 
a Determined by 1H NMR; b Estimated after 1H NMR analysis; c Diffusion coefficient (D) and hydrodynamic radius 
(Rh) determined by fitting the intensities of the arrayed DOSY NMR spectra into Stejskal-Tanner equation. ND= 
not determined. 
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Figure II.27. NMR spectra of PCSH3 in D2O: (A) 1H NMR; (B) DOSY NMR. 
II.2.4.1. DLS Measurements- ζ-Potential 
 To select the best candidate and the best +/- ratio, we performed 
DLS measurements, finding negative ζ-potential values for PCSH1 and 
for PCSH2 polyplexes (Table II.11) even at a high +/- ratio. However, 
PCSH3 polyplexes demonstrated a positive net charge and, therefore, 
were selected to move forward.  
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Table II.11. Physicochemical characteristics of System 3 polyplexes. 
pDNA polyplex Id +/- 
ζ-potential a  
(mV) 
PdI a 
PCSH1 polyplex 3 -24.3 ± 3.4 0.377 ± 0.074 
6 -21.3 ± 1.8 0.434 ± 0.128 
12 -25.4 ± 2.1 0.455 ± 0.032 
24 -18.6 ± 7.0 0.808 ± 0.161 
36 -8.8 ± 0.6 0.195 ± 0.012 
48 -14.5 ± 0.6 0.245 ± 0.022 
60 -10.4 ± 0.5 1.000 
PCSH2 polyplex 3 -16.8 ± 0.3 0.319 ± 0.038 
6 -17.9 ± 0.2 0.498 ± 0.064  
12 -12.4 ± 0.8 0.341 ± 0.040  
24 -14.6 ± 0.6 0.361 ± 0.057 
36 -11.4 ± 0.4 0.698 ± 0.059 
PCSH3 polyplex 3 2.0 ± 0.242 0.347 ± 0.008 
 6 1.1 ± 0.0 0.550 ± 0.109 
 12 -2.6 ± 0.104 0.440 ± 0.054 
 24 6.3 ± 0.413 0.489 ± 0.036 
 36 5.2 ± 0.265 0.796 ± 0.050 
 48 5.0 ± 0.297 0.993 ± 0.012 
a As determined by DLS in 20 mM HEPES buffer at 25˚C. Polyplexes 
were diluted 1:20 before measurement. PdI= polydispersity index. 
NA= not appropriate. Variations refer to the median of three 
measurements of the sample. 
II.2.4.2. Biological Evaluation: Gene Transfer and Cell Viability In 
Vitro 
We examined the influence of the SHC oligomer used on 
transfection efficiency by luciferase pDNA gene transfer to N2a cells, 
finding that the PCSH efficiently transferred pDNA (Figure II.28). 
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Figure II.28. Normalised transfection efficiency of SHC and PCSH polyplexes at 
low +/- and N/P ratios in the N2a cell line. PEI data is representative of two 
different experiments. Luciferase activity was normalised to HEPES (control) 
luciferase activity. Data expressed as mean ± SD, n≥3. No statistical significance 
found between polyplexes and PEI (n.s.= p > 0.05) as determined using one-
sided ANOVA. 
A recently published study by Scholz et al. [73] demonstrated that 
linear sequences of 5 Stp building block units could not form stable 
complexes with nucleic acids. The development of effective transfection 
carriers required the addition of extra moieties such as cysteines 
(stabilisation of polyplexes by disulphide formation between oligomers) 
[74, 75], tyrosine trimmers [76], or fatty acids (hydrophobic stabilisation 
of formed particles) [68, 74, 77]. In the case of SHC polyplexes, the 
addition of histidine and cysteine moieties improved gene transfer 
when compared with S polyplexes, although not to the level obtained 
for PCSH. Hence, such moieties can positively influence pDNA transfer 
at high N/P ratios without affecting cell viability.  
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Figure II.29. Normalised transfection efficiency of SHC and PCSH polyplexes at 
high +/- and N/P ratios in the N2a cell line. PEI data is representative of two 
different experiments. Luciferase activity was normalised to HEPES (control) 
luciferase activity. Data expressed as mean ± SD, n≥3. No statistical significance 
found between polyplexes and PEI (n.s.= p > 0.05) as determined using one-
sided ANOVA. 
Given the low cytotoxicity of both compounds (PCSH and SCH 
polyplexes), we tested higher +/- and N/P values to select the best ratio. 
As shown in Figure II.29, whereas transfection efficiency did not 
improve with increased SHC polyplex N/P ratio, in the case of PCSH, the 
limit was +/- 84, surpassing the efficiency of SHC at N/P 48 with no 
significant reduction in cell viability against N2a cells (Figure II.30 and 
II.31). 
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Figure II.30. Determination of cell viability for SHC and PCSH polyplexes in the 
N2a cell line. Data expressed as mean ± SD, n≥4. 
 
Figure II.31. Determination of cell viability for PCSH polymer. Data expressed 
as mean ± SD, n≥4. 
To further elucidate gene delivery efficacy, confocal fluorescence 
microscopy (24 h incubation) was used to study the successful 
transcription in the nucleus of PSCH polyplex at its optimal conditions 
(+/- 84) in N2a cells. pDNA encoding for green fluorescent protein (GFP) 
was selected in order to form the complexes. After transfection, we 
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mainly observed the GFP signal dispersed in the cytosol of N2a cells 
(Figure II.32) in a comparable manner to the results obtained with PEI. 
 
Figure II.32. Confocal microscopy images of PSCH conjugate (+/- 84) and PEI 
(positive control, N/P 5) after 24 h of transfection in N2a cell line. Green 
fluorescence corresponds to GFP and blue fluorescence to the nuclei marker 
DAPI. 
II.2.4.3. Red Blood Cell (RBC) Lysis Assay 
We performed a red blood cell (RBC) lysis assay to evaluate the lytic 
activity of both SHC and PCSH and its possible contribution to 
endosomal escape. For this purpose, we measured haemoglobin release 
at different pH values (pH 7.4, 6.5, 5.5) using a range of concentrations 
(0.1, 0.05 and 0.01 mg/mL). No significant lytic activity was observed for 
the tested compounds, consistent with their low cytotoxicity (Figure 
II.33). 
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Figure II.33. Erythrocyte leakage assay at different pH values: compounds were 
incubated with erythrocytes at different concentrations at 37°C at indicated pH 
values. Haemoglobin release was measured after 1 h. Data expressed as mean 
± SD, n≥4. 
II.2.5. System 4: PGA-Coated SHC Polyplexes 
Due to the similar behaviour of SHC and PCSH polyplexes, we 
designed an alternative system aimed at improving the activity of SHC 
by promoting complex stability. For this purpose, we coated SHC 
polyplex with several different PGA-based compounds (PGA50, PGA100 
and PEG5000-PGA88 (DB88)). Initially, we created SHC polyplexes in the 
same manner as previously described, although with shorter pDNA 
incubation time (15 min vs. 30 min). Following this step, we added the 
PGA-based coating solutions and incubated for an additional 15 min 
yielding three different families of coated systems (Table II.12). 
Table II.12. Families of studied coated systems.  
Coated System Id 
SHC polyplex coated with PGA50 P50SHC polyplex 
SHC polyplex coated with PGA100 P100SHC polyplex 
SHC polyplex coated with DB88 DB88SHC polyplex 
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II.2.5.1. pDNA Binding Assay by Electrophoresis 
 
Figure II.34. pDNA binding ability determined by agarose gel shift assay at 
different N/P ratios and different coatings.  
Figure II.34 demonstrates the different pDNA binding ability of SHC 
polyplexes compared with the coated systems. After coating with 
PGA50, the resulting system presented a negative ζ-potential (Table 
II.13), a possible reason for the more rapid migration compared with 
SHC polyplexes, even given the remaining difference between the pDNA 
control and the sample. In the case of the PGA100 and DB88 coatings, the 
retention was also different, although the DB88SHC polyplex system 
presented a positive ζ-potential at high N/P ratios. Moreover, for the 
DB88 system, the PdI value improved with a greater N/P ratio.  
II.2.5.2. DLS Measurements- Particle Size and ζ-Potential 
We performed DLS measurements at pH 7.4 (pH of complex 
formation) (Table II.13). 
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Table II.13. Physicochemical characteristics of System 4 polyplexes.  
Polyplex Id +/- 
Sizea 
(d., nm) 
ζ –potentiala 
(mV) 
PdIa 
SHC polyplex SHC polyplex 3 137.9 ± 4.0 11.3 ± 0.3 0.244 ± 0.015 
 6 93.7 ± 1.4 12.7 ± 0.5 0.271 ± 0.024 
 12 123.2 ± 4.0 13.8 ± 0.3 0.158 ± 0.008 
 24 121.0 ± 8.9 20.9 ± 0.9 0.384 ± 0.019 
SHC polyplex coated with PGA50 P50SHC polyplex 3 105.3 ± 78.9 -32.4 ± 1.6 0.473 ± 0.039 
 6 100.9 ± 13.2 -33.2 ± 1.0 0.263 ± 0.019 
 12 89.45 ± 42.45 -33.0 ± 0.5 0.327 ± 0.031 
 24 66.38 ± 21.17 -31.5 ± 0.5 0.267 ± 0.002 
SHC polyplex coated with PGA100 P100SHC polyplex 3 122.1 ± 1.3 -34.7 ± 0.8 0.217 ± 0.009 
 6 195.4 ± 5.8 -38.5 ±0.8 0.294 ±0.014 
 12 126.1 ± 20.3 -36.3 ± 1.1 0.400 ± 0.043 
 24 106.7 ± 10.4 -33.6 ± 0.3 0.223 ± 0.013 
SHC polyplex coated with DB88 DB88SHC polyplex 3 131.2 ± 7.9 -32.7 ± 0.8 0.659 ± 0.017 
 6 131.9 ± 18.7 -32.4 ±0.6 0.383 ±0.004 
 12 66.70 ± 17.74 -20.5 ± 0.2 0.357 ± 0.021 
 24 86.04 ± 3.15 -10.6 ± 0.4 0.227 ± 0.010 
 36 77.58 ± 2.58 3.23 ± 0.374 0.155 ± 0.009 
a As determined by DLS in 20 mM HEPES buffer at 25˚C. Polyplexes were diluted 1:20 before measurement. Size values are 
expressed in terms of number. Variations refer to the median of three measurements of the sample.
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II.2.5.3. Biological Evaluation: Gene Transfer and Cell Viability In 
Vitro 
We evaluated transfection efficiency in the N2a cell line using three 
coatings (PGA50, PGA100, and DB88) and the same amount as for SHC (c). 
Preliminary results (Figure II.35) demonstrated lower transfection 
activity with coated polyplexes compared to pure SHC polyplexes, but 
improved cell viability (Figure II.36).  
 
Figure II.35. Normalised gene transfer in N2a cells at different N/P ratios for 
(A) SHC, and DB88SHC polyplexes, and (B) PGA50SHC and PGA100SHC polyplexes.  
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Figure II.36. Cell viability of (A) SHC and DB88SHC polyplexes, (B) PGA50SHC and 
PGA100SHC polyplexes at different N/P ratios. Data expressed as mean ± SD, 
n≥4. 
In view of these results, we selected the DB88 coating as the best 
candidate at increasing concentrations (c, 2c and c/2) showing that the 
c/2 system presented similar behaviour to the SHC polyplexes with 
better cell viability profile. However, higher ratios did not improve the 
activity as much as anticipated (Figure II.37). 
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Figure II.37. Normalised gene transfer for DB88SHC polyplexes at different N/P 
ratios and different amount of coating agent. Luciferase activity was 
normalised to HEPES (control) luciferase activity. Data expressed as mean ± SD, 
n≥3. 
II.3. CONCLUSIONS 
Due to the polyanionic nature of DNA or RNA, typically cationic or 
neutral delivery vehicles have been used for gene delivery. As a new 
approach, this thesis chapter focused on the design, development and 
validation of non-viral polypeptide-based carriers for oligonucleotide 
delivery based on a negatively-charged PGA backbone partly derivatised 
with oligoaminoamide residues. To this end, PGA-derivatives modified 
with different pentameric succinyl tetraethylene pentamines (Stp5) 
were designed. Optionally, histidines for modulation of endosomal 
buffer capacity and cysteines for pDNA or siRNA complex stabilisation 
were included, followed by characterisation of biophysical properties 
and gene transfer efficiency in N2a neuroblastoma or 4T1 breast cancer 
cell culture. 
The first three developed systems were based on PGA polymers 
(homopolymers or block-co-polymers) modified with a monodisperse 
Stp-based oligoaminoamide. In System 1, we orthogonally modified 
PGA side-chains with oligomer S by means of amide bond formation 
using the S terminal amine (Figure II.3). In System 2, we modified PGA 
side-chains analogously with SH (additionally containing histidines to 
improve the endosomolytic effect) [78], SC (containing cysteine to 
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stabilise the pDNA complex via disulphide formation) [68, 77], or SHC 
(containing both histidines and cysteine). To generate System 3, we 
performed the conjugation via bioreducible disulphide bonds using the 
terminal cysteine of SHC. System 4 differed from the previous systems 
in several ways. Firstly, we generated a polyplex between pDNA and 
oligoaminoamide SHC, and subsequently coated the positively charged 
pDNA complex with a negatively charged PGA-polymer in an attempt to 
improve the biocompatibility of SHC. We employed two different 
lengths of PGA and diblock PEG-PGA as coating agents. 
Unfortunately, our studies suggest that the systems assessed are 
not suitable for siRNA delivery. We propose the poor stability of 
complexes as the major factor contributing to a lack of transfection 
ability. Nanoparticle formulation with siRNA presents some important 
differences to plasmid formulation. Although both self-assemble by 
electrostatic forces, plasmids are several hundred-fold larger than 
siRNA, suggesting that different kinds of polycations may be optimal. 
This again demonstrates that pDNA and siRNA differ considerably in 
their properties and suitable delivery vectors must be tailored 
individually [86]. 
 Concerning pDNA, the conjugation of Stp derivatives to the PGA 
chain through amide bond formation (System 1 and System 2) resulted 
in stable non-toxic nanosystems with the ability to efficiently transfer 
pDNA. This improved the efficiency of both PGA and Stp-based 
compounds as transfection agents, with a more pronounced effect for 
Stp derivatives bearing histidine moieties. Moreover, the complexation 
capacity depended on the content of the oligoaminoamide. 
Complexation of pDNA with System 1 or 2 polymers exceeded the 
effectiveness of PEI in gene delivery. Thus, the presence of PGA 
promoted the enhanced transfection capacity of the Stp5 family.  
In the case of System 3, SHC conjugated to PGA by disulphide bonds 
improved cell viability, even given the relatively high amount of PGA-
based polymer required. Upon coating (System 4), no significant 
improvements were observed regarding gene transfer efficiency, 
mainly as SHC itself already demonstrated a high gene transfer 
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capability. However, coating did allow for a slight enhancement in cell 
viability. We also expected that a coating strategy will provide 
advantages when compared with SHC in an in vivo settings due to the 
enhanced permeability and retention (EPR) effect and possible 
alterations to pharmacokinetics. Further experiments are ongoing to 
demonstrate this point. 
II.4. MATERIALS AND METHODS 
II.4.1. Materials 
All chemicals were reagent grade and used without further 
purification. Protected Fmoc-α-amino acids, 2-chlorotrityl chloride 
resin, N,N-dimethylformamide (DMF), N,N-diisopropylethylamine 
(DIPEA) and trifluoroacetic acid (TFA) were purchased from Iris Biotech. 
Triisopropylsilane (TIS), 1-hydroxybenzotriazole (HOBt), and 
phenazinemethosulfate (PMS) were purchased from Sigma-Aldrich. 
(Benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate 
(PyBOP®) and microreactors were obtained from MultiSynTech. HEPES 
was purchased from Biomol GmbH, agarose NEEO Ultra-Qualität from 
Carl Roth GmbH and GelRedTM from VWR. The pCMVLuc and pCMV-GFP 
pDNAs were obtained from Plasmid Factory. PGA sodium salt and PEG-
co-PGA block-co-polymers were provided from Polypeptide Therapeutic 
Solutions SL (PTS, Spain). The DMTMM·Cl coupling reagent was 
synthesised according to previous descriptions [82]. Pyridyl dithiol 
ethylamine HCl salt was synthesised essentially as described in van der 
Vlies et al. [87]. Jet-PEI was obtained from Polyplus-Transfection. 
Dulbecco’s Modified Eagle’s Medium (DMEM), RPMI, phosphate buffer 
saline (PBS), fetal bovine serum (FBS) and trypsin, were provided from 
Gibco. 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium (MTS) was supplied by Promega. 
Paraformaldehyde electron microscopy grade was purchased from 
Electron Microscopy Sciences.  All solvents were of analytical grade and 
used as received. Deuterated solvents CDCl3 and D2O were purchased 
from Deutero GmbH. Dialysis was performed by using a Float-A-Lyzer®. 
Sephadex G-10 material for size exclusion chromatography was 
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obtained from GE Healthcare. MilliQ water is defined as deionised 
water with a conductance below 0.06 µS. 
II.4.2. Cell Culture 
Mouse neuroblastoma cells (N2a) were grown in DMEM 
supplemented with 10% FBS, 4 mM stable glutamine, 100 U/mL 
penicillin, and 100 μg/mL streptomycin, at 37 °C in a humidified 
atmosphere containing 5% CO2 and 95% air. 
Murine neuroblastoma cells, stably transfected with an enhanced 
green fluorescent protein GL3 firefly luciferase fusion protein 
(N2a/eGFPLuc) [77, 85, 88], were cultured at 37 °C in DMEM with 1 g/L 
glucose, supplemented with 10% FBS, 4 mM glutamine, 100 U/mL 
penicillin, and 100 μg/mL streptomycin. For maintenance, the cells were 
detached with a trypsin-ethylenediaminetetraacetic acid (EDTA) 
solution (0.25%) and seeded at the desired concentration. 
Metastatic murine breast cancer murine (4T1) were grown in RPMI 
medium supplemented with 10% FBS at 37 °C in a humidified 
atmosphere containing 5% CO2 and 95% air. 
II.4.3. Characterisation Techniques 
II.4.3.1. Nuclear Magnetic Resonance (NMR) Spectroscopy 
1H and DOSY NMR spectra were recorded on a Bruker AC 300 or on 
a Bruker AV500 at room temperature (RT) and at a frequency of 300 
MHz and 500 MHz respectively. Pulsed field gradient NMR spectroscopy 
was used to measure translational diffusion by fitting the integrals or 
intensities of the NMR signals to the Stejskal-Tanner [89, 90] equation: 
I= I0 exp[-Dγ2g2δ2(Δ-δ ⁄ 3)] where I is the observed intensity, I0 the 
reference intensity (unattenuated signal intensity), D the diffusion 
coefficient, γ the gyromagnetic ratio of the observed nucleus, g the 
gradient strength, δ the length of the gradient, and Δ the diffusion time. 
Two-dimensional diffusion-ordered NMR spectroscopy (DOSY) was 
performed with a stimulated echo sequence using bipolar gradient 
pulses. The lengths of delays were held constant at Δ= 100 ms, and 32 
spectra of 64 scans each were acquired with the strength of the 
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diffusion gradient varying between 5% and 95%. The lengths of the 
diffusion gradient and the stimulated echo were optimised for each 
sample. Typical values were δ = 3 ms for the analysis of both oligomers 
and PGA-based conjugates. All data were processed and analysed using 
the MestreNova 6.2 software. 
II.4.3.2. Matrix-Assisted Laser Desorption/Ionization (MALDI) 
Mass Spectrometry 
A 0.8 μL matrix droplet consisting of a saturated solution of Super-
DHB (sum of 2,5-dihydroxybenzoic acid and 2-hydroxy-5-
methoxybenzoic acid) in acetonitrile / water (1 : 1) containing 
0.1 % (v/v) TFA was spotted on a MTP AnchorChip (Bruker Daltonics, 
Bremen, Germany). After the Super-DHB matrix crystallized, 0.8 µL of 
the sample solution (10 mg/mL in water) was added to the matrix spot. 
Samples were analysed using an Autoflex II mass spectrometer (Bruker 
Daltonics, Bremen, Germany). 
II.4.3.3. Dynamic Light Scattering (DLS) 
The polyplex solution was measured in a cell DTS 1070 with laser 
light scattering using a Zetasizer Nano ZS with backscatter detection 
(Malvern Instruments, Worcestershire, UK). For size measurements, the 
equilibration time was 0 min, the temperature was 25˚C, and an 
automatic attenuator was used. The refractive index of the solvent 
(MilliQ water) was 1.330 and hence, the viscosity was 0.8872. For 
analysis of the polyplexes, the refractive index of polystyrene latex 
(1.590) was used. Each sample was measured 3 times with 10 sub-runs. 
The ζ-potential was calculated using the Smoluchowski model. 
Therefore, 10-30 sub-runs of 10 s at 25°C (n=3) were measured.  
II.4.3.4. Transmission Electron Microscopy (TEM) 
Pictures were obtained from a FEI Tecnai G2 Spirit (FEI Europe, 
Eindhoven, Netherlands) transmission electron microscope using the 
Morada digital camera (Olympus Soft Image Solutions GmbH, Münster, 
Germany). Samples were prepared as detailed: a Mesh grid was placed 
over one sample solution drop for 3 min and then the grid was 
transferred to a drop of uranyl acetate (2% in milliQ water for 1 min). 
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Excess of uranyl acetate was dried and the grid was placed in the grid 
holder and observed under the microscope. 
II.4.4. Protocols 
II.4.4.1. Loading of a 2-Chlorotrityl Chloride Resin with an Fmoc-
protected Amino Acid 
After swelling of 750 mg of a 2-chlorotrityl chloride resin (1.2 mmol 
chloride) in water-free DCM for 10 min, the first Fmoc- protected amino 
acid Fmoc-L-Trp(Boc)-OH (0.75 equivalents, eq.) and DIPEA (1.5 eq.) 
were added to the resin for 1 h. The reaction solvent was drained and a 
mixture of DCM/MeOH/DIPEA (80/15/5) was added twice for 10 min. 
After the removal of the reaction mixture, the resin was washed 5 times 
with DCM.  
About 30 mg of the resin was removed and dried to determine the 
loading of the resin. Therefore, an exact amount of resin was treated 
with 1 mL deprotection solution (20% piperidine in DMF) for 1 h. 
Following these steps, the solution was diluted and absorption was 
measured at 301 nm. The loading was then calculated according to the 
equation: resin load [mmol/g] = (A*1000)/(m [mg]*7800*df) with df as 
dilution factor. 
The resin was treated twice with 20% piperidine in DMF and twice 
with 20% piperidine DMF with 2% DBU (1,8-Diazabicyclo[5.4.0]undec-
7-eneto) remove the Fmoc- protection group. Reaction progress was 
monitored by Kaiser test [91]. Afterwards, the resin was washed with 
DMF, DCM and n-hexane and dried in a vacuum. 
II.4.4.2. Synthesis of Stp Oligomers S, SH, SC, and SHC 
Stp oligomers (S, SH, SC, and SHC) were synthesised using a 2-
chlorotrityl resin preloaded with the first C-terminal amino acid (Fmoc-
L-Trp(Boc)-OH) as solid support (resin-loading protocol can be found in 
Section II.4.4.1). Artificial Fmoc-oligoamino acid Fmoc-Stp(Boc3)-OH was 
synthesised as previously described [68, 75]. Oligomers of this artificial 
oligoamino acid, optionally together with the natural amino acids 
histidine (Fmoc-L-His(Trt)-OH) and/or cysteine (Boc-L-Cys(Trt)-OH), 
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were synthesised manually under standard Fmoc solid phase peptide 
synthesis conditions using syringe microreactors. Coupling steps were 
carried out using 4 eq. Fmoc-amino acid, 4 eq. HOBt, 4 eq. PyBOP and 8 
eq. DIPEA in DCM-DMF 1 : 1 (10 mL g−1 resin) for 90 min. Fmoc 
deprotection was accomplished by 4 × 10 min with 20% piperidine in 
DMF (10 mL g−1 resin). After each coupling and deprotection step, a 
washing procedure comprising 3 × 1 min DMF, 3 × 1 min DCM 
incubation (10 mL g−1 resin), and a Kaiser test were performed. In the 
case of a positive Kaiser test result after coupling, the last coupling step 
was repeated. In case of a negative result after deprotection, the last 
deprotection step was repeated. Finally, all oligomers were cleaved 
from the resin by incubation with TFA-TIS-H2O 95 : 2.5 : 2.5 (10 mL g−1 
resin) for 90 min. The cleavage solution was concentrated by flushing 
nitrogen and the oligomers were precipitated in 40 mL of pre-cooled 
methyl tert-butyl ether (MTBE)-n-hexane 1 : 1. All oligomers were 
purified by size exclusion chromatography using an Äkta purifier system 
(GE Healthcare Bio-Sciences AB, Uppsala, Sweden), a Sephadex G-10 
column, and 10 mM hydrochloric acid solution-acetonitrile 7 : 3 as a 
solvent. All oligomers were lyophilised. Oligomer sequences were 
validated by mass spectrometry and 1H NMR. 
Oligomer S, W-Stp5: 1H NMR (500 MHz, D2O, δ): 2.3-2.6 (m, 20 H), 
2.95-3.55 (m, 82 H), 4.40-4.55 (t, 1 H), 7.05-7.65 (m, 5 H). 
Oligomer SC, W-Stp5-C: 1H NMR (500 MHz, D2O, δ): 2.3-2.6 (m, 20 
H), 2.95-3.55 (m, 84 H), 3.95-4.55 (m, 2 H), 7.05-7.65 (m, 5 H). 
Oligomer SH, W-(StpH)5: 1H NMR (500 MHz, D2O, δ): 2.3-2.6 (m, 20 
H), 2.95-3.55 (m, 92 H), 3.90-4.55 (m, 6 H), 7.05-7.65 (m, 10 H), 8.40-
8.75 (m, 5 H). 
Oligomer SHC, W-(StpH)5-C: 1H NMR (500 MHz, D2O, δ): 2.3-2.6 (m, 
20 H), 2.95-3.55 (m, 94 H), 4.10-4.55 (m, 7 H), 7.05-7.65 (m, 10 H), 8.40-
8.75 (m, 5 H). 
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II.4.4.3. General Synthesis of PGA-Stp-Based Conjugates via 
Amide Bond Formation 
One eq. of PGA sodium salt (MW 151 per unit, 50 GAU) was 
dissolved in a minimum amount of milliQ water. Then one eq. of 
DMTMM·Cl (MW 276.1) was added, also dissolved in milliQ water. Ten 
min later, 0.5 eq. of Stp-based polyamidoamine was added and the pH 
adjusted to 8 with 1M NaHCO3. The reaction was allowed to proceed for 
16 h stirring at RT. Dialysis using Float-A-Lyzer® at the corresponding 
molecular weight cut-off (MWCO) was performed in order to purify the 
polymer. A white powder was obtained after freeze-drying.  
1H NMR (300 MHz, D2O, δ): 7.75-7.19 (m, 5xH), 4.51 (m, 1xH), 4.35 
(m, 1H), 3.39-1.98 (m, 80xH + 4H). x: percentage of modification. 
II.4.4.4. Synthesis of PGA-Based Conjugates via Disulphide Bond 
Formation 
Synthesis of pyridyl disulphide modified PGA (PGA-PD). PGA-PD was 
synthesised using DMTMM·Cl with a modification of a previously 
published method [80]. One eq. of PGA sodium salt (MW 151 per unit, 
50 GAU) was dissolved in milliQ water. Then 0.6 eq. of DMTMM·Cl, also 
dissolved in milliQ water was added. 10 min later, 0.3 eq. of pyridyl 
disulphide was added and the pH adjusted to 8 with 1M NaHCO3. The 
reaction was allowed to proceed overnight stirring at RT. Dialysis using 
Float-A-Lyzer® was performed in order to purify the polymer. A white 
powder was obtained after freeze drying. 
1H NMR δ (300 MHz, D2O, δ): 8.43 (1xH, m), 7.88 (2xH, m), 7.33 
(1xH, m), 4.33 (1H, m), 3.48 (2xH, m), 2.95 (2xH, m), 2.39-1.90 (4H, m). 
x: percentage of modification. 
Synthesis of PCSH. One eq. of PGA-PD and 0.5 eq. of oligomer SHC 
were separately dissolved in PBS at pH 7.4. Both solutions were mixed 
and the reaction allowed to proceed for 5 h stirring at RT. Dialysis using 
Float-A-Lyzer® at 3000 MWCO was performed for 16 h. A yellowish 
powder was obtained after freeze-drying. 
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1H NMR (300 MHz, D2O, δ): 7.75-7.19 (m, 15xH), 4.51 (m, 1H), 4.35 
(m, 1xH), 3.39-1.98 (m, 118xH + 4H). x: percentage of modification. 
II.4.4.5. Polyplex Formation 
Polyplex formulations for transfection and gel shift experiments 
were prepared as follows: 200 ng of pDNA or 500 ng of siRNA and the 
calculated amount of polymer at indicated +/- or N/P ratios were diluted 
in separate tubes in 10 µL of 20 mM HEPES at pH 7.4 each. Only 
protonatable nitrogens, not amide nitrogens, were considered in the +/- 
ratio and N/P ratio calculations. The nucleic acid and the polymer 
solution were mixed by rapidly pipetting up and down (at least 5 times) 
and incubated for 30-40 min at RT. 
II.4.4.6. pDNA and siRNA Binding Assay by Electrophoresis 
For pDNA, a 1% agarose gel was prepared by dissolving agarose in 
TAE buffer (Tris base, acetic acid and EDTA) and boiling at 100°C. After 
cooling to 50°C and after the addition of EtBr, the agarose gel was set in 
an electrophoresis unit. Polyplexes containing 200 ng of pDNA in 20 µL 
20 mM HEPES and loading buffer were placed into the sample lanes. 
Electrophoresis was performed at 80 V for 80 min. For siRNA, a 2.5% 
agarose gel containing EtBr was prepared. Polyplexes containing 500 ng 
of siRNA in 20 µL HEPES and loading buffer were placed into the sample 
lanes. Electrophoresis was performed at 80 V for 40 min. 
II.4.4.7. Ethidium Bromide (EtBr) Exclusion Assay 
Oligomer solution was added at increasing +/- ratios to 10 µg pDNA 
or siRNA in 1 mL HEPES containing 0.4 µg EtBr. After each addition, the 
EtBr fluorescence was measured at the excitation wavelength λex= 510 
nm and emission wavelength λem= 590 nm using a Cary Eclipse 
spectrophotometer (Varian, Germany). 0.4 µg EtBr in 1mL HEPES 
presented the blank value. Maximal fluorescence intensity was set 
100% for the EtBr solution containing free nucleic acid (10 µg) and 
decreases in fluorescence were measured after stepwise addition of the 
oligomer solution.   
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II.4.4.8. Luciferase Gene Transfer In Vitro and Luciferase Assay 
N2a cells or 4T1 cells were seeded in 96-well plates in 100 μL 
medium (10000 or 5000 cells per well respectively). After 24 h, the 
medium was exchanged for 80 μL fresh medium. The formed polyplexes 
containing 200 ng of pCMVLuc encoding plasmid per well were added 
in a volume of 20 μL to each well and incubated at 37˚C. LPEI at non-
toxic optimum N/P 6 was used for comparison. All experiments were 
performed in quintuplicate. 24 h after transfection, cells were treated 
with 20 µL of Bright-Glo™ reagent. Luciferase activity was read 
spectrophotometrically using Victor2 WallaceTM plate reader. 
II.4.4.9. Luciferase Gene Silencing In Vitro and Luciferase Assay 
Gene silencing experiments were performed in N2a/EGFPLuc cells 
stably expressing the CMV‐EGFPLuc cassette (Clontech) encoding a 
fusion of enhanced green fluorescent protein and GL3 firefly luciferase 
under the control of the CMV promoter. Cells were grown in RNase-free 
cell culture flasks as described above. siRNA delivery (0.5 μg/well of 
either GFP-siRNA or control-siRNA) was performed in RNase-free 96-
well plates (5000 cells per well, triplicates). Cells were seeded 24 h prior 
to transfection and then the medium replaced with 80 µL fresh growth 
medium containing 10% FCS. 20 µL of transfection complexes solution 
for siRNA delivery at different +/- ratios were added to each well and 
incubated at 37°C. 48 h after transfection, luciferase activity was 
determined as described above. Relative light units (RLU) were 
presented as percentage of the luciferase gene expression obtained 
with buffer treated control cells. 
II.4.4.10. MTS Assay for Cell Viability Evaluation 
N2a cells or 4T1 cells were seeded into 96-well plates at a density 
of 10,000 or 5000 cells/well respectively. After 24 h, culture medium 
was replaced with 80 μL fresh growth medium containing 10% FCS and 
20 μL of transfection complexes solution at different +/- ratios were 
added. All studies were performed in quintuplicate. 24 h post 
transfection, 20 μL of manufacturer solution containing MTS/PMS 
(20:1) was added to each well, and the cells were incubated for a further 
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2 h. Optical density of each well was measured spectrophotometrically 
at 490 nm using Victor2 WallaceTM plate reader. The absorbance values 
were represented as the percentage of cell viability taken as 100% cell 
viability of untreated control cells. 
II.4.4.11. Red Blood Cell (RBC) Lysis Assay 
Erythrocytes (RBC, red blood cells) were isolated from fresh whole 
mouse blood obtained by cardiac puncture after death and placed in a 
heparinised tube. Blood was diluted with PBS pH 7.4 up to 10 mL and 
then it was centrifuged (3000 rpm, 10 min, 4°C) three times, removing 
the supernatant after each centrifugation and re-suspending the cells in 
sterile PBS. The final RBC pellet was weighed and re-suspended at 2% 
(v/v) in PBS. To study the haemolytic activity of the systems, they were 
dissolved in PBS stock solutions adjusted to pH 6.5 or 7.4 and citrate 
solution adjusted to pH 5.5. Then samples were added to wells (n=3, 
100 μL) covering the concentration range 0.1-0.01 mg/mL of systems. 
Buffer at the corresponding pH was used as a control together with 
Triton X–100 1% (w/v) to determine a 100% RBC lysis. The plates were 
then incubated at 37°C for 1 h. To assess haemoglobin (Hb) release the 
plates were then centrifuged (3000 rpm, 10 min, 20°C) and the 
supernatant of each well was transferred into a new plate. The Hb 
released was assessed by measuring the absorbance at 570 nm using 
Victor2 WallaceTM plate reader. The percentage of haemolysis of each 
sample was calculated relative to 100% haemolysis obtained from 
incubation with Triton-X 100. 
II.4.4.12. Confocal Fluorescence Microscopy 
100 µL of 0.01% PLL were added on Chamber SlideTM (0.8 cm2/well) 
to coat the culture surface. After 5 min, the solution was removed by 
aspiration and PBS was used to wash the surface. Then, PLL was allowed 
to dry for 2 h before introducing cells and medium. N2a cells were 
seeded at a density of 25,000 on Chamber Slide™ (31,250 cells/cm2) in 
200 μL of medium and allowed to seed for 24 h at 37˚C. Culture medium 
was replaced with 160 μL fresh medium and 40 μL of pCMV-GFP 
polyplex solution was added. The cells were incubated for 24 h, at 37˚C 
and, then, the medium was removed and cells were washed twice with 
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PBS. In order to fix the cells, 200 μL of 2% paraformaldehyde at pH 7.4 
was added and left to react for 20 min at RT in the dark. The medium 
was removed again and cells were washed twice with PBS. Then, 
samples were mounted using VectaShield® mounting medium with 
DAPI. Images were captured with a confocal microscope Leica TSC SP8 
AOBS (Leica Microsystems Heidelberg and MBH, Germany) equipped 
with a 63 oil immersion objective. GFP was excited at 488 nm by a 496 
nm laser and DAPI by a 405 nm. Images were taken on an 8-bit gray 
scale and processed with LEICA LAS AF Lite Software (Leica 
Microsystems Heidelberg and MBH, Germany). 
II.4.4.13. Statistical Analysis  
The results presented are an average of experiments performed in 
at least triplicate with standard deviation (SD). In all cases, we 
considered differences to be significant when p <0.001 or p <0.01; n.s. 
= non-significant > 0.05. 
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The work presented within this thesis chapter was carried out in 
close collaboration with Dr. Elena Gallon and Dr. Inmaculada Conejos 
Sánchez. 
III.1. INTRODUCTION AND BACKGROUND 
As stated in Chapter II, gene therapy is an experimental technique 
offering a wide spectrum of applications including regulation, repair, 
and replacement of mutated genes to treat genetic diseases. Gene 
therapy currently represents a promising option for inherited genetic 
disorders, certain viral infections, and also some types of cancer. Cancer 
is often associated with complex genetic alterations and constitutes an 
incurable illness. Classical gene therapy, in terms of the substitution of 
deficient genes by transfer of genetic material, represents the first 
therapeutic application of nucleic acids [1, 2]. The first gene therapy 
achieved market approval by the European Commission in 2012 
(alipogene tiparvovec, Glybera® [3]) and by April 2017 [4] 2400 clinical 
gene therapy trials encompassing three decades of work were 
completed, ongoing, or approved  worldwide.  Safety data accumulated 
during this time has permitted the development and improvement of 
safer and more efficient gene therapy approaches. 
Among the diverse subtypes of oligonucleotides evaluated for gene 
therapy, perhaps the best-known and most studied is the application of 
small interfering RNA (siRNA) for RNA interference (RNAi). RNAi gene 
specific silencing in nematodes was discovered in 1998 by Fire and 
Mello [5]. However, this technique was not effective in mammalian 
cells, where the long (over 30 base pairs (bp)) double stranded RNA 
(dsRNA) induced immune reactions and cell death. The  use of a shorter 
21 bp RNA avoided unwanted immune responses and allowed effective 
gene silencing in mammalian cells [6]. The ability to selectively 
downregulate single genes at the post transcriptional level led to a 
revolution in basic cell biology, opening a completely new and potent 
platform for drug development. The siRNA mechanism (Figure III.1) 
starts with the introduction of dsRNA or synthetic siRNA into cells. 
When dsRNA enters the cell, it is recognised by the Dicer enzyme which 
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cleaves the dsRNA into fragments of 21-23 bp (siRNA) [7]. Alternatively, 
synthetically produced siRNA can be introduced directly [6].  
 
Figure III.1. Mechanism of siRNA silencing by introduction of dsRNA or 
synthetic siRNA. 
Once in the cytosol, siRNA fragments are recognised by the multi-
protein RNA-induced silencing complex (RISC), and unwound by 
Argonaute2 (AGO2). While the sense strand is released and degraded, 
the antisense strand remains incorporated in the RISC  complex [8].  If 
complementary messenger RNA (mRNA) is present, the siRNA guided 
RISC complex will bind the mRNA, leading to degradation or 
translational inhibition [9, 10]. The RISC-antisense strand complex 
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remains stable during this process and, therefore, can attach to another 
corresponding mRNA, thereby propagating gene silencing. Overall, this 
process constitutes an important and precise epigenetic tool for the 
regulation of gene expression. After unravelling this mechanism, many 
opportunities for therapeutic purposes emerged and its translation to 
clinical trials has evolved rapidly [11]. 
Although siRNA has been extensively studied for application as a 
pharmaceutical drug [12, 13], “naked” siRNA suffers the same 
limitations as many other macromolecules (proteins, peptides, 
antibodies, DNA, etc.) during the delivery process. These restrictions 
include enzymatic degradation over renal clearance, interaction with 
blood components, activation of the immune system, and inefficient 
uptake by target cells. Therefore, siRNA requires an appropriate carrier 
system to fulfil its potential. As natural nucleic acid vehicles, viruses 
(such as adenovirus, retrovirus, and adeno-associated virus) are the 
most investigated vectors for gene therapy [4, 14]. Despite their high 
efficiency, these viral vectors exhibit serious disadvantages which 
restrict its progress. Immunogenicity, limited cargo loading, high 
production costs, and the risk of promoting cancer by insertional 
mutagenesis are their main drawbacks [14-16], which led to the 
development of more advantageous synthetic structures [17]. 
New and improved nucleic acid carriers must be multifunctional, 
bioresponsive to a dynamic environment, and specific. Their design has 
to consider the delivery route and the individual hurdles which are likely 
to be encountered [18]. Recently, polypeptides have been evaluated as 
siRNA carriers [19] as they allow stable nucleic acid 
complexation/conjugation and encourage cellular uptake, subsequent 
endosomal escape and intracellular cargo release at the target site. 
Additionally, polypeptides exhibit reduced cytotoxicity, 
immunogenicity as well as biodegradability [20]. However, viruses are 
advantageous over polypeptides in that they have evolved to use 
natural mechanisms to enter cells [21].  
In brief, polypeptides represent a simpler, cost-effective, and 
potentially less immunogenic class of gene delivery agents than viruses 
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[22]. However, polypeptides still face some major challenges, including 
a lack of cell and tissue specificity and inefficient endosomal escape. A 
manufactured drug substance should be homogenous and composed of 
a single, defined species. By the contrast, it is important to note that, 
most of the reported polypeptides used for gene therapy by far have 
been synthesised through random polymerisation techniques, ending 
up in high polydispersity products and poor architecture control. Total 
control of crucial parameters such as chain length, molecular weight 
(MW), polydispersity, microstructure, final conformation as well as 
localisation of charge or hydrophobic-hydrophilic balance are key to 
adequately tailor nanomedicine body distribution, fate, biological 
activity and toxicity [23-25]. Therefore, the development and 
exhaustive physicochemical characterisation of defined polypeptides 
with a fully defined structure and content would provide precise data 
and enable the design of more efficient delivery systems [26-28]. 
Improvement of polymerisation techniques (mainly N-
carboxyanhydride ring-opening polymerisation (NCA-ROP)) [29] and 
synthetic chemistry have permitted the production of polypeptides 
with narrow polydispersity, minimal side product formation, high 
reproducibility, and precise functionalisation of the polypeptide 
backbone [30]. 
This thesis chapter is focused on the design, development, and 
validation of non-viral polypeptide-based carriers for oligonucleotide 
delivery. Three different polymeric platforms based on natural or 
synthetic polyaminoacids were evaluated, aiming to improve gene 
silencing by conferring them the capability of modulating the 
endosomal buffer capacity, improving pharmacokinetics and achieving 
efficient gene transfer by using among others: (i) polypeptides with 
different ζ-potential in order to explore safety vs. transfection efficiency 
and (ii) covalent conjugation approaches vs. complexation to explore 
the need of trigger release vs. nanoconstruct stability. These platforms 
were based on poly-L-glutamic acid (PGA), poly-L-arginine (PArg) and 
poly-L-ornithine (P(Orn))  obtained through  controlled NCA-ROP 
techniques [26, 27] and adequately derivatised by post-polymerisation 
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modification [31] to achieve the adequate ζ-potential and orthogonal 
conjugation sites (Figure III.2 summarises the different systems 
studied). 
 
Figure III.2. Summary of the developed systems. 
III.2. RESULTS AND DISCUSSION 
III.2.1. Poly-L-Glutamic Acid (PGA)-Based Systems (Systems 1-3) 
Positively charged cationic polymers have been extensively 
proposed as vectors for negatively charged oligonucleotides as they 
readily form complexes due to their intrinsic attraction [32, 33]. 
However, the major problem of cationic polymers is their unwanted 
interaction with erythrocytes and the subsequent haemolysis and 
haemagglutination. Furthermore, many cationic polymers are not 
biodegradable and repeated administration may, therefore, lead to 
lysosomal storage disease. To overcome this problem, a well-defined 
PGA was selected as biocompatible, and biodegradable carrier [34-36], 
functionalising its main chain with secondary and ternary amines. The 
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resultant polypeptide-based carriers were evaluated as possible gene 
delivery vehicles. These modifications aim to diminish the negative 
charge inherent to PGA providing in addition multiple advantageous 
qualities, such as an enhancement in endosomolytic capacity [37]  
enhancing the possible release of the nucleic acid into the cytosol.  
 III.2.1.1. Systems 1 and 2 - PGA-Based Systems: Functionalisation 
with Endosomolytic Molecules. Complexation and Conjugation of 
Oligonucleotides 
III.2.1.1.1. Synthetic Approaches 
In order to achieve PGA complexation/conjugation with 
oligonucleotides, a rational design was followed reducing the negative 
charges in parallel with conferring vector specific functions through the 
addition of endosomolytic moieties: histidine (Hist) or morpholine 
(Morph). Both were introduced via DMTMM·Cl (4-(4,6-Dimethoxy-
1,3,5-triazin-2-yl)-4-methylmorpholinium chloride) activation of the 
polypeptide chain carboxyl groups (Figure III.3) [31]. The mechanism of 
action of DMTMM·Cl was already described in Chapter II, Section II.2.2. 
L-histidine methyl ester and 3-morpholinopropylamine contain an 
imidazole ring (pKa3 6.5) and a morpholine ring (pKa 6.2), respectively, 
which increase the buffering capacity of endosomes. This aids the 
endosomal escape of modified oligonucleotides after cell endocytosis, 
a crucial and rate-limiting step to trigger transfection. The imidazole and 
morpholine rings have been previously used for this purpose in several 
non-viral gene carriers, such as dendrimers [38], cationic polymers [39-
41], and lipids [42, 43]. Moreover, various studies have shown that the 
modification of highly positively charged polymers, peptides, and 
liposomes with imidazole-containing groups (such as histidine) resulted 
in reduced cytotoxicity in comparison with the parent systems, without 
reducing their endosomolytic capacity [44]. 
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Figure III.3. Schematic representation of PGA-Hist and PGA-Morph synthesis 
via DMTMM·Cl activation. 
System 1 compounds are detailed in Table III.1. Since the length of 
the PGA backbone may induce significant conformational fluctuations 
and influence the complexing capacity, different lengths of PGA (20 and 
50 GAU (glutamic acid units)) were evaluated to select the best 
candidate. Reactions proceeded quantitatively as determined by 1H 
NMR (Figure III.4 and Figure III.5). 
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Figure III.4. 1H NMR spectrum with assignments for PGA-Hist. 
 
Figure III.5. 1H NMR spectrum with assignments for PGA-Morph. 
To further diminish the remaining negative charge of the PGA 
chain, amino-2-propanol (ApOH) or L-arginine methyl ester (Arg, 
provides an additional positive charge) were conjugated using the same 
coupling strategy (Figure III.6).  
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Figure III.6. Schematic representation of PGA-Hist or PGA-Morph 
functionalised with amino-2-propanol (left) and L-arginine methyl ester (right). 
R= previously introduced Hist or Morph moieties. 
Taking into account the total charge values shown in Table III.1, 
PHArg2 (PGA50-Hist15%-Arg75%, 33(+)) and PMArg2 (PGA50-
Morph60%-Arg31%, 11(+)) were expected to induce the least 
electrostatic repulsion with the oligonucleotide. Binding ability of both 
conjugates was tested by gel shift assay using a small doubled stranded 
DNA, dsDNA (22 bp) as a model of oligonucleotide. However, System 1 
PGA derivatives did not form stable complexes even at high charge-ratio 
(+/-). To solve this problem, conjugation of the nucleic acid to the PGA 
chain (System 2) was explored through a biodegradable and reversible 
linkage (disulphide bond), modifying some of the already synthesised 
System 1 derivatives. Disulphide bonds guarantee site-specific 
conjugation and oligonucleotide release in the reducing environment 
encountered in the cell cytoplasm [45, 46]. Pyridyl disulphide (PD) 
molecules were incorporated into the already synthesised PGA-vectors 
(Figure III.7) using the same protocol as described in Chapter II (Section 
II.2.4). Under the same rational design previously explained, three 
different lengths of PGA were studied (20, 50 and 100 GAU). All the 
resulting products are disclosed in Table III.2. 
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Table III.1. System 1 conjugates synthesis and characterisation.  
Conjugate Polymer Id GAU 
Loadinga (mol%) 
Total charge 
at pH 7b 
MWb 
(g/mol)  Morph Hist Arg ApOH 
free 
COOH 
PGA-Hist-Arg PHArg1 20 - 15 50 - 35 3 (+) 4685 
PHArg2 50 - 15 75 - 10 33 (+) 13373 
PGA-Hist-ApOH PHApOH 50 - 15 - 50 35 18 (-) 9288 
PGA-Morph-Arg PMArg1 20 52 - 21 - 27 2 (-) 4656 
PMArg2 50 60 - 31 - 9 11 (+) 12716 
PGA-Morph-ApOH PMApOH 50 60 - - 25 15 8 (-) 11108 
a Determined by 1H NMR; b Estimated after 1H NMR analysis. MW= molecular weight. 
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Figure III.7. Schematic representation of pyridyl disulphide conjugates. R= Hist 
or Morph; X= ApOH or Arg. 
The conjugation of dsDNA to the PGA backbone via disulphide 
bond formation occurs by the simple addition of the oligonucleotide 
with an additional terminal thiol group, (-SH) into a solution containing 
the PGA derivative (Figure III.8). 
 
Figure III.8. Schematic representation for the synthesis of PGA-dsDNA 
conjugates. 
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Table III.2. System 2 polypeptide family. 
Conjugate Polymer Id GAU 
Loadinga (mol%) 
Total 
charge at 
pH 7b 
MWb 
(g/mol) Morph Hist Arg ApOH PD 
free 
COOH 
PGA-Hist-Arg-PD PHArgPD1 20 - 15 50 - 10 25 5 (+) 4977 
PHArgPD2 50 - 24 33 - 7 36 1 (-) 12048 
PHArgPD3 100 - 16 23 - 8 53 30 (-) 21728 
PGA-Morph-Arg-PD PMArgPD1 20 52 - 21 - 5 22 1 (-) 4802 
PMArgPD2 50 60 - 31 - 4 5 13 (+) 13008 
PMArgPD3 50 50 - 24 - 1 25 1 (-) 11807 
PMArgPD4 50 63 - 24 - 6 7 9 (+) 12848 
PMArgPD5 50 41 - 20 - 7 32 6 (-) 11513 
PMArgPD6 50 50 - 25 - 4 21 2 (+) 12092 
PMArgPD7 100 47 - 14 - 6 33 19 (-) 22940 
PGA-Morph-ApOH-PD PMApOHPD 50 60 - - 25 7 8 4 (+) 11618 
a Determined by 1H NMR; b Estimated after 1H NMR analysis. 
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Taking into account the total charge values shown in Table III.2, 
PMArgPD2 (PGA50-Morph60%-Arg31%-PD4%, 13(+)), PMApOHPD 
(PGA50-Morph60%-ApOH25%-PD7%, 4(+)), and PHArgPD1 (PGA20-
Hist15%-Arg50%-PD10%, 5(+)) were expected to induce the least 
electrostatic repulsion with the oligonucleotide. These polymers 
allowed the study of the role of Arg and ApOH on the PGA main chain 
trying to enhance its cytosolic potential.  
III.2.1.1.2. DNA Binding Assay Electrophoresis 
Oligonucleotide conjugation with the three selected polymers 
(PMArgPD2, PMApOHPD and PHArgPD1) was qualitatively evaluated 
through agarose gel electrophoresis technique. The optimisation of the 
experimental conditions for dsDNA conjugation to the selected carriers 
was performed. To certify such conjugation efficiency, 1,4-dithiothreitol 
(DTT, a reducing agent) was added (Figure III.9) [47].  
 
Figure III.9. dsDNA conjugation efficiency  to PMArgPD2 determined by an 
agarose gel shift assay using different equivalents of the PGA-based polymer (1 
to 16 eq PMArgPD2) per 0.04 equivalents of dsDNA (500 ng), with and without 
DTT. 
Figure III.9 shows DNA presence (signified by white bands) in the 
loading wells of the samples without DTT and with lower amounts of 
free DNA (bottom band) as compared with the control dsDNA. 
Additionally, the bands in the loading wells disappear upon addition of 
DTT and the free DNA signal increases. Therefore, it could be said that 
a successful dsDNA conjugation to the PGA backbone via disulphide 
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bond formation may has occurred. The best ratio was 16 equivalents of 
polymer per 0.04 equivalents of dsDNA with almost free DNA absence.  
On the other hand, PMApOHPD conjugate required 
polymer/dsDNA ratios of 1-40 equivalents per 0.07 equivalents of 
dsDNA (500 ng), according to the ratio of PD groups in the PGA 
derivative (Figure III.10). DNA-conjugate retention was worse as 
compared to PMArgPD2, probably due to the different resulting -
potential. Nonetheless, the observed signal for the polymer was 
different from control (dsDNA) concluding that dsDNA was at least 
partly conjugated.  
 
Figure III.10. dsDNA conjugation efficiency to PMApOHPD determined by an 
agarose gel shift assay by using different equivalents of the PGA-based 
polymer. 1-40 eq. PMApOHPD per 0.07 equivalents dsDNA (500 ng). 
Polymer PHArgPD1 (PGA20-Hist15%-Arg50%-PD10%) did not show 
dsDNA retention suggesting that DNA conjugation had not occurred. 
After these results, it is clear that the nature of the molecule used for 
side-chain modification (morpholine better than histidine) is more 
important than the degree of PD derivatisation. Therefore, PMArgPD2 
was selected as the best candidate to move forward.  
III.2.1.1.3. Red Blood Cell (RBC) Lysis Assay 
As the synthesised conjugates are proposed for intravenous (IV) 
administration, their ability to induce red blood cell (RBC) lysis in vitro 
was carried out as a preliminary measure of haematocompatibility [48].  
For this purpose, PMArgPD2, PMApOHPD, and PHArgPD1 polymers 
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were incubated with RBCs (Figure III.11). None of the conjugates 
showed haemolytic properties either at physiological pH (7.4) or at 
endosomal pH (5.5) indicating their suitability for IV administration. 
Triton X-100 and PBS (pH 7.4) or citrate buffer (pH 5.5) at the 
corresponding pH were used as positive and negative control, 
respectively. 
 
Figure III.11. Erythrocyte leakage assay at different pH values: compounds 
were incubated with erythrocytes at different concentrations at 37°C at 
indicated pH values. Haemoglobin release was measured after 1 h. Data 
expressed as mean ± SD, n=3 
III.2.1.1.4. Buffer Capacity- Potentiometric Titration 
The buffer capacity of the polymer PMArg2 (PGA50-Morph60%-
Arg31%), a precursor of PMArgPD2, was tested by alkalimetric titration 
at a pH range of 5.0 and 7.4. This range represents the physiologically 
relevant acidification from pH 7.4 in the blood or cell cytosol to pH 5.0 
in the endosome/lysosome. Figure III.12 shows the titration curves with 
the highlighted endosomal range. The titration curve of PMArg2 
demonstrated a significant difference between both pHs compared 
with NaCl used as reference titration, mainly indicating an endosomal 
buffer capacity due to the deprotonation of morpholine rings (35% 
buffer capacity calculated through Equation III.1, Section III.4.4.16). The 
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gradient of the curve had its minimum around pH 6. However, above pH 
8 the titration curve showed a similar course as NaCl since the amount 
of morpholine rings available for deprotonation decreases 
exponentially with increasing pH.  
The polymer PMArg2 exhibited a continuous buffering capability 
over a broad range, including the endosomal area and above, which 
suggests that the polymer presents sufficient buffering capacity for 
endosomal escape. 
 
Figure III.12. Potentiometric titration of PMArg2 (PGA50-Morph60%-Arg31%). 
Amounts corresponding to 15 μmol protonatable amines. 
III.2.1.1.5. Cell Culture Media and Plasma Stability  
Stability of the conjugates in cell culture media was carried out 
using DTT to certify that dsDNA was still conjugated. As observed in 
Figure III.13 (left), dsDNA release occurs in a time dependent manner in 
presence of cell media. However, the results with DTT at 5 h suggest 
that a small amount of stable dsDNA-conjugate still exists. 
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Figure III.13. Stability of PGA-Morph-Arg-PD conjugate to dsDNA in cell culture 
media without FBS (left) and in plasma (right). *Without plasma. 
Additionally, plasma stability by an agarose gel shift assay was also 
performed trying to mimic physiological conditions. Figure III.13 (right) 
demonstrates again the low stability of System 2 conjugates even at 
short incubation times. 
III.2.1.1.6. Biological Evaluation of System 2 Conjugates: Cell 
Viability and Gene Transfer In Vitro  
Cytotoxicity of the novel DNA conjugates was explored in B16F10 
cell line in order to select the highest concentration for later activity 
studies. As it can be observed in Figure III.14, all the tested 
concentrations were non-toxic and 37 µM dsDNA concentration was 
selected for further in vitro experiments. 
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Figure III.14. Cell viability assay of DNA conjugates using different 
concentrations of dsDNA, developed in B16F10 cells and determined by MTS 
assay 24 h post-incubation. HEPES was used as control. Data expressed as 
mean ± SD, n≥4.  
Activity studies by means of a silencing luciferase assay were 
carried out. Evaluation of gene silencing at 24 h and 48 h, using a 21bp 
thiolated luciferase double stranded siRNA (ds-siRNA), demonstrated 
that any of System 2 conjugates were not capable to achieve gene 
silencing, even at high siRNA concentrations (Figure III.15).  
  
Figure III.15. Gene silencing from System 2 conjugates in B16F10 cell line using 
different concentrations of ds-siRNA. HEPES was used as control. Data 
expressed as mean ± SD, n≥4.    
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These results further corroborated those shown in Section 
III.2.1.1.5, concerning plasma and cell culture media stability. System 2 
conjugates demonstrated low stability even at short incubation times. 
Otherwise, the endosomal escape would not be efficient enough for the 
oligonucleotide release.  Immunofluorescence assays are being carrying 
out to resolve such issues. 
Taking into account the results obtained for System 2, System 3 
was designed using PGA derivatives with higher MW. 
III.2.1.2. System 3 - PGA-Based Systems: Functionalisation of 
Higher Molecular Weight PGA with Endosomolytic Molecules and PEG 
Protection. Conjugation of Oligonucleotides 
III.2.1.2.1. Synthetic Approaches 
Greater MW PGA derivatives were explored in order to enhance 
oligonucleotide stability in plasma, main limitation in previous reported 
systems. At the same time, such MW enhancement could benefit 
passive targeting by the Enhanced Permeability and Retention (EPR) 
effect [49]. Therefore, two novel strategies were evaluated as 
alternatives to Systems 1 and 2. First, PEG5000-co-b-PGA88 (DB) 
derivative as a delivery agent was evaluated. PEG is a non-
biodegradable hydrophilic polymer which provides stealth properties to 
the conjugate avoiding conjugate recognition by the immune system 
and increasing molecule size. Secondly, a higher MW PGA (PGA300) was 
also used. 
PGA post-polymerisation modifications explained above were also 
used to functionalise PGA300 and DB with Morph, Arg, and PD, obtaining 
the polypeptides presented in Table III.7. 
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Table III.7. System 3 conjugates tested as possible non-viral vectors. 
Conjugate Polymer Id GAU 
Loadinga (mol%) 
Total Charge 
at pH 7b 
MWb 
(g/mol) 
Morph Arg PD free COOH 
DB-Morph-Arg-PD DB88MArgPD 88 52 8 4 36 8 (-) 25664 
PGA-Morph-Arg-PD P300MArgPD 300 53 14 7 26 36 (-) 70446 
a Determined by 1H NMR; b Estimated after 1H NMR analysis. 
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To verify the identity and purity of each polymer and to compare 
their sizes and diffusion coefficients, bidimensional DOSY experiments 
(Figure III.16, Table III.8) were carried out.  
 
Figure III.16. DOSY NMR spectrum for (A) PGA300 and PGA300-Morph-Arg-PD 
(P300MArgPD); and (B) DB88 and DB88-Morph-Arg-PD (DB88MArgPD). 
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Table III.8. Diffusion coefficients and hydrodynamic radius (Rh) of System 3 
PGA-derivatives. 
Conjugate Polymer 
Da  
(m2/s) 
Rha 
(nm) 
DB88 8.22e-12 24.4 
DB88-Morph-Arg-PD 3.39e-12 64.3 
PGA300 8.27e-12 21.8 
PGA300-Morph-Arg-PD 3.14e-12 63.9 
a Diffusion coefficient (D) and hydrodynamic radius (Rh) 
determined by fitting the intensities of the arrayed DOSY 
NMR spectra into Stejskal-Tanner equation. 
NMR results indicate that, after derivatisation, both polymers 
(P300MArgPD and DB88MArgPD) display an increase in size, which 
further diminishes their diffusion coefficient. This indicates that the size 
of PGA-derivatives is influenced by the moieties added, which can treble 
the initial hydrodynamic radius (Rh). 
III.2.1.2.2. DNA Binding Assay Electrophoresis 
To evaluate System 3 polyplex formation (Table III.7), agarose gel 
electrophoresis test was performed (Figure III.17).  
 
Figure III.17. dsDNA binding ability of P300MArgPD and DB88MArgPD 
determined by agarose gel shift assay using different amounts of PGA-based 
polymer keeping constant the amount of dsDNA, with and without DTT.  
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As it can be observed in the figure above, a lower DNA binding 
capacity for P300MArgPD and DB88MArgPD was obtained in comparison 
to the PGA50-derivatives of Systems 1 and 2. Although the MW of 
P300MArgPD is higher than the MW of DB88MArgPD (70446 g/mol vs. 
25664 g/mol), the theoretical total charge at pH7 is lower in the case of 
P300MArgPD (36(-) for P300MArgPD vs. 8(-) for DB88MArgPD). Despite 
this, polymer P300MArgPD displayed better DNA binding ability as 
compared to DB88MArgPD.  For this reason, we selected P300MArgPD to 
repeat the agarose gel electrophoresis using increased amounts of 
polymer while keeping the amount of oligonucleotide constant. 
However, increasing the amount of polymer only led to a very small 
improvement of DNA binding.  
Given the low effectiveness in the conjugation of the different PGA 
derivatives to the oligonucleotide (regardless of their MW), another 
strategy based on poly-L-arginine was developed. 
III.2.2. Poly-L-Arginine (PArg)-Based Systems (Systems 4-5) 
Cationic polymers, such poly-L-lysine (pLL) and polyethylenimine 
(PEI), have been extensively studied as vectors for gene therapy as they 
readily form polyelectrolyte complexes with the corresponding 
oligonucleotide. This fact results in a greater compaction and an 
enhanced stability toward nucleases [50, 51]. For this reason, herein, 
we explored new designs based on the basic amino acid arginine due to 
its known efficiency as a delivery agent for plasmid DNA (pDNA) and 
siRNA both in vitro and in vivo [52]. Additionally, arginine-rich peptides 
are able to enter cells via endocytosis [53] and, interestingly, there 
exists a dependence of chain length on cellular localisation, membrane 
permeability, and toxicity [54]. However, the major disadvantages of 
using such cationic moieties for in vivo proposes are their cytotoxicity 
and low biodegradability, issues that have been also taken into account 
in the synthetic processes selected.  
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III.2.2.1. System 4 - PGA-Coated PArg-Based Polyplexes 
III.2.2.1.1. Synthetic Approaches 
Under the same rational as PGA, different backbone lengths of 
PArg (50, 92 and 150 units) were explored to study the potential for 
complexation. System 4 would give rise to electrostatic interactions 
with DNA instead of controlled covalent attachment. After 
complexation, the systems were coated with PGA or DB in order to 
secure haemo- and bio-compatible systems and to provide “stealth” 
properties to polyplexes for future in vivo application (Figure III.18).  
 
Figure III.18. Schematic representation for System 4 complexes.  
III.2.2.1.2. DNA Binding Assay Electrophoresis 
After optimising the nitrogen to phosphate (N/P) ratio for each 
system (Figure III.19), the high capacity of PArg to form stable 
complexes even at low N/P ratios was observed.  
 
Figure III.19. Optimisation of N/P ratio by checking the dsDNA binding ability 
of PArg through agarose gel electrophoresis. 
Coating optimisation was also performed by gel shift assay (Figure 
III.20), finding out that PGA destabilised the system and PArg30 provided 
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less stable complexes compared with PArg92 and PArg150. Thus, 
PArg92/dsDNA + DB88 and PArg150/dsDNA + DB88 at N/P 6 were selected 
for subsequent experiments due to their high stability and 
reproducibility. 
 
Figure III.20. Optimisation of coating agent by checking the PArg-dsDNA 
binding ability through agarose gel electrophoresis. 
 
Figure III.21. Binding ability for PArg complexes by using different amounts of 
coating agent (c= 80 µg/mL PArg per 500 ng of oligonucleotide). 
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The amount of coating agent (DB88) related to PArg amount (c= 80 
µg/mL per 500 ng of oligonucleotide) was also optimised by testing 
different quantities of DB for each length of PArg (Figure III.25). N/P 6 
and (½)c (40 µg/mL per 500 ng of oligonucleotide), half the amount of 
DB per amount of PArg, were selected as the composition to move 
forward. 
III.2.2.1.3. DLS Measurements- Particle Size and ζ-Potential 
Using the selected amount of DB88 (DB:PArg ratio 1:2) a reduction 
in ζ-potential after the coating was observed, as expected. ζ-potential 
still remained positive in both cases after complexation (Table III.9). 
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Table III.9. Physicochemical characterisation of System 4/dsDNA polyplexes.  
Polyplex 
Sizea  
(d., nm) 
ζ-potentiala 
(mV) 
PdIa 
PArg92/dsDNA 69.3 ± 5.3 41.4 ± 1.5 0.242 ± 0.015 
PArg92/dsDNA + DB88 coating 69.3 ± 5.6 19.1 ± 0.5 0.350 ± 0.047 
PArg150/dsDNA 38.9 ± 25.6 40.5 ± 1.5 0.243 ± 0.006 
PArg150/dsDNA + DB88 coating 68.8 ± 11.7 17.9 ± 0.6 0.378 ± 0.019 
a As determined by DLS at N/P 6 and half amount of DB per amount of PArg, in 20 mM HEPES 
buffer at 25˚C. Polyplexes were diluted 1:20 before measurement. Size values are expressed 
in terms of number. d.= diameter. PdI= polydispersity index. Variations refer to the median 
of three measurements of the sample. 
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III.2.2.1.4. Heparin Displacement Assay 
Stability of System 4 compounds was evaluated by measuring 
dsDNA release in the presence of a competing polyanion: heparin. The 
lowest concentration of heparin required for dsDNA displacement 
provides an estimation of the complex stability against polyanions [55]. 
Following incubation of the studied polyplexes with increasing levels of 
heparin, all complexes were stable even at 0.25 IU per 20 µL (Figure 
III.22). This equals to 1250 IU/100 mL, while the average heparin levels 
in human plasma are 15 IU/100 mL [56]. 
 
Figure III.22. Heparin displacement assay for System 4 polyplexes by agarose 
gel electrophoresis. 
III.2.2.1.5. Biological Evaluation of System 4 Complexes: Cell 
Viability and Gene Silencing In Vitro  
Again, MTS assays were performed to test cell viability in the 
B16F19 cell line. Different siRNA concentrations were studied keeping 
constant the PArg/siRNA ratio (Figure III.23).  13.87 µM siRNA (4 mg/mL 
PArg) was considered the limit to perform the subsequent in vitro 
experiments.  
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Figure III.23. Cell viability assay of siRNA complexes using different 
concentrations of siRNA developed in B16F10 cells and determined by MTS 
assay 24 h post-incubation. HEPES was used as control. Data expressed as 
mean ± SD, n≥4.  
 In the subsequent activity study (silencing luciferase expression, 
protocol described in Section III.4.4.19), significant transfection was not 
observed, even using high siRNA concentrations. An inefficient 
endosomal escape could be a possible reason for the absence of 
silencing. The addition of and endosomolytic agent into the coating 
agent backbone could solvent this issue. System 5 was then proposed.  
III.2.2.2. System 5 - Coated PArg-Based Polyplexes. Endosomolytic 
PGA-Derivatives as Coating Agents 
III.2.2.2.1. DNA Binding Assay Electrophoresis 
In order to improve the endosomolytic properties of System 4, 
PGA-Morph and PGA-Hist (PGA50 and PGA100) were employed as coating 
agents, generating System 5. The previously optimised ratio N/P 6 for 
polyplex formation using PArg92 and PArg150 was selected. 
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Figure III.24. DNA binding assay electrophoresis for PArg polyplexes at N/P 6 
with PGA-Hist and PGA-Morph coatings. The amount of coating agent related 
to PArg amount (c= 80 µg/mL per 500 ng of oligonucleotide). 
Figure III.24 demonstrates that all the systems formed stable 
coatings even using different amounts of coating agent. In addition, 
change in ζ-potentials towards positive values were observed (Table 
III.10, Section III.2.2.2.2). 
 III.2.2.2.2. DLS Measurements- ζ-Potential 
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Table III.10. Physicochemical characterisation of System 5 complexes. 
PArg 
PArg Concentration 
(µg/mL per 500 ng 
oligonucleotide) 
Coating Agent 
Coating Agent Concentration 
(µg/mL) 
ζ-potentiala 
(mV) 
PArg92 80 - - 41.4 ± 1.5 
 80 PGA100-Morph 80 23.8 ± 0.2 
 80 PGA50-Hist 80 33.2 ± 1.2 
 80 PGA50-Hist 160 26.0 ± 0.2 
PArg150 80 - - 40.5 ± 1.5 
 80 PGA100-Morph 80 21.4 ± 0.9 
 80 PGA50-Hist 80 32.7  ± 0.9 
a As determined by DLS at N/P 6 in 20 mM HEPES buffer at 25˚C.  Polyplexes were diluted 1:20 before 
measurement. Variations refer to the median of three measurements of the sample. 
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III.2.2.2.3. Biological Evaluation of System 5 Complexes: Cell 
Viability and Gene Silencing In Vitro  
MTS assays were performed to test cell viability in the B16F19 cell 
line. Different siRNA concentrations were studied keeping constant the 
polymer/siRNA ratio at N/P 6 as well as the amount of coating agent 
(equal to PArg, in mg/mL) (Figure III.25).  1.85 µM siRNA was considered 
the limit to perform the subsequent in vitro experiments. 
 
Figure III.25. Cell viability assay of System 5 complexes using different 
concentrations of siRNA, developed in B16F10 cells and determined by MTS 
assay 24 h post-incubation. HEPES was used as control. Data expressed as 
mean ± SD, n≥4.  
In the subsequent activity study (silencing luciferase expression, 
Figure III.26), significant transfection was not observed, even using high 
siRNA concentrations. The amount of endosomolytic agent in the 
coating polymer at non-toxic concentrations could be not enough for an 
efficient endosomal escape. Furthermore, the electrostatic bonding 
between the oligonucleotide and PArg might be too stable resulting in 
a lack of dissociation within the endosome. 
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Figure III.26. Gene silencing from System 5 complexes at N/P 6 line using 1.85 
µM siRNA and the same amount of coating agent than PArg, in B16F10 cells. 
HEPES was used as control. Data expressed as mean ± SD, n≥4.    
In view of the results, another strategy was proposed based on the 
synthetic polyaminoacid P(Orn), precursor of PArg. 
III.2.3 Poly-L-Ornithine (P(Orn))-Based Systems (Systems 6-8) 
Continuing with the exploration of the different alternatives within 
the field of polypeptides, it was proposed to developed a new strategy 
based on the positively charged synthetic polyaminoacid P(Orn). As in 
the case of PArg, ornithine is expected to enhance gene delivery due to 
the cationic charge of its pendant amino groups at physiological pH.  
However, P(Orn) binding slightly weaker than PArg (pKa 10.7 ornithine 
vs. pKa 12.5 arginine) will give rise to systems capable of being 
dissociated within the endosome. The cationic charge contributed to 
the binding and condensation of the oligonucleotide and, in parallel 
with lysine, is used in cell penetrating peptides [20, 57, 58]. P(Orn) has 
been shown to be up to 10-fold more efficient than other cationic 
polymers such as PLL (the most commonly utilised model cationic 
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polymer in laboratory gene delivery investigations) in the transfection 
of a variety of cell lines (e.g. B16 murine melanoma cells) [59, 60]. 
Three different P(Orn)-based designs were developed in order to 
find the best combination for an effective gene delivery. Complexation 
(Systems 6 and 8) and conjugation (System 7) strategies were 
considered for this purpose (Figure III.27) 
 
Figure III.27. Schematic representation for the tested P(Orn) systems. 
III.2.3.1. System 6 - Coated P(Orn)-Based Polyplexes 
III.2.3.1.1. DNA Binding Assay Electrophoresis 
In System 6, we used P(Orn) (50 ornithine units) as a sequestering 
agent and PGA-based derivatives as coating agents. N/P ratio and the 
amount of coating agent (PGA100 and DB88) were optimised by gel shift 
assay proving the P(Orn) ability to form complexes even using small N/P 
ratios (Figure III.28). 
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Figure III.28. (A) dsDNA binding ability of P(Orn) at different N/P ratios. (B) 
Coating agent optimisation by agarose electrophoresis. c= 26.5 µg/mL P(Orn) 
per 500 ng dsDNA for N/P 2 and 58.5 µg/mL P(Orn) per 500 ng dsDNA for N/P 
4. 
III.2.3.1.2. DLS Measurements- ζ-Potential 
Table III.12 shows how ζ-potential changes according to the coating 
agent as well as the amount of coating agent used. Systems with 
positive ζ-potential values were selected as the most appropriate 
candidates in order to check their stability in the presence of heparin 
(Section III.2.3.1.3). 
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Table III.12. ζ-potential for the selected P(Orn) complexes. 
P(Orn) 
P(Orn) concentration  
(µg/mL per 500 ng 
oligonucleotide) 
N/P Coating Agent 
Coating Agent Concentration  
(µg/mL) 
ζ-potentiala 
 (mV) 
P(Orn)50 26.5 2 - - 20.5 ± 0.4 
 26.5 2 PGA100 13.25 27.2 ± 0.8 
 26.5 2 PGA100 26.5 -7.2 ± 0.2 
 26.5 2 DB88 26.5 12.5 ± 0.8 
 26.5 2 DB88 53.0 -7.0 ± 0.5 
P(Orn)50 58.5 4 - - 39.2 ± 3.3 
 58.5 4 PGA100 58.5 24.0 ± 1.15 
 58.5 4 DB88 58.5 10.9 ± 0.4 
a As determined by DLS in 20 mM HEPES buffer at 25˚C.  Polyplexes were diluted 1:20 before measurement. Variations refer to 
the median of three measurements of the sample. 
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III.2.3.1.3. Heparin Displacement Assay 
The relative stability of System 6 compounds was evaluated by 
measuring dsDNA release in the presence of the heparin as described 
previously. Following incubation of the studied systems with 10 IU of 
heparin, we found a poor stability for all the complexes tested at an 
amount of heparin lower than the average heparin levels in human 
plasma (15 IU/100 mL) (Figure III.29).  
 
Figure III.29. Heparin displacement assay for System 6 complexes by agarose 
gel electrophoresis. c= 26.5 µg/mL P(Orn) per 500 ng dsDNA for N/P 2 and 58.5 
µg/mL P(Orn) per 500 ng dsDNA for N/P 4. 
Seeking greater stability, we designed System 7 aiming to entrap 
covalently the oligonucleotide, thus resisting the path to the desired 
target without suffering any damage. 
III.2.3.2. System 7 - P(Orn)-Based Conjugates for Oligonucleotide 
Conjugation 
III.2.3.2.1. Synthetic Approaches 
In order to compare the coated P(Orn) complexes with P(Orn) 
conjugates, System 7 was developed by functionalising the P(Orn) (50 
units ornithine) backbone with PD (Figure III.30). The P(Orn)-derivative 
obtained, POPD (8 mol% PD), is presented in Table III.13. 
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Figure III.30. Schematic representation of POPD synthesis. 
The 1H NMR spectrum in D2O with corresponding assignments for 
the synthesised POPD compound is depicted in Figure III.31. 
 
Figure III.31. 1H NMR spectrum with assignments for POPD. 
III.2.3.2.2. DNA Binding Assay Electrophoresis 
dsDNA (22 bp dsDNA) was covalently linked to P(Orn) backbone via 
disulphide bond formation, as in the case of System 2, testing 
afterwards the degree of the reaction and the stability of the final 
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conjugate (Figure III.32). TCEP (tris(2-carboxyethyl)phosphine) was used 
as reducing agent. 
 
Figure III.32. Gel shift and heparin displacement assays for POPD using 
different amounts of polymer keeping constant the amount of dsDNA (500 ng). 
Figure III.32 demonstrates that if conjugation occurs, free DNA is 
complexed after cleavage. The addition of TCEP (0.5 M) had no effect 
while, the addition of heparin 1 IU triggered a clear shift of the dsDNA 
suggesting that there is no conjugation but there is complexation. Due 
to the poor stability of Systems 6 and 7, a new system was conceived 
(System 8). 
III.2.3.3. System 8 - P(Orn)-Based Conjugates for Oligonucleotide 
Complexation 
III.2.3.3.1. Synthetic Approaches 
For System 8, P(Orn) (50 units ornithine) was functionalised in 
three different manners using PEG (MW 2000, PEG2000 and 3000, 
PEG3000), PEG-Fmoc (MW 3000, PEG3000-Fmoc) and PD via amide bond 
formation obtaining four systems: POP1 and POP2 (P(Orn) modified 
with PEG2000 and PEG3000 respectively), POPF (P(Orn) modified with 
PEG3000-Fmoc), and POPD (P(Orn) modified with PD). The addition of the 
non-ionic, hydrophilic PEG polymer aims to provide stealth properties 
to the final polyplex avoiding recognition by immune system as well as 
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increasing molecule size, thereby reducing clearance from the 
bloodstream impeding rapid excretion through the reticulum 
endothelium system (RES) [61]. Otherwise, the presence of the 
hydrophobic pendent Fmoc moiety will induce conformational changes 
allowing to compare the behaviour of both POP and POPF conjugates.  
The obtained products are schematically represented in Figure III.33 
and their composition is shown in Table III.13. 
 
Figure III.33. Schematic representation for the obtained P(Orn) derivatives. 
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Table III.13. Composition of P(Orn) derivatives estimated by 1H NMR. 
Conjugate Polymer Id Loading (mol%) 
P(Orn)-PEG2000 POP1 1.8 
P(Orn)-PEG3000 POP2 1.4 
P(Orn)-PEG3000-Fmoc POPF 2.7 
P(Orn)-PD POPD 8 
 
The 1H NMR spectrum in D2O with corresponding assignments for 
the synthesised POP1 and POP2 compounds are depicted in Figure 
III.34. 
 
Figure III.34. 1H NMR spectrum with assignments for POP1 and POP2. 
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III.2.3.3.2. DNA Binding Assay Electrophoresis 
Polyplex formation was carried out in HEPES 20 mM pH 7.4, and 
oligonucleotide complexation was proved by gel shift assay, comparing 
P(Orn) derivatives with non-modified P(Orn) in order to select the best 
N/P ratio (Figure III.35). N/P 4 was selected for further assays. 
 
Figure III.35. Gel shift assay for P(Orn)-based polyplexes at different N/P ratios. 
III.2.3.3.3. RBC Lysis Assay 
Following the same rational and characterisation explained for the 
previous systems, polyplex ability to induce RBC lysis in vitro  was 
determined as a preliminary  indicator of haematocompatibility [48]. 
Haemolytic profiles obtained are represented in Figure III.36. P(Orn) 
derivatives demonstrated to be non-haemolytic and, therefore, do not 
promote breakage of the RBC membrane confirming their suitability for 
IV administration. 
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Figure III.36. Erythrocyte leakage assay for P(Orn) derivatives at different pH 
values: compounds were incubated with erythrocytes at different 
concentrations at 37°C at indicated pH values. Haemoglobin release was 
measured after 1 h. Data expressed as mean ± SD, n= 3. 
III.2.3.3.4. DLS Measurements- Particle Size and ζ-Potential 
Variations in size and ζ-potential of each P(Orn) derivative- 
polyplex varied slightly comparing data at pH 7.4 and pH 5.5 (Table 
III.14). These results suggest that the polyplexes will be stable, in terms 
of pH, along the delivery pathway until reach the desired target.
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Table III.14. Particle size and ζ-potential for P(Orn) derivatives at N/P 3 and two different pH, 7.4 and 5.5. 
siRNA 
polyplex 
pH 7.4 pH 5.5 
Sizea 
(d, nm) 
ζ-potentiala  
(mV) 
PdIa 
Sizea 
(d, nm) 
ζ-potentiala 
 (mV) 
PdIa 
P(Orn) 55.8 ± 5.2 29.2 ± 0.4 0.443 ± 0.011 38.9 ± 9.6 31.3 ± 1.6 0.352 ± 0.031 
POPD 68.5 ± 3.2 24.1 ± 1.8 0.267 ± 0.020 43.5 ± 9.5 30.5 ± 0.6 0.217 ± 0.011 
POP1 35.7 ± 1.9 18.2 ± 0.6 0.366 ± 0.004 36.1 ± 9.1 17.1 ± 1.3 0.365 ± 0.015 
POP2 27.2 ± 8.9 10.6 ± 1.4 0.353 ± 0.085 36.5 ± 2.6 7.2 ± 0.9 0.255 ± 0.015 
POPF 36.5 ± 2.2  16.9 ± 1.9 0.410 ± 0.010 31.5 ± 13.7 15.7 ± 0.5 0.377 ± 0.019 
a As determined by DLS in 20 mM HEPES buffer at 25˚C. Polyplexes were diluted 1:20 before measurement. Size 
values are expressed in terms of number. Variations refer to the median of three measurements of the sample.
 
 
III.2.3.3.5. Biological Evaluation of System 8 Complexes: Gene 
Silencing, Cell Viability, and Cellular Internalisation In Vitro  
Gel shift assay with System 8 complexes at N/P 4 was performed to 
assess their stability in cell culture media in view of later in vitro studies. 
As it can be observed in the figure below (Figure III.37), free siRNA was 
not detected after 5h incubation at 37˚C proving the stability of the 
polyplexes under these conditions and their suitability for next 
experiments. 
 
Figure III.37. Gel shift assay for System 8 complexes at N/P 4 with and without 
cell culture media. Complexes in cell culture media at 37˚C were incubated 
during 5 h and diluted 1:4. 
After these encouraging results, gene knockdown efficiency was 
investigated following the same silencing study with luciferase (Section 
III.4.4.19, Figure III.38). B16F10Luc cells were incubated 24 hours with 
the different P(Orn) derivatives complexed with luc siRNA at N/P 3 and 
N/P 4 ratios. 
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Figure III.38. (A) Gene silencing form System 8 conjugates in B16F10 cell line at 
N/P 3 and N/P 4, 24 h post-incubation. (B) Determination of cell viability for 
System 8 complexes in B16F10 cells at N/P 3 and N/P 4 ratios, determined by 
MTS assay 24 h post-incubation. HEPES was used as control. Data expressed as 
mean ± SD, n≥4.    
In the case of N/P 4 ratio, gene silencing was reliable but cell 
mortality was higher than 20%. Pursuant to ISO 10993-5, percentages 
of cell viability above 80% are considered as non-cytotoxicity; within 
80%–60% weak; 60%–40% moderate and below 40% strong cytotoxicity 
respectively [62]. However, at N/P 3, cell viability increased and 40% of 
gene silencing was obtained. 
Aiming to demonstrate gene silencing sustainability, incubation 
time was increased (48 h) and a clear improvement in terms of silencing 
was obtained while low toxicity was maintained (Figure III.39).  
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Figure III.39. (A) Gene silencing data form System 8 complexes at N/P 3 in 
B16F10 cell line, 48 h post-incubation. (B) Cell viability of the polyplexes in 
B16F10 cell line by MTS assay at N/P 3 ratio and 48 h post-incubation. Data 
expressed as mean ± SD, n≥4. 
Aiming to determine the cell trafficking pathway, a kinetic study 
using the InCell Analyzer device to observe the cellular internalisation 
of the P(Orn) derivatives at different times, from 0 min to 5 hours, was 
carrying out.   
Figure III.40A shows one of the images obtained concluding a clear 
time-dependent internalisation of POP2-6FAM-siRNA. Figure III.40B 
shows cell internalisation vs. time for all the P(Orn) derivatives. 
 
Figure III.40.  (A) Cell Internalisation for POP2 at 2 h post-treatment by using 
InCell Analyzer Device. Green: 6-FAM; Blue: Hoechst. (B) Cell Internalisation vs. 
time for POP1, POP2, POPF, and POPD. 
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III.3. CONCLUSIONS 
siRNA induced RNA interference is a promising strategy for the 
treatment of various cancers via the regulation of previously 
undrugable targets. However, the delivery process remains as the most 
crucial limitation and this hampers therapeutic/clinical development. 
Along this thesis chapter, different multifunctional polymeric platforms 
based on natural or synthetic polyaminoacids (PGA, PArg, and P(Orn)) 
and their derivatives were synthesised and physicochemically 
characterised to discover a successful vehicle for an effective gene 
delivery. It has to be remarked that all systems were display a low index 
of polydispersity (Ɖ   ̴ 1.2) due to the controlled polymerisation 
techniques employed for their obtaining [26, 27, 31] and, therefore, 
precise and well-defined structures, allowing reproducibility and the 
determination of a clear structure activity relationship. 
PGA-based systems were successfully designed and synthesised 
exploring both conjugation and complexation strategies. However, the 
lack of stability and an inefficient endosomal escape made us focus on 
the use of polycations under the same rational as previously mentioned 
PGA systems. The well-known polycationic PArg was explored for 
oligonucleotide complexation. The guanidine headgroup of arginine 
would be the critical structural component responsible for the possible 
biological activity. PArg have been widely used as cell-penetrating agent 
in the biomedical fields. Polyarginines composed of simple and short 
sequences are readily applicable as gene delivery carriers and cell 
permeable enhancers [63-65]. However, in gene delivery systems, such 
polymers by themselves cannot easily be used as an encapsulating 
agent due to their unstable linear structures, low molecular weights, 
and relatively low electron charge density compared to nucleic acids 
such as DNA and siRNA. To overcome the weak condensation for both 
short sequences of polyarginine and nucleic acid, different well-defined 
polymers with more than 50 units of polycation arginine were selected 
for oligonucleotide complexation. Furthermore, after complexation, the 
systems were coated with PGA or DB in order to end up with haemo- 
and bio-compatible systems and to provide “stealth” properties to 
polyplexes for future in vivo application. Nevertheless, probably due to 
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an inefficient endosomal release, these compounds were not able to 
transfect efficiently, even using coating agents with endosomolytic 
moieties. The amount of endosomolytic agent in the coating polymer at 
non-toxic concentrations could be not enough.  
Continuing the exploration of alternatives within the field of 
polypeptides, another strategy based on positively charged synthetic 
P(Orn) was investigated. As in the case of PArg, ornithine was expected 
to enhance the gene delivery ability due to the cationic charge of its 
pendant amino groups at physiological pH. These can contribute to the 
binding and condensation of the oligonucleotide and, in parallel with 
lysine, form parts of cell penetrating peptides [66]. P(Orn) (50 units 
ornithine) was functionalised in three different manners using PEG (MW 
2000, PEG2000 and 3000, PEG3000), PEG-Fmoc (Mw 3000, PEG3000-Fmoc) 
and PD via amide bond formation obtaining four systems: POP1 and 
POP2 (P(Orn) modified with PEG2000 and PEG3000 respectively), POPF 
(P(Orn) modified with PEG3000-Fmoc), and POPD (P(Orn) modified with 
PD). The addition of the non-ionic, hydrophilic PEG polymer aims to 
provide stealth properties to the final polyplex avoiding recognition by 
immune system as well as increasing molecule size, thereby reducing 
clearance from the bloodstream impeding rapid excretion through the 
reticulum endothelium system (RES) [63]. Otherwise, the presence of 
the hydrophobic pendent Fmoc moiety will induce conformational 
changes allowing to compare the behaviour of both POP and POPF 
conjugates.  Their nanosize and positive surface charge were found to 
be favourable for in vitro application (non-cytotoxic and non-
haemolytic). More importantly, the polyplexes successfully transfected 
a luciferase-transfected melanoma cell model (B16F10-luc-G5), 
evidencing the potential of this polypeptidic platform.  Further analyses 
are being carried out in order to validate this system. 
III.4. MATERIALS AND METHODS 
III.4.1. Materials 
All chemicals were reagent grade and used without further 
purification. N-butyl polyglutamic-L-acid sodium salt (PGA), methoxy-
poly(ethylene glycol)-poly(L-glutamic acid) sodium salt diblock (DB), n-
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butyl poly-L-arginine hydrochloride (PArg), and n-butyl poly-L-ornithine 
hydrochloride (P(Orn)) were from Polypeptide Therapeutic Solutions SL 
(PTS, Spain). DMTMM·Cl was synthesised essentially as described in ref 
[67]. L-Histidine methyl ester dihydrochloride (Hist, 97%) and L-arginine 
methyl ester dihydrochloride (Arg, 98%) were purchased from ACROS 
OrganicsTM. 3-Morpholinopropylamine (Morph) and amino-2-propanol 
(ApOH, 93%) were obtained from Sigma-Aldrich. MeO-PEG(2000)-
COOH, MeO-PEG(3000)-NHS, and Fmoc-PEG(3000)- NHS were obtained 
from Iris Biotech. Single stranded DNA (ssDNA, 16-22 nucleotides) 
sequences, thiol hexane labelled single stranded DNA sequence (ssDNA-
C6-SH), 6-FAM single stranded DNA sequence (ssDNA-FAM) were 
obtained from Biomers.net GmbH. Luciferase GL3 double stranded 
siRNA (ds-siRNA), 21 nucleotides per strand, D-001400-01-20, control 
ds-siRNA and transfecting agent DharmaFECT® 1 were provided by 
Fisher Scientific. Pyridyl dithiol ethylamine HCl salt was synthesised 
essentially as described in ref [68]. Deuterated solvent D2O was 
purchased from Deutero GmbH. Water is defined in this chapter as 
deionised water with a conductance below 0.06 µS. Dialysis were 
performed in dialysis devices featuring proprietary Ultra-pure Biotech 
Cellulose Ester (CE) Membrane with 1, 3 or 10 kDa MWCO (Float-A-
Lyzer®). Preparative SEC was performed using Sephadex G-25 superfine 
from GE. 
III.4.2. Cell Culture 
Murine melanoma cells B16F10-luc-G5 which stably expresses 
firefly luciferase were grown in DMEM medium supplemented with 10% 
FBS, 2 mM L-glutamine, 100 IU/mL penicillin, 100 µL/mL streptomycin 
at 37°C in a humidified atmosphere containing 5% CO2 and 95% air. 
III.4.3. Characterisation Techniques 
III.4.3.1. Nuclear Magnetic Resonance (NMR) Spectroscopy 
1H and DOSY NMR spectra were recorded on a Bruker AC 300 or on 
a Bruker AV500 at room temperature (RT) and at a frequency of 300 
MHz and 500 MHz respectively. Pulsed field gradient NMR spectroscopy 
was used to measure translational diffusion by fitting the integrals or 
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intensities of the NMR signals to the Stejskal-Tanner [69, 70] equation: 
I= I0 exp[-Dγ2g2δ2(Δ-δ ⁄ 3)] where I is the observed intensity, I0 the 
reference intensity (unattenuated signal intensity), D the diffusion 
coefficient, γ the gyromagnetic ratio of the observed nucleus, g the 
gradient strength, δ the length of the gradient, and Δ the diffusion time. 
Two-dimensional diffusion-ordered NMR spectroscopy (DOSY) was 
performed with a stimulated echo sequence using bipolar gradient 
pulses. The lengths of delays were held constant at Δ= 100 ms, and 32 
spectra of 64 scans each were acquired with the strength of the 
diffusion gradient varying between 5% and 95%. The lengths of the 
diffusion gradient and the stimulated echo were optimised for each 
sample. Typical values were δ = 3 ms for the analysis of both oligomers 
and PGA-based conjugates. All data were processed and analysed using 
the MestreNova 6.2 software. 
III.4.3.2. Dynamic Light Scattering (DLS) 
For DLS measurement, the polymer solution was measured in a cell 
DTS 1070 with laser light scattering using a Zetasizer Nano ZS with 
backscatter detection (Malvern Instruments, Worcestershire, UK). For 
size measurements, the equilibration time was 0 min, the temperature 
was 25˚C, and an automatic attenuator was used. The refractive index 
of the solvent, in our case water, was 1.330 and hence, the viscosity was 
0.8872. For polyplex analysis of the particles the refractive index of 
polystyrene latex (1.590) was used. Each sample was measured 3 times 
with 10 subruns. The Zeta () potential was calculated by the 
Smoluchowski model. Therefore 10 up to 30 subruns of 10 s at 25°C 
(n=3) were measured.  
III.4.3.3. Cellular Internalisation via InCell Analyzer Device 
B16F10 cells were seeded in a black 96-well plate with flat and clear 
bottom at a density of 7500 cells/cm2 (100 µL cell suspension per well) 
and allowed to adhere for 24 h and then medium was replaced with 
80μL fresh growth medium. 20 µL of fluorophore-labelled polymer 
solution were added and the cells incubated for 0 to 5 h at 37˚C. At each 
sample time, cells were placed on ice, then the medium was removed 
and the cells were washed twice with 100 µL ice-chilled PBS-BSA 0.1% 
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and then 200 µL PBS were added. 30 min before washing the cells with 
PBS-BSA 0.1%, the nuclear marker Hoechst (1 µL from a solution 5 mM) 
was added in order to identify possible co-localisations. Cell-associated 
fluorescence was then analysed using an InCell Analyzer 1000 device. 
Cells incubated without polymer conjugate were used to account for 
the background fluorescence. 
III.4.4. Protocols 
III.4.4.1. General Method for PGA-Hist Synthesis 
In a one neck round bottom flask fitted with a stir bar and stopper, 
1 eq. of PGA sodium salt was suspended in milliQ water. Afterwards 1.3 
eq. of DMTMM·Cl was added dissolved also in milliQ water. 10 minutes 
later, 1 eq. of L-histidine methyl ester dihydrochloride was added and 
the pH was adjusted to 8 by adding some drops of 1M NaHCO3 solution. 
Reaction was allowed to proceed 16 hours stirring at room temperature 
(RT). Dialysis using Float-A-Lyzer at the corresponding MWCO was 
performed in order to purify the polymer. A white powder was obtained 
after freeze-drying.  
1H NMR δH (300 MHz, D2O): 8.58 (1xH, s), 7.31 (1xH, s), 4.37 (1H, m), 
4.14 (1xH, s), 3.81 (3xH, s), 3.36-3.18 (2xH, m), 2.31-1.96 (4H, m). x: 
percentage of modification. 
III.4.4.2. General Method for PGA-Morph Synthesis 
In a one neck round bottom flask fitted with a stir bar and stopper, 
1 eq. of PGA sodium salt was suspended in milliQ water. Afterwards 1.3 
eq. of DMTMM·Cl, also dissolved in milliQ water, was added. 10 minutes 
later, 1 eq. of 3-morpholinopropylamine was added and the pH was 
adjusted to 8 by adding drops of 1M NaHCO3 solution. The reaction was 
allowed to proceed 16 hours stirring at RT. Dialysis using Float-A-Lyzer 
at the corresponding MWCO was performed in order to purify the 
polymer. A white powder was obtained after freeze-drying.  
1H NMR δH (300 MHz, D2O): 4.33 (1H, m), 3.98 (2xH, s), 3.30-3.15 (4xH, 
m), 3.36-3.18 (2xH, m), 2.39-1.98 (4H + 2xH, m). x: percentage of 
modification. 
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III.4.4.3. General Method for PGA-X-ApOH Synthesis 
In a one neck round bottom flask fitted with a stir bar and stopper, 
1 eq. of PGA-X (X means Hist or Morph) was suspended in milliQ water. 
Afterwards 1 eq. of DMTMM·Cl, also dissolved in milliQ water, was 
added. 10 minutes later, 1 eq. of amino-2-propanol was added and the 
pH was adjusted to 8 by adding drops of 1M NaHCO3 solution. The 
reaction was allowed to proceed 16 hours stirring at RT. Dialysis using 
Float-A-Lyzer at the corresponding MWCO was performed in order to 
purify the polymer. A white powder was obtained after freeze-drying.  
1H NMR δH (300 MHz, D2O): 4.33 (1H, m), 3.21-2.94 (3xH, m), 3.30-3.15 
(4xH, m), 2.34-1.98 (4H, m), 1.16 (3xH, s). x: percentage of modification. 
III.4.4.4. General Method for PGA-R-Arg Synthesis 
In a one neck round bottom flask fitted with a stir bar and stopper, 
1 eq. of PGA-R (R means Hist or Morph) was suspended in milliQ water. 
Afterwards 1 eq. of DMTMM·Cl, also dissolved also in milliQ water, was 
added. 10 minutes later, 1 eq. of L-arginine methyl ester 
dihydrochloride was added and the pH was adjusted to 8 by adding 
drops of 1M NaHCO3 solution. The reaction was allowed to proceed 16 
hours stirring at RT. Dialysis using Float-A-Lyzer at the corresponding 
MWCO was performed in order to purify the polymer. A white powder 
was obtained after freeze-drying.  
1H NMR δH (300 MHz, D2O): 4.45 (1xH, s), 4.33 (1H, m), 3.79 (2xH, s), 
2.39-1.87 (4H + 4xH, m). x: percentage of modification. 
III.4.4.5. Oligonucleotide Complexation to PGA-R-X 
Polyplex formulations for gel shift experiments were prepared as 
follows: 200 ng of dsDNA and the calculated amount of PGA-R-X (where 
R is Hist or Morph and X is ApOH or Arg) at indicated +/- ratios were 
diluted in separate tubes in 10 µL of 20 mM HEPES buffered pH 7.4 each. 
Only protonatable nitrogens, not amide nitrogens, were considered in 
the +/- calculations. The nucleic acid and the polymer solution were 
mixed by rapidly pipetting up and down (at least 5 times) and incubated 
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for 30-40 min at RT in order to form the polyplexes necessary for gel 
shift experiments. 
III.4.4.6. General Method for PGA-R-X-PD Synthesis 
In a one neck round bottom flask fitted with a stir bar and stopper, 
1 eq. of PGA-R-X (R means Hist or Morph, and X means ApOH or Arg ) 
was suspended in milliQ water. Afterwards 0.2 eq. of DMTMM·Cl was 
added dissolved also in milliQ water. 10 minutes later, 0.1 eq. of pyridyl 
dithiol ethylamine HCl salt was added and the pH was adjusted to 8 by 
adding some drops of 1M NaHCO3 solution. Reaction was allowed to 
proceed 16 hours stirring at RT. Dialysis using Float-A-Lyzer at the 
corresponding MWCO was performed in order to purify the polymer. A 
white powder was obtained after freeze-drying.  
1H NMR δH (300 MHz, D2O): 8.43 (1xH, m), 7.88 (2xH, m), 7.33 (1xH, m), 
4.33 (1H, m), 3.48 (2xH, m), 2.95 (2xH, m), 2.39-1.90 (4H, m). x: 
percentage of modification. 
III.4.4.7. General Oligonucleotide Conjugation to PGA-R-X-PD 
To conjugate the thiol labelled dsDNA to PGA-R-X-PD, 1-32 eq. of 
PGA-R-X-PD (depending on the case) were dissolved in PBS and mixed 
with the same volume of thiolated dsDNA containing x eq. of 
oligonucleotide (x is the percentage of PD modification) and the 
reaction mixture was incubated overnight at 37˚C with continuous 
shaking (500 rpm). 
III.4.4.8. General Oligonucleotide Complexation to PArg or P(Orn) 
and Coating  
System 4, 5 and 7 compounds were prepared by mixing the amount 
of dsDNA (200 ng) or siRNA (500 ng) and PArg or P(Orn) at indicated 
nitrogen/phosphate (N/P) ratios each in HEPES 20 mM pH 7.4. The 
nucleic acid was added to the polycation, rapidly mixed and incubated 
for 15 min at RT. After that, the corresponding amount of coating agent 
(PGA100 or DB88) was added and incubated again during 15 min at RT. 
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III.4.4.9. POPD Synthesis 
30 mg of P(Orn) 50 units (0.153 mmol, 1 eq.) were dissolved in 1 
mL of PBS-EDTA under agitation at RT. Then, 0.1 eq. of PD (4.8 mg, 0.015 
mmol) were dissolved in 200 µL of DMSO and added drop by drop to 
the P(Orn) solution. After one hour in agitation, the reaction was 
lyophilised. Residue was resuspended in 300 µL of milliQ water and 
purified using a PD10 column containing Sephadex G25 resin.  
1H NMR δH (300 MHz, D2O): 8.41-7.31 (4xH, m), 4.34 (1H, m), 3.21-3.06 
(4xH + 2H, m), 1.82 (4H, m). x: percentage of modification. 
III.4.4.10.System 7 Polyplex Formation 
System 7 polyplexes were prepared by dissolving the amount of 
dsDNA or siRNA and oligomers at indicated nitrogen/phosphate (N/P) 
ratios each in HEPES 20 mM pH 7.4. The nucleic acid was added to the 
polycation, rapidly mixed and incubated for 20-30 min at RT. 
III.4.4.11. Synthesis of POP1 
All reagents were weighed in 5 mL vials and stoppered with rubber 
septa. Vials were purged under N2 and P(Orn) was dissolved in 1 mL 
DMSO anhydrous under magnetic stirring. PEG was dissolved in 1 mL 
DMSO under the same conditions and after the solution was taken with 
a syringe and dropped in the P(Orn) vial. A catalytic amount of 
DMTMM·BF4 (dissolved in 300 µL DMSO) was added with the same 
protocol. Then, pH was adjusted to 8 with DIEA and reaction was left 
under magnetic stirring for 72 h. 
The reaction was transferred to a 5 mL round bottom flask and 
DMSO was evaporated under vacuum. The obtained residue was 
dissolved in 300 µL of milliQ water and it was purified over a PD10 
column. Fractions were lyophilised and the obtained solids were 
analysed by 1H NMR and DOSY (D2O). 
1H NMR δH (300 MHz, D2O): 4.41 (1H, m), 3.74(44xH + 4H m), 3.07 (2H, 
m), 1.82 (4H, m). x: percentage of modification. 
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III.4.4.12. Synthesis of POP2 
All reagents were weighed in 5 mL vials and stoppered with rubber 
septa. Vials were purged under N2 and P(Orn) was dissolved in 2 mL 
DMSO anhydrous under magnetic stirring. PEG was dissolved in 1 mL 
DMSO under the same conditions and placed in the P(Orn) vial. A 
catalytic amount of DMAP (dissolved in 200 µL DMSO) was added with 
the same protocol. Then, pH was adjusted to 8 with DIEA and reaction 
was left under magnetic stirring for 36 h. 
The reaction was transferred to a 5 mL round bottom flask and 
DMSO was evaporated under vacuum. The obtained residue was 
dissolved in 300 µL of milliQ water and it was purified using a PD10 
column (500 µL fraction, t.1-2 of 1 mL each, 30 fractions). Fractions were 
lyophilised and the obtained solids were analysed by 1H NMR and DOSY 
(D2O). 
1H NMR δH (300 MHz, D2O): 4.41 (1H, m), 3.74(68xH + 4H m), 3.07 (2H, 
m), 1.82 (4H, m). x: percentage of modification. 
III.4.4.13. Synthesis of POPF 
All reagents were weighed in 5 mL vials and stoppered with rubber 
septa. Vials were purged under N2 and P(Orn) was dissolved in 2 mL 
DMSO anhydrous under magnetic stirring. PEG was dissolved in 1 mL 
DMSO under the same conditions placed in the P(Orn) vial. A catalytic 
amount of DIEA (dissolved in 200 µL DMSO) was added with the same 
protocol. Then, pH was adjusted to 8 with DIEA and reaction was left 
under magnetic stirring for 72 h. 
The reaction was transferred to a 5 mL round bottom flask and 
DMSO was evaporated under vacuum. The obtained residue was 
dissolved in 300 µL of milliQ water and it was purified using a PD10 
column (500 µL fraction, t.1-2 of 1 mL each, 30 fractions). Fractions were 
lyophilised and the obtained solids were analysed by 1H NMR and DOSY 
(D2O). 
1H NMR δH (300 MHz, D2O): 4.41 (1H, m), 3.74(68xH + 4H m), 3.07 (2H, 
m), 1.82 (4H, m). x: percentage of modification. 
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III.4.4.14. DNA and siRNA Binding Assay by Electrophoresis  
For dsDNA, a 1% agarose gel was prepared by dissolving agarose in 
TAE buffer (Tris base, acetic acid and EDTA) and boiling to 100°C. After 
cooling down to 50°C and the addition of EtBr, the agarose gel was cast 
in the electrophoresis unit. Polyplexes or conjugates containing 200 ng 
of dsDNA in 20 µL HEPES and loading buffer were placed into the sample 
wells. Electrophoresis was performed at 80 V for 80 min. For siRNA, a 
2.5% agarose gel containing EtBr was prepared. Polyplexes or 
conjugates containing 500 ng of siRNA in 20 µL HEPES and loading buffer 
were placed into the sample wells. Electrophoresis was performed at 80 
V for 40 min. 
III.4.4.15. Red Blood Cell (RBC) Lysis Assay 
Erythrocytes (RBC, red blood cells) were isolated from fresh whole 
mouse blood obtained by cardiac puncture after death and placed in a 
heparinised tube. Blood was diluted with PBS pH 7.4 up to 10 mL and 
then centrifuged (3000 rpm, 10 min, 4°C) three times, removing the 
supernatant after each centrifugation and re-suspending the cells in 
sterile PBS. The final RBC pellet was weighed and re-suspended at 2% 
(v/v) in PBS. To study the haemolytic activity of the systems, the systems 
were dissolved in PBS stock solutions adjusted to pH 6.5 or 7.4 and 
citrate solution adjusted to pH 5.5. Then samples were added to wells 
(n=3, 100 μL) covering the concentration range 0.1-0.01 mg/mL of 
systems. Buffer at the corresponding pH was used as a control together 
with Triton X–100 1% (w/v) to determine a 100% RBC lysis. The plates 
were then incubated at 37°C for 1 h. To assess haemoglobin (Hb) release 
the plates were then centrifuged (3000 rpm, 10 min, 20°C) and the 
supernatant of each well was transferred into a new plate. The Hb 
released was assessed by measuring the absorbance at 570 nm using 
Victor2 WallaceTM plate reader. The percentage of haemolysis of each 
sample was calculated relative to 100% haemolysis obtained from 
incubation with Triton-X 100. 
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III.4.4.16. Buffer Capacity- Potentiometric Titration 
The polymer sample containing 15 μmol protonatable amines was 
diluted in a total volume of 3.5 mL NaCl solution (50 mM) and the pH 
was adjusted to 2.1 by addition of 0.1 M HCl. Afterwards, a back titration 
with 50 mM NaOH solution was performed until a pH of 11 was reached. 
Furthermore a titration with 50 mM NaCl was performed and the 
consumption of NaOH in this control titration was subtracted from the 
consumption in the polymer titrations at the corresponding pH values. 
Percentage of buffer capacity C in a certain pH range (x - y), where ΔV 
stands for the volume consumption of NaOH in the considered pH 
range, was calculated according to Equation III.1 
𝐶𝑝𝐻𝑥−𝑦 =
∆𝑉𝑝𝐻𝑥−𝑦×0.05𝑀
0.015 𝑚𝑚𝑜𝑙
 × 100                                               Equation III.1 
where C is the total buffer capacity between the indicated pH values (%) 
and ΔV is the volume difference between the indicated pH values (mL). 
III.4.4.17. Plasma Stability by Gel Shift Assay 
For the investigation of plasma stability, polymer-DNA conjugates 
prepared as in Section III.4.4.7, were incubated in a solution containing 
20% mice serum at 37˚C and different incubation times: 0 h, 0.5 h, 1 h, 
2 h, and 5 h. Then, an agarose electrophoresis assay was performed 
using the same protocol than in Section III.4.4.14. 
III.4.4.18. Cell Culture Media Stability by Gel Shift Assay 
For the investigation of cell culture media stability, polymer-DNA 
conjugates prepared as in Section III.4.4.7, were incubated in a solution 
containing 80% cell culture media at 37˚C and different incubation 
times. Then, an agarose electrophoresis assay was performed using the 
same protocol than in Section III.4.4.14. 
III.4.4.19. Luciferase Gene Silencing In Vitro and Luciferase Assay 
B16F10 luc cells were plated on 96-well plates (7500 cells/well) in 
100 µL of medium containing 10% FBS 24 h prior to the transfection. 
Cells were incubated with the developed systems or the positive control 
(DharmaFECTTM) containing luc siRNA or control siRNA. At 48 h after 
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treatment cells were treated with 20 µL of Bright-Glo™ reagent. 
Luciferase activity was read spectrophotometrically using Victor2 Wallac 
plate reader. Relative light units (RLU) were presented as percentage of 
the luciferase gene expression obtained with buffer treated control 
cells. 
III.4.4.20. MTS Assay for Cell Viability Evaluation 
B16F10 luc cells were seeded into 96-well plates (7500 cells/well) 
in 100 µL of medium containing 10% FBS. After 24 h, culture medium 
was replaced with 80 μL fresh growth medium containing 10% FCS and 
20 μL of transfection complexes solution at different +/- ratios were 
added. All studies were performed in quintuplicate. 48 h post-
treatment, 20 μL of manufacturer solution containing MTS/PMS (20:1) 
was added to each well, and the cells were incubated for a further 2 h. 
Optical density of each well was measured spectrophotometrically at 
490 nm using Victor2 Wallac plate reader. The absorbance values were 
represented as the percentage of cell viability taken as 100% cell 
viability of untreated control cells. 
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The work presented within this thesis chapter was carried out 
thanks to a collaboration between the Polymer Therapeutics lab and the 
research group of Dr. Barbara Cellini at the Department of Neurological 
Biomedical and Movement Sciences at the University of Verona (Italy). 
A publication entitled “Use of Polymer Conjugates for the 
Intraperoxisomal Delivery of Engineered Human Alanine:Glyoxylate 
Aminotransferase as a Protein Therapy for Primary Hyperoxaluria Type 
I” in the journal Nanomedicine: Nanotechnology, Biology and Medicine 
has been the result of this collaborative work [1]. 
IV.1. INTRODUCTION AND BACKGROUND 
The delivery of active proteins to cells or living organisms 
constitutes another example of therapy that requires effective cytosolic 
transport. This therapeutic approach is used for many pathologic 
conditions and a variety of protein drugs are already in the market [2]. 
In the case of loss-of-function genetic diseases caused by enzyme 
deficits, enzyme administration replenishes the target organism with 
the absent or defective protein, thus partly or completely rescuing the 
clinical phenotype. Although the initial application of this approach was 
limited to circulating proteins, in the last few decades enzyme 
replacement therapy has been successfully applied to other disorders 
including phenylketonuria, the deficit of adenosine deaminase, and 
some lysosomal storage diseases [3-5].  
Alanine:glyoxylate aminotransferase (AGT) is a pyridoxal 5’-
phosphate (PLP)-dependent enzyme that catalyses an overall 
transamination reaction converting L-alanine and glyoxylate to 
pyruvate and glycine, respectively [6]. The protein is a homodimer 
(molecular weight (MW) 86 KDa) belonging to the fold Type I family of 
PLP-enzymes. Each monomer comprises an N-terminal stretch of 20 
residues that wraps the surface of the adjacent subunit, a large domain 
(residues 21-282) forming most of the active site and of the 
dimerisation interface, and a small domain (residues 283-392) 
containing the peroxisomal targeting sequence (PTS) (Figure IV.1A). As 
with most peroxisomal proteins, AGT folds in the cell cytosol and is then 
translocated to peroxisomes in its fully-folded dimeric state. 
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Peroxisomal import occurs through the formation of a complex 
between AGT and the Pex5p carrier. The interaction is weak and is 
mediated by a non-canonical –KKL type 1 PTS (PTS1) and by an 
“extended PTS1” formed by residues 381–388 and 327–330 (Figure 
IV.1B) [7]. 
 
Figure IV.1. AGT dimeric structure. (A) The AGT dimer (PDB file 1H0C) is 
coloured as follow: one monomer is pale orange and the other is grey with 
exposed Cys residues represented as red sticks. PLP is represented as green 
sticks. (B) Representation of the interaction between the C-term domain of 
Pex5p receptor (green) and AGT (grey). On AGT the PTS1 and the extended 
PTS1 are coloured cyan and blue, respectively; Cys387 is coloured red. 
AGT deficit causes Primary Hyperoxaluria Type I (PH1), a rare 
genetic disease characterised by an abnormally high concentration of 
urinary oxalate. This leads to the deposition of calcium oxalate (CaOx) 
crystals in the kidneys and urinary tract causing urolithiasis and 
nephrocalcinosis [8-10]. This can progress to end-stage-renal-disease 
and to a potentially fatal condition called systemic oxalosis with CaOx 
deposition in various tissues [11, 12]. The only pharmacologic approach 
Chapter IV 
225 
 
available to treat PH1 is the administration of vitamin B6, although this 
is only effective in a minority of the patients (25-35%). The best option 
for unresponsive subjects is liver transplantation, which replaces the 
entire enzyme pool but entails several undesired side effects [12, 13]. 
Thus, the design of new treatment strategies represents an urgent 
need. 
PH1 displays a loss-of-function pathogenesis because the absence 
of functional AGT prevents the detoxification of glyoxylate inside liver 
peroxisomes, leading to its cytosolic accumulation and oxidation to the 
metabolic end-product oxalate [8, 10]. Thus, an enzyme administration 
strategy to replenish the liver with active AGT may relieve disease 
symptoms. In this regard, a study recently demonstrated that an AGT-
cell-penetrating Tat-peptide fusion protein (Tat-AGT) can be 
successfully transduced in a mammalian model of PH1 and restores the 
glyoxylate detoxification ability of the cells [14]. Although these data 
provided the proof-of-principle for the feasibility of AGT administration, 
the direct intravenous administration of Tat-AGT is not feasible as it 
would elicit an aggressive immune response [15].  
In the present thesis chapter, we evaluated the feasibility of the 
delivery of AGT by conjugating the enzyme with a polymeric 
nanocarrier. This masks the proteins from the immune system, 
improves its stability in the bloodstream, and increases cargo transport 
across the plasma membrane [16]. Multifunctional telechelic 
biodegradable polymers represent an exciting technology in the field of 
protein delivery by means of polymer conjugation approaches. Many 
polymer conjugates are already in the market with demonstrated 
clinical benefit including the well-known PEGylated proteins [17-20]. 
Polypeptide-based carriers, in particular poly-L-glutamic acid 
homopolymers (PGA) as polymer-drug conjugates and 
polyethylenglycol (PEG)-PGA block-co-polymers as polymeric micelles 
have been widely exploited as delivery systems as they have 
demonstrated safety and excellent pharmacologic properties in the 
clinic [17, 21]. However, PGA-derived carriers have not been widely 
studied for protein conjugation [22]. Recently, in our laboratory, the 
formation of disulphide bonds between reactive thiol groups after PGA 
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derivatisation and free cysteines (Cys) exposed on the protein surface 
has been described [23, 24]. Once internalised, the reducing 
environment of the cell cytosol can cleave the covalent linkage, thus 
allowing the release of the free protein cargo [24, 25]. Based on this, a 
strategy has been constructed to efficiently conjugate recombinant 
purified AGT with a PEG-PGA block-co-polymer functionalised with 
pyridyl dithiol (PD) groups able to react with free thiol groups forming a 
reversible disulphide bond. We show that conjugation with PEG-PGA 
does not significantly alter the functional properties of AGT and endows 
the protein with the ability to cross the plasma membrane and localise 
in the cytosol of a cellular model of PH1. Engineering AGT by the 
insertion of a stronger PTS and the mutation of one of the polymer 
anchoring points located on the “extended PTS1” partly decreases the 
conjugation efficiency. However, this allows peroxisomal targeting of 
the conjugates, resulting in the enhanced ability to detoxify 
intraperoxisomal glyoxylate with respect to the wild-type protein.  
IV.2. RESULTS AND DISCUSSION 
IV.2.1. Synthetic Methodologies 
IV.2.1.1. Synthesis of Pyridyl Disulphide Modified PEG-PGA 
We modified PEG-PGA diblock with pyridyl dithiol ethylamine using 
4-(4,6-Dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride 
(DMTMM·Cl) as a carboxylic acid activator according to methodology 
previously described in Chapter II. After purification via ultrafiltration, 
we analysed the freeze-dried product by NMR to determine the degree 
of modification. This achieved a total loading of 14 mol% corresponding 
to 11 glutamic acid units (GAU) out of the total 80. From the percentage 
of modification, the MW of the pyridyl dithiol PEG-PGA was calculated 
to be 15,715 Da. 
IV.2.1.2. Conjugation of PEG-PGA with AGT 
To conjugate purified recombinant AGT with PEG-PGA the 
formation of reduction-sensitive disulphide bonds after PGA 
derivatisation with free Cys exposed on the protein surface was used 
[24, 25]. The crystal structure of AGT shows that Cys253, Cys366 and 
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Cys387 are located near the surface of the protein and could be 
employed as conjugation sites (Figure IV.1A) [26]. As a preliminary 
experiment, we used the thiol-reactive probe 5,5-dithiobis(2-
nitrobenzoate) (DTNB) to verify the presence of solvent-exposed 
cysteine residues potentially available for the conjugation process. It 
was discovered that three out of the six Cys residues present on each 
monomer were reactive toward DTNB, although with different kinetics. 
Titration of the first thiol group of each monomer occurred with a t1/2 of 
4.4 min, while the titration of the other two groups occurred with a t1/2 
of 65 min, thus suggesting that one of the Cys was more exposed to the 
solvent. Moreover, by measuring the transaminase activity of the DTNB-
treated enzyme, it was found that the titration did not significantly 
compromise the enzyme catalytic activity. These data support the use 
of a strategy based on the formation of disulphide bonds to allow PEG-
PGA conjugation. 
The conjugation was carried out by mixing equal volumes of AGT 
and PEG-PGA. Preliminary experiments were performed at different 
polymer:protein molar ratios (from 5:1 to 15:1) and also at different 
incubation times (from 1 to 48 h) to achieve optimal conjugation 
conditions. The achieved yield was greater than 90% by using a 5:1 ratio 
and by incubating the mixture over night at 25°C. The unbound polymer 
was then removed by forced dialysis. Conjugation of AGT with PEG-PGA, 
altered the electrophoretic pattern of AGT, which appeared as a 
smeared band at MWs higher than that of the unconjugated monomer 
(Figure IV.2). As PEG-PGA alone does not give any signal upon staining 
[24, 27], the smeared band is probably indicative of different levels of 
conjugation. The incubation of PEG-PGA-AGT conjugates with 10 mM 
reduced glutathione for 1 h at 37°C, a condition mimicking the reducing 
environment of the cell cytosol, led to the disappearance of the smear 
and the complete recovery of the band corresponding to the 
unconjugated monomer.  
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Figure IV.2. Evaluation of the PEG-PGA-AGT conjugation efficiency. 6 
μg of protein were loaded in each lane and stained with Coomassie Blue. Lanes 
were loaded as follow: 1. PEG-PGA-AGT conjugation mixture; 2 PEG-PGA-AGT 
conjugates treated with GSH. 3. Unconjugated AGT. 
These results confirm that pyridyl dithiol functionalised PEG-PGA 
can be used to efficiently conjugate AGT at room temperature. The 
process can be reversed by application of mild reducing conditions, 
confirming specificity of the conjugation and supporting the possibility 
of intracellular payload release. 
IV.2.2. Biochemical Characterisation of the PEG-PGA-AGT 
Conjugates 
One main challenge in the development of protein-polymer 
conjugates is the possible irreversible modification of the protein that 
may compromise its functionality [25]. To assess if PEG-PGA conjugation 
of AGT altered the biochemical properties of the enzyme, we compared 
spectroscopic and kinetic properties of the PEG-PGA-AGT conjugates 
with those of the unmodified protein. The molar extinction coefficient 
at 280 nm cannot be used to determine protein concentration in the 
conjugates due to interference from the polymer moiety. Thus, we 
determined AGT concentration by Bradford assay or an indirect assay 
based on the measurement of the PLP content of the sample (taking 
into account that AGT binds two moles of PLP per dimer). In each 
experiment, the results obtained using the two methods did not differ 
by more than 10%.  
 As already described [6], purified recombinant AGT displays an 
absorbance band in the visible region centred at 423 nm associated with 
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a positive dichroic band at 429 nm, and a shoulder at about 340 nm, 
associated with a negative dichroic band at 335 nm. These bands have 
been previously attributed to the ketoenamine and enolimine 
tautomers of the internal aldimine. Additionally, the circular dichroism 
(CD) spectrum displayed positive dichroic bands in the aromatic region 
at 285 and 290 nm and a negative dichroic band in the 256–266 nm 
region, probably related to the position of aromatic amino acids located 
in the microenvironment of the active site [6]. As shown in Figure IV.3A, 
conjugated and unconjugated AGT displayed similar dichroic features in 
the UV-visible region, thus indicating that the conjugation process did 
not significantly alter the coenzyme binding mode and the AGT tertiary 
structure. This is in agreement with the finding that intrinsic 
fluorescence emission spectra of the two species are characterised by 
an identical emission maximum at 337 nm and by a similar emission 
intensity (Figure IV.3B).  
 
Figure IV.3. Spectral properties of PEG-PGA-AGT (dotted line) and 
unconjugated AGT (continuous line). (A) CD spectra were taken at 8 µM 
enzyme concentration. (B) Intrinsic fluorescence spectra were taken at 1 µM 
enzyme concentration (λexc 280 nm). All measurement were performed in 100 
mM KP buffer pH 7.4. 
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Next, the steady-state kinetic parameters of conjugated and 
unconjugated AGT for the overall transamination of the L-
alanine/glyoxylate pair was measured (Table IV.1). PEG-PGA-AGT 
conjugates displayed Km for the substrates comparable to those of 
native AGT and a maximum specific activity value equal to  ̴80% with 
respect to unconjugated AGT. Upon GSH treatment, the specific activity 
of the released enzyme was not significantly different from that of the 
unconjugated enzyme. Thus, the conjugation process has only a limited 
impact on the catalytic properties of AGT and the small modification 
caused by the polymer does not irreversibly compromise the protein 
properties. This is in line with the finding that the DTNB titration does 
not alter the AGT activity. 
Table IV.1. Kinetic parameters for the L-alanine/glyoxylate transamination of 
unconjugated and conjugated AGT. 
Species Substrate Co-substrate Kcat (s-1) Km (mM) 
AGT L-alanine 
Glyoxylate 
Glyoxylate 
L-alanine 
45 ± 2a 
45 ± 3a 
31 ± 4a 
0.23 ± 0.05a 
PEG-PGA-AGT L-alanine 
Glyoxylate 
Glyoxylate 
L-alanine 
33 ± 1 
35 ± 2 
39 ± 3 
0.18 ± 0.04 
PEG-PGA-AGT 
after GSH 
treatment 
L-alanine 
Glyoxylate 
Glyoxylate 
L-alanine 
48 ± 5 
42 ± 4 
35 ± 4 
0.21 ± 0.05 
a From ref. [5] 
Dynamic Light Scattering (DLS) and Size-Exclusion Chromatography 
(SEC) analyses were also used to gain insight into the molecular 
dimensions of the PEG-PGA-AGT conjugates. As shown in Figure IV.4A, 
the unconjugated polymer was mainly present as two species 
characterised by a hydrodynamic diameter of 5.1 ± 0.3 nm and 199 ± 10 
nm. Since the DLS intensity signal is proportional to the sixth power of 
a particle diameter, the specie at the lower diameter was the most 
abundant in solution. Unconjugated AGT displayed a hydrodynamic 
diameter of 7.9 ± 0.3 nm, in agreement with previous reports [28-30]. 
Upon conjugation, a main peak with a size of 15 ± 4 nm was present, 
consistent with the formation of the protein-polymer complex. 
Accordingly, while the elution volume of unconjugated AGT on SEC was 
Chapter IV 
231 
 
30.6 mL, PEG-PGA-AGT conjugates eluted as a mixture of two peaks at 
23.2 and 25.6 mL, along with a shoulder at 30 mL, the elution volume of 
unconjugated AGT (Figure IV.5B). By collecting fractions corresponding 
to each peak and analysing by sodium dodecyl sulphate-polyacrylamide 
gel electrophoresis (SDS-PAGE), we found that fraction 1 mainly 
contained conjugates at high molecular weight (HMW) (>200 KDa) and 
fraction 2 mainly contained conjugates at low molecular weight (LMW) 
(<200 KDa). Meanwhile, fraction 3 was predominantly made up of the 
small amount of unconjugated AGT remaining in the mixture. The 
formation of conjugates at different MWs is not unexpected based on 
the previous SDS-PAGE results and can be rationalised in terms of a 
different conjugation degree, which in turn depends on the different 
reactivity of the three -SH groups exposed on the surface of each AGT 
subunit. In agreement with this hypothesis, no free -SH was titrated in 
the HMW fraction of conjugates, thus implying that they are 
characterised by the highest conjugation degree. Since a higher 
conjugation degree should improve the transduction efficiency [31-34], 
we investigated if an increased PEG-PGA/AGT ratio drove the formation 
of HMW conjugates. However, neither a 10:1 nor a 15:1 ratio led to any 
significant change in the relative population of the different PEG-PGA-
AGT conjugates, probably due to steric hindrance and accessibility of 
the protein reactive sites.  
 
Figure IV.4. Molecular dimension analyses of AGT and PEG-PGA-AGT. (A) DLS 
evaluation of the average diameter of the species. (B) Elution profile 
(absorbance at 280 nm) of AGT 7.5 μM (- -) and PEG-PGA-AGT conjugation 
mixture 7.5 μM (-). The solutions were loaded on a Superdex S200 H10/30 SEC 
column and fractions were collected by peak. In the inset the SDS-PAGE 
analyses of SEC fractions of PEG-PGA-AGT. Al measurements were performed 
in phosphate buffered saline (PBS). 
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Overall, these data indicate that AGT can be efficiently bound to 
PEG-PGA leading to the formation of conjugates at different MWs 
without significantly compromising the enzyme structural and 
functional properties. This finding is an important prerequisite for the 
use of the PEG-PGA-AGT conjugates as therapeutics, as it guarantees 
that the protein will function once internalised in the cell.  
IV.2.3. Cellular Uptake of PEG-PGA-AGT Conjugates in Eukaryotic 
Cells 
While the ability of PGA-based nanocarriers to be internalised into 
eukaryotic cells has already been well documented, the internalisation 
mechanisms are still debated [33, 34]. We investigated the cellular 
uptake of PEG-PGA-AGT conjugates using a well-recognized cellular 
model of PH1 based on Chinese Hamster Ovary (CHO) cells stably 
expressing glycolate oxidase (GO) [35]. The system has proven to be 
useful not only to understand the molecular bases of the disease, but 
also to test the effectiveness of compounds used to rescue the effect of 
disease-causing mutations [36-42]. 
In preliminary experiments, PEG-PGA-AGT conjugates were added 
at 1 μM concentration to the culture medium of CHO-GO cells for 
different times, ranging from 1 to 24 hours. Thereafter, we harvested, 
extensively washed (to remove conjugates present in the medium) and 
lysed cells, before subjecting the lysates to Western-blotting and 
enzyme activity assays. The expression levels and specific activities of 
CHO-GO cells stably expressing wild-type AGT (CHO-GO-AGT) or treated 
with unconjugated AGT as positive and negative controls, respectively, 
were analysed. Although the presence of intracellular AGT and the 
transaminase activity were detectable starting from 1 hour after 
treatment, maximal internalisation occurred around 7 hours and 
remained stable until 24 hours (Figure IV.5).  
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Figure IV.5. Time course analysis of the delivery of PEG-PGA-AGT to CHO-GO 
cells. CHO-GO cells were treated with 1 μM PEG-PGA-AGT. At different times 
(0, 1, 2, 5, 7, and 24 hours) cells were harvested and analysed by Western-blot 
and enzymatic activity assays. (A) 6 μg of lysate of cells treated with PEG-PGA-
AGT or of CHO-GO-AGT cells were subjected to SDS-PAGE, immunoblotted with 
anti-AGT from rabbit (1:6000) and then detected with a chemiluminescent 
substrate. (B) Histogram representative of the immunoblot band. Bars 
represent the mean ± standard error mean (SEM) of three different 
experiments.  
To test if the transduction efficiency varied with the conjugation 
degree, cells were treated with either HMW or LMW conjugates 
purified by SEC. As shown in Figure IV.6, a faint band of immunoreactive 
AGT was observed upon treatment with LMW conjugates (LMWC), but 
a stronger signal upon treatment with HMW conjugates (HMWC). These 
data suggest that HMWC are more efficiently transduced in cells, in line 
with the finding that larger particles are usually endowed with an 
enhanced ability to be internalised [32].  
 
Figure IV.6. Internalisation of HMWC and LMWC in CHO-GO cells. Cells were 
treated with 5 μM HMWC, LMWC or unconjugated AGT for 24 hours. For 
western-blot analyses 6 μg of cell lysate were subjected to SDS-PAGE, 
immunoblotted with anti-AGT from rabbit (1:6000) and detected using a 
chemiluminescent substrate. 
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Upon treatment of CHO-GO cells with increasing amounts of HMW 
PEG-PGA-AGT, as exhibited in Figure IV.7A and Figure IV.7B, the 
presence of intracellular AGT starting from 0.6 μM concentration and 
this increased up to 5 μM concentration was detected. It should be 
noted that, the treatment concentration of the conjugates being equal, 
the amount of immunoreactive AGT and the specific activity level 
achieved by CHO-GO cells transduced with unpurified conjugates was 
about 3-fold lower than that observed in cells treated with purified 
HMWC, in line with the increased transduction ability of the latter. 
 
Figure IV.7. Dose-response analysis of CHO-GO cells treated with HMW PEG-
PGA-AGT and unpurified PEG-PGA-AGT. Cells were treated with increasing 
concentrations of HMW PEG-PGA-AGT or with 5 μM unpurified PEG-PGA-AGT 
for 24 hours. (A) Western-blot. 6 μg of cell lysate were subjected to SDS-PAGE, 
immunoblotted with anti-AGT from rabbit (1:6000) and detected using a 
chemiluminescent substrate. (B) Histogram representative of specific activity 
values of CHO-GO cells treated with increasing concentration of HMW PEG-
PGA-AGT (grey) or with 5 μM unpurified PEG-PGA-AGT (black). The AGT 
transaminase activity was measured by incubating 100 μg of lysate with 0.5 M 
L-alanine, 10 mM glyoxylate and 200 μM PLP at 25°C in 100 mM KP, pH 7.4. 
Bars represent the mean of three different experiment + SEM. Immunoblot 
lanes and histogram bars are coded as follow lane 1 to 5: CHO-GO cells treated 
with HMW PEG-PGA-AGT at 0.3, 0.6, 1.15, 2.5 and 5.0 μM concentration, 
respectively; lane 6: CHO-GO cells treated with 5 μM unpurified PEG-PGA-AGT. 
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The internalisation of PEG-PGA-AGT conjugates was further 
investigated by confocal microscopy to confirm that transaminase 
activity and presence of immunoreactive AGT in CHO-GO cells treated 
with PEG-PGA-AGT was due to the presence of intracellular AGT and not 
to conjugates non-specifically bound to the plasma membrane. 
Furthermore, this analysis can provide insight into the subcellular 
localisation of the protein. As a first approach, we performed imaging 
experiments in which AGT was labelled with a fluorescein 
isothiocyanate (FITC) fluorescent probe before conjugation and 
visualised in live cells. Due to the high absorbance of the dye in the 
visible region, we could not analyse the effect of the labelling on the 
absorbance, dichroic, and fluorescence features of the enzyme. 
However, by comparing the enzyme activity of the labelled and 
unlabelled enzyme, we found that AGT-FITC displays transaminase 
activity at saturating substrate concentrations equal to 36 s-1, a value 
very similar to the kcat of the unlabelled enzyme [6]. This strongly 
suggests that the labelling does not significantly alter the AGT functional 
and structural properties.  
AGT-FITC was conjugated to PEG-PGA and the resultant conjugates 
were purified as previously described. CHO-GO cells were treated for 24 
h with either PEG-PGA-AGT-FITC conjugates or unconjugated AGT-FITC 
at 5 μM AGT-equiv. concentration, then extensively washed and 
immediately analysed cells by live cell microscopy after plasma 
membrane staining with the Cell MaskTM Deep Red dye. While no FITC 
signal was present in cells treated with unconjugated AGT-FITC, a clear 
signal was detected within the plasma membrane of cells treated with 
PEG-PGA-AGT-FITC conjugates, as shown in Figure IV.8A. The protein 
appeared partly spread-out in the cytosol and partly located in discrete 
compartments. In agreement with these data, immunofluorescence 
microscopy (IFM) experiments also indicated that AGT was both 
diffused in the cytosol and present as bright spots (Figure IV.8B). 
However, the bright spots staining for AGT did not co-localise with the 
peroxisomal marker (Figure IV.8C), thus suggesting that the conjugated 
protein was not imported into peroxisomes or the levels present were 
below detection limits. 
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Figure IV.8. Analysis of PEG-PGA-AGT internalisation in CHO-GO cells. Cells 
were treated for 24 hours with 5 μM unconjugated or conjugated AGT-FITC (A) 
or 5 μM PEG-PGA-AGT (B). (A) In live cell imaging AGT-FITC is shown in green 
and the plasma membrane is labelled with Cell MaskTM Deep Red (red). (B) For 
IFM experiments cells were fixed, AGT and peroxisomes were detected by 
using the anti-AGT-antibody (green) and the anti-peroxisomal protein antibody 
(red), respectively. Nuclei were stained with DAPI (blue). Merge and individual 
channel images came from a single z-stack. (C) RGB profile plotted along the 
line drawn in the merged image. Scale bar: 10 μm. 
Overall, these data demonstrate that the conjugation to PEG-PGA 
provides catalytically active AGT with the capacity to cross the plasma 
membrane and localise in the intracellular milieu, even if the protein 
seems to be mainly localised in the cell cytosol rather than imported 
into peroxisomes.  
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The details surrounding uptake and intracellular trafficking of 
polymeric nanosystems are still debated and different studies point to 
governance by multiple mechanisms, including macropinocytosis, 
caveolae-mediated endocytosis, and clathrin-mediated endocytosis. 
Notably, macropynosomes can acidify but do not interact with 
lysosomes thus contents escape degradation [34, 43], while contents 
carried via the caveolae-mediated pathway can also possibly avoid 
lysosomal degradation [44]. Therefore, while PEG-PGA-AGT conjugates 
are internalised through various mechanisms and a portion of them 
becomes entrapped inside endosomes, another portion may be 
released in the cell cytosol. Matrix peroxisomal proteins fold in the cell 
cytosol and are then translocated into peroxisomes in the fully folded 
form thanks to the interaction with a specific carrier [45]. AGT should 
be released from the cytosolic portion of PEG-PGA-AGT conjugates and 
should interact with the peroxisomal import machinery. However, the 
failure to detect co-localisation between the AGT signal and the 
peroxisomal marker in IFM experiments led us to conclude that the 
import of transduced AGT was either prevented or strongly affected 
following polymer conjugation of the protein. As previously mentioned, 
the import of AGT depends on the interaction with Pex5p, which is 
mediated by a weak PTS1 made up of a -KKL C-terminal tripeptide [7]. A 
study has recently reported that the substitution of the -KKL sequence 
with the canonical -SKL sequence enhances by ≈50-fold the binding 
affinity of AGT for Pex5p [46]. Moreover, the binding between AGT and 
Pex5p involves ancillary stretches of amino acids in the C-terminal 
region called “extended PTS1” (Figure IV.1B) [7, 47] and the mutation of 
residues located at or near the ancillary targeting region may alter the 
relative position of the receptor with respect to AGT, thus 
compromising the import of the protein [46]. As one of the reactive Cys 
residues exposed on the AGT surface (Cys387) is part of the “extended 
PTS1”, we cannot exclude that PEG-PGA-AGT conjugates underwent a 
partial reduction and that part of the polymer remained bound to 
Cys387, thus explaining the compromised import into peroxisomes.  
 
 
Chapter IV 
238 
 
IV.2.4. Engineering of AGT to Promote Peroxisomal Localisation 
On the basis of the above results and considerations, it was 
reasoned that engineering AGT by the insertion of an -SKL targeting 
sequence at the C-terminus and/or by the mutation of Cys387 may 
promote the correct peroxisomal localisation of the transduced protein. 
Thus, we inserted the K390S mutation in AGT either alone or in 
combination with the C387S mutation, the latter choice dictated by the 
need to induce the smallest perturbation of the chemical-physical 
features of the C-terminus. As a preliminary experiment, we confirmed 
that, when expressed in CHO-GO cells, both variants showed clear 
peroxisomal localisation (data not shown). This implies that the 
mutations do not affect the interaction with the peroxisomal import 
machinery. Thus, purification was made to homogenise and 
characterise the K390S single variant (AGT-SKL) and the C387S/K390S 
double variant (AGT-SSKL). The Lys390 and the Cys387 mutations did 
not induce any significant change to AGT enzymatic activity (Table IV.2) 
and they did not affect the spectroscopic features of the enzyme (data 
not shown).  
Table IV.2. Kinetic parameters for the AGT-SKL and AGT-SSKL variants. 
AGT variant Substrate Co-substrate Kcat (s-1) Km (mM) 
AGT-SKL L-alanine 
Glyoxylate 
Glyoxylate 
L-alanine 
43 ± 2 
42 ± 2 
52 ± 8 
0.11 ± 0.02 
AGT-SSKL L-alanine 
Glyoxylate 
Glyoxylate 
L-alanine 
46 ± 2 
47 ± 2 
53 ± 8 
0.16 ± 0.02 
 
Recombinant purified AGT-SKL displayed a conjugation efficiency 
to PEG-PGA analogous to that of wild-type AGT and gave similar 
amounts of HMW and LMW conjugates purified by SEC. However, the 
C387S/K390S double mutation displayed a 50% reduction in 
conjugation efficiency and no changes were observed upon increasing 
the protein:polymer ratio from 1:5 to 1:15. Moreover, AGT-SSKL only 
formed LMW conjugates. As expected, the unconjugated variant 
exhibited two Cys residues per monomer titrated by DTNB with kinetics 
characterised by a t1/2 of 40 min. These data suggest that the Cys387 
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mutation eliminated the most solvent exposed thiol group and this may 
explain why the conjugation equilibrium of AGT-SSKL shifted toward the 
unconjugated protein with respect to wild-type AGT. Nevertheless, 
PEG-PGA-AGT-SSKL conjugates displayed no exposed cysteine residues, 
thus indicating that the variant achieved the highest possible 
conjugation degree.  
CHO-GO cells were treated for 24 h with either purified PEG-PGA-
AGT-SKL or PEG-PGA-AGT-SSKL conjugates as well as with the 
corresponding unconjugated variants at 5μM concentration as negative 
controls. Then transduced cells were analysed by confocal microscopy 
and, as expected, we did not observe intracellular AGT after treatment 
with the unconjugated variants (data not shown). Treatment of CHO-
GO cells with PEG-PGA-AGT-SKL conjugates led to the accumulation of 
AGT both in the cytosol and in discrete compartments whose signal did 
not co-localise with that of the peroxisomal marker (Figure IV.9), a 
pattern similar to that observed with PEG-PGA-AGT conjugates. 
Interestingly, upon treatment of CHO-GO cells with PEG-PGA-AGT-SSKL 
conjugates, the majority of AGT localised inside peroxisomes, even 
given the presence of AGT staining that did not co-localise with 
peroxisomes (Figure IV.9). These data indicate that the removal of the 
polymer-attachment point at the C-terminus of AGT and the insertion 
of a stronger peroxisomal targeting sequence promoted correct 
peroxisomal localisation. Since the peroxisomal import was not 
effective for the PEG-PGA-AGT-SKL conjugates, it can be concluded that 
the C387S mutation made the conjugates incompatible with the import 
machinery. Based on these results, it can be speculated that when PEG-
PGA-AGT conjugates are transduced into CHO-GO cells, they do not 
undergo complete reduction in the cytosolic environment and that the 
polymer linked to Cys387 may change the conformation of the C-
terminus thus compromising the interaction with Pex5p and 
consequently preventing the peroxisomal import. In the AGT-SSKL 
variant, the C387S mutation does not affect the subcellular localisation 
of AGT per se, but rather avoids the binding of a polymer moiety at the 
C-terminus. This effect, along with the K390S mutation that promoted 
the peroxisomal import [46], explains why the transduction with PEG-
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PGA-AGT-SSKL conjugates results in the presence of intraperoxisomal 
AGT in CHO-GO cells.  
 
Figure IV.9. Analysis of the subcellular localisation of PEG-PGA-AGT-SKL and 
PEG-PGA-AGT-SSKL in CHO-GO cells. Cells were treated for 24 hours with 5 μM 
PEG-PGA-AGT-SKL (A) or 5 μM PEG-PGA-AGT-SSKL (B). Cells were then fixed, 
AGT and peroxisomes were detected by using the anti-AGT-antibody (green) 
and the anti-peroxisomal protein antibody (red), respectively. Nuclei were 
stained with DAPI (blue). Below are reported the RGB profiles plotted along the 
line drawn in the merged image. Merge and individual channel images came 
from a single z-stack. Scale bar: 10 μm. 
To quantify the internalisation yield of AGT-SSKL, the transaminase 
activity of the transduced cells was measured. As expected, any activity 
was detected in cells treated with the unconjugated variant, while cells 
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treated with PEG-PGA-AGT-SSKL conjugates exhibited a specific activity 
of 11.5 nmol/min/mg, a value 7.2-fold lower compared with the value 
obtained in cells transduced with PEG-PGA-AGT conjugates. Taking into 
account the similar kcat values of the double variant in the purified form 
and the wild-type AGT (Table IV.2), the specific activity observed upon 
treatment with the conjugates indicates the amount of transduced 
protein present inside the cell. On this basis, we concluded that PEG-
PGA-AGT-SSKL conjugates are characterised by a lower transduction 
efficiency with respect to PEG-PGA-AGT. This result can be understood 
considering that the conjugation of AGT-SSKL with PEG-PGA only 
generates LMWC, which are expected to have a lower internalisation 
yield with respect to the HMWC formed by wild-type AGT.  
IV.2.5. Glyoxylate-Detoxification Activity of the PEG-PGA-AGT 
Conjugates 
To test whether the internalisation of conjugated AGT was 
effective in restoring the glyoxylate detoxification ability, 1 mM 
glycolate was added to CHO-GO cells transduced for 24 h with either 
PEG-PGA-AGT or PEG-PGA-AGT-SSKL conjugates at 5 μM concentration 
and measured cell viability after 24 h. Cells treated with unconjugated 
AGT and cells stably expressing AGT as negative and positive control, 
respectively, were used. Treatment with glycolate leads to the 
formation of glyoxylate inside CHO-GO cell peroxisomes, due to the 
catalytic activity of GO. Glyoxylate is toxic for the cell, but if catalytically 
active AGT is present, it detoxifies glyoxylate to glycine and prevents cell 
death. Thus, the viability of CHO-GO cells in the presence of glycolate is 
an indirect measure of the amount of functional AGT present in the cell 
[35].  
Figure IV.10 demonstrates a viability of cells stably expressing AGT 
of around 80%, while a 20% viability of untreated cells and of cells 
treated with unconjugated AGT. Treatment with PEG-PGA-AGT or PEG-
PGA-AGT-SSKL conjugates increased cell viability up to 70% and 45%, 
respectively. These data indicate that the conjugation of AGT to PEG-
PGA mediates the delivery of a functional enzyme with the ability to 
restore the glyoxylate detoxification of CHO-GO cells. It was noted that 
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cells treated with PEG-PGA-AGT-SSKL displayed an AGT specific activity 
about 7-fold lower than that of cells treated with PEG-PGA-AGT. 
Nevertheless, we found that cell viability upon transduction with PEG-
PGA-AGT-SSKL was only 1.5-fold lower as compared to cells transduced 
with PEG-PGA-AGT. Although cell viability does not linearly depend on 
the AGT specific activity of the cells, these results suggest that, given an 
equal transduction efficiency, PEG-PGA-AGT-SSKL conjugates are 
significantly more effective in restoring the glyoxylate detoxifying ability 
of the cells. This may be explained by the finding that conjugated wild-
type AGT has a cytosolic localisation, while the conjugated AGT-SSKL 
variant is able to reach the peroxisomal matrix, where glyoxylate is 
formed. In this regard, the finding that conjugated AGT present in the 
cytosol still protects cells from glycolate toxicity is probably due to the 
fact that glyoxylate formed inside peroxisomes is exported to the 
cytosol, where it can be detoxified by the enzyme.  
 
Figure IV.10. Specific activity and viability in the presence of glycolate of CHO-
GO cells treated with different conjugated and unconjugated AGT variants. 
Grey bars: cell viability after 24 hours of treatment with 0.9 mM glycolate 
measured by the crystal violet colorimetric assay and expressed as percentage 
with respect to the untreated control. Six replicates have been measured for 
each sample. Black bars: AGT transaminase activity in the cell lysate detected 
by incubating 100 μg of lysate with 0.5 M L-alanine, 10 mM glyoxylate and 200 
μM PLP at 25°C in 100 mM KP, pH 7.4. Histogram Bars are coded as follow: 
CHO-GO; untreated cells, PEG-PGA-AGT; CHO-GO cells treated with 5 μM PEG-
PGA AGT for 24 h, PEG-PGA-AGT-SSKL; CHO-GO cells treated with 5 μM PEG-
PGA AGT-SSKL for 24 h, CHO-GO-AGT; CHO-GO cells stably expressing AGT and 
AGT; CHO-GO cells treated with 5 μM unconjugated AGT for 24 h. Vertical bar 
indicate the SEM. 
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IV.2.6. Stability and Haemocompatibility Studies 
 To assess stability in the circulation, PEG-PGA-AGT conjugates and 
unconjugated AGT were incubated in human plasma at 37°C and time-
dependent changes of the total amount of soluble protein in each 
sample were determined. The results reported in Figure IV.11A indicate 
the progressive disappearance of the signal corresponding to 
immunoreactive AGT for the unconjugated protein starting from 24 h 
and reaching a value of 30% at 48 h incubation. However, a loss of 
immunoreactive AGT was observed upon incubation of PEG-PGA-AGT 
conjugates in plasma, thus suggesting that conjugation protects the 
enzyme from degradation. A similar behaviour was observed with PEG-
PGA-AGT-SSKL conjugates.  
We then performed an ex vivo red blood cells (RBC) haemolysis 
assay to assess the biocompatibility of the conjugates. Human RBCs  
were incubated at 37°C with PEG-PGA-AGT or PEG-PGA-AGT-SSKL 
conjugates at 5 μM concentration and  the percentage of haemolysis 
after a 1 h incubation was determined. Phosphate buffered saline (PBS) 
and 0.9% NaCl as negative controls and 1% Triton X-100 as the positive 
control were used. The results (Figure IV11B) indicate that the presence 
of the conjugates did not significantly increase haemolysis with respect 
to the negative controls.  
Overall, the data obtained suggest that the conjugates are stable 
in biological fluids and will not induce toxic effects in circulating cells. 
Considering that circulation stability and biocompatibility are two of the 
most important parameters influencing the performance of polymeric 
conjugates under in vivo conditions [2, 48], these results represent 
important findings in view of the possible future development of PEG-
PGA-AGT and PEG-PGA-AGT-SSKL for therapeutic applications. 
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Figure IV.11. Stability and haemocompatibility of AGT conjugates. (A) 5 μM 
conjugated and unconjugated AGT were incubated in human serum at 37°C. At 
different times 2 μl of the mixtures were withdrawn, subjected to SDS-PAGE, 
immunoblotted with anti-AGT from rabbit (1:6000) and detected by using a 
chemiluminescent substrate. The WB bands of conjugated (grey) and 
unconjugated (black) AGT were quantified and plotted as function of time. (B) 
Absorbance at 570 nm representative of the haemolytic activity under the 
indicated conditions. 
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IV.3. CONCLUSIONS 
We report a strategy to conjugate AGT to PEG-PGA diblock-co-
polymers through the formation of disulphide bonds, as well as the 
successful use of the obtained conjugates to restore glyoxylate 
detoxification in eukaryotic cells mimicking a PH1 phenotype. Our 
protocol allowed us to achieve a high conjugation yield without 
significant effects to the functional properties of the enzyme. The 
obtained conjugates are internalised by CHO-GO cells, a well-accepted 
cellular model of PH1, and are mainly found in discrete compartments 
in the cytosol. Furthermore, they efficiently detoxify endogenously 
produced glyoxylate. By applying a protein engineering approach, we 
generated a mutated form of AGT bearing the substitution of Cys387-
to-Ser and of Lys390-to-Ser (AGT-SSKL), to favour the interaction with 
the peroxisomal targeting machinery. PEG-PGA-AGT-SSKL conjugates 
internalised into CHO-GO cells are imported into peroxisomes and are 
more effective in glyoxylate detoxification with respect to PEG-PGA-
AGT conjugates. In vitro data confirm a high stability in plasma and an 
excellent hemocompatibility of conjugated AGT, thus suggesting that 
the conjugates are suitable for intravenous injection. Overall, these data 
support the exploitation of this system to replenish PH1 patients with a 
catalytically active and correctly localised enzyme able to counteract 
the deficit responsible for oxalate accumulation. As polymer-based 
nanoconjugates have been widely employed for the delivery of 
therapeutic proteins, mainly due to their versatility and 
biocompatibility [19, 20, 49], these results using a biodegradable carrier 
constitute a fundamental step in the future development of a safer 
enzyme administration therapy effective for all PH1 patients 
independent of the type of mutation.  
The correct targeting of a protein drug is an important issue, 
particularly in the case of disorders involving peroxisomal enzymes 
whose functionality is strongly influenced by the subcellular localisation 
[50]. Previous reports on the administration of catalase inside 
peroxisomes to rescue reactive oxygen species (ROS)-induced damage 
were based on the use of an enzyme derivative endowed with a non-
covalently bound cell-penetrating peptide [51-53]. To the best of our 
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knowledge, the strategy outlined in this chapter is the first report of a 
PGA-based conjugate designed for the efficient delivery of a 
catalytically active therapeutic protein to the peroxisome. Thus, it 
represents an exciting strategy to implement for other diseases caused 
by deficiencies of peroxisomal enzymes.  
IV.4. MATERIALS AND METHODS 
IV.4.1. Materials 
 PLP, L-alanine, sodium glyoxylate, L-lactic dehydrogenase from 
rabbit muscle, isopropyl-β-D-thiogalactoside (IPTG), EDTA and 
imidazole were all purchased from Sigma Aldrich. Ham’s F12 Glutamax 
medium, PBS, FITC, zeocin and Hoechst were purchased from Life 
Technologies. The rabbit polyclonal anti-AGT human antibody was 
kindly provided by Prof. C.J. Danpure of University College London (UK); 
the anti-rabbit HRP antibody and the AlexaFluor 488 and 555 were 
purchased from Life Technologies. Methoxy-poly(ethylene glycol)-
poly(L-glutamic acid) sodium salt diblock (mPEG(2000)-PGA(80)[Na]; 
Mn = 14200, Mw/Mn = 1.16) was provided from Polypeptide 
Therapeutic Solutions SL (PTS, Spain). DMTMM chloride was 
synthesised according to literature [22]. Pyridyl dithiol ethylamine HCl 
salt was synthesised as described in [54]. 1H NMR spectra were obtained 
at 300 MHz using a FT-spectrometer (Bruker) and analysed using the 
MestReNova 6.2 software. Vivaspin centrifugal concentrator tubes 
were from GE Healthcare. 
IV.4.2. Synthesis of Pyridyl Disulphide (PD) Modified Diblock 
(PEG-PGA-PD) 
PD-modified diblock was synthesised by post-polymerisation 
modification with DMTMM chloride using a modified published method 
[55]. In detail, 100 mg of diblock PEG-PGA in its sodium salt form (0.570 
mmol, 1 equivalent (eq.)) was suspended in 6 mL of milliQ water. Next, 
47.2 mg of DMTMM chloride (0.170 mmol, 0.3 eq.) dissolved in 2 mL of 
water were added, and the mixture was stirred for 15 min to activate 
the carboxyl acid groups of PGA. Then, 19 mg of pyridyl dithiol 
ethylamine (0.085 mmol, 0.15 eq.) dissolved in 2 mL of water were 
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added, the pH was adjusted to 8 by the addition of 1M NaHCO3 solution, 
and the reaction mixture was stirred overnight. Finally, the reaction 
mixture was purified by ultrafiltration using vivaspin tubes with a 
molecular weight cut-off (MWCO) of 3 kDa. The purified product was 
recovered by freeze-drying. Yield: 85%. Labelling efficiency: 99%.  
1H NMR (300 ppm, D2O, δ): 8.43 (1xH, m), 7.84 (2xH, m), 7.28 (1xH, 
m), 4.36 ppm (1H, m), 3.74 ppm (s, PEG chain), 2xH, m), 2.95 (2xH, m), 
2.39-1.90 (4H, m). x: percentage of modification. 
IV.4.3. Protein Expression and Purification 
The vectors coding the K390S variant (AGT-SKL) and the 
C387S/K390S double variant (AGT-SSKL) were obtained from the AGT-
Ma-NoHis construct [56] using the QuikChange II site-directed 
mutagenesis kit (Stratagene). The mutations were introduced by using 
the primers: 5’-GAT GGT CTC ACA GCT TGC TCT TGG GGC AGT GCT G 
and its complement, and the primer 5’-GGT CTC ACA GCT TGC TCT TGG 
GGC TGT GCT GCA GGG C-3' and its complement for the K390S and the 
C387S mutation, respectively. All mutations were confirmed by DNA 
sequencing. Protein expression and purification were performed as 
previously reported [57]. Protein concentration was determined using 
the apparent molar absorption coefficient of 95400 M-1 cm-1 at 280 nm. 
The PLP content was determined either by releasing the cofactor in 0.1 
M NaOH using the apparent molar absorption coefficient of 6600 M–1 
cm–1 at 388 nm, or by high performance liquid chromatography (HPLC) 
analysis as previously described [57]. 
IV.4.4. AGT-FITC Conjugation 
10 mg of FITC (Molecular Probes) was dissolved in 1 mL of dimethyl 
sulfoxide (DMSO), following the manufacturer protocol. 100 µL of the 
FITC solution was added to 1 mL of AGT (1 mg/mL) in 0.1 M NaHCO3, pH 
9.0, to reach a final FITC: AGT ratio of 100:1 (w/w). The mixture was 
then incubated in the dark at room temperature for 1 hour. In order to 
remove excess FITC, the mixture was loaded on a PD-10 column 
previously equilibrated in phosphate saline buffer and the eluate was 
collected in 0.5 mL fractions. 5 μL of each fraction was diluted in 100 μL 
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of PBS on a 96 well/plate and the absorbance at 495 nm was measured. 
Fractions with the highest absorbance were pooled and the protein 
content was quantified by Bradford assay.  
IV.4.5. Polymer-AGT Conjugation 
 Purified recombinant AGT, AGT-FITC, AGT-SKL, and AGT-SSKL were 
diluted in PBS to a final concentration of 15 μM. PEG-PGA was dissolved 
in 150 mM ammonium acetate, pH 6 to a final concentration of 75 μM. 
The two solutions were mixed in equal volumes to obtain a 5:1 molar 
ratio between polymer and protein. The mixture was incubated 
overnight at 25°C to allow conjugation and then concentrated by using 
Amicon Ultra centrifugal devices (MWCO 30 kDa) and washed twice 
with PBS to remove the excess of PEG-PGA. The conjugation efficiency 
was verified by SDS-PAGE under non-reductive conditions or after 1h 
incubation at 37°C with 10 mM reduced glutathione. 
IV.4.6. Conjugate Purification 
AGT-Ma, AGT-SKL, and AGT-SSKL conjugates were loaded onto a 
Sephacryl S300 SEC column (GE Healthcare), equilibrated in PBS, using 
an AKTA FPLC system (Amersham Biosciences). Elution was monitored 
by following absorbance at 280 nm and fractions corresponding to each 
peak were collected. The protein content of each fraction was 
determined using Bradford assay and the conjugation degree was 
verified by SDS-PAGE. 
IV.4.7. Enzymatic Activity Assays 
The transaminase activity of the analysed AGT variants in the 
purified recombinant form and conjugated form were determined by 
incubating each enzyme sample (0.1 μM) with saturating 
concentrations of the two substrates (0.5 M L-alanine, 10 mM 
glyoxylate) in 100 mM potassium phosphate buffer (KP) pH 7.4 in the 
presence of 200 μM PLP. Mixtures were incubated at 25°C for 10 
minutes, and the reaction was stopped by adding 10% trichloroacetic 
acid (w/v). The amount of pyruvate produced was measured by a 
spectrophotometric assay coupled with lactate dehydrogenase [6]. For 
the measurement of the AGT specific activity in CHO-GO cells, 90 μg of 
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cell lysate were incubated with 0.5 M L-alanine and 10 mM glyoxylate 
at 25°C in 100 mM KP, pH 7.4 in the presence of 200 μM PLP. The 
reaction time was set to 10 min for cells stably expressing AGT and to 
60 min for cells transduced with PEG-PGA-AGT and PEG-PGA-AGT-SSKL 
conjugates. The reactions were stopped by adding 10% TCA (w/v) and 
pyruvate production was measured by the spectrophotometric assay 
described above [6].  
IV.4.8. Titration of Cysteinyl Groups 
For the titration of exposed -SH groups, a solution of PEG-PGA 
conjugates or unconjugated protein at 5 μM concentration in 100 mM 
KP, pH 7.4 was treated with DTNB at 100-fold excess over the protein 
cysteinyl content as determined by amino acid composition. The 
increase in the absorbance at 412 nm was registered with time and a 
molar extinction coefficient of 13600 M-1 cm-1 was used to calculate the 
concentration of titrated -SH groups from the total absorbance change. 
The rate constants for the reaction of the exposed -SH groups with 
DTNB were calculated by fitting the time-dependent change in the 
absorbance at 412 nm to a double or a single exponential curve for PEG-
PGA-AGT or PEG-PGA-AGT-SSKL, respectively. 
IV.4.9. Spectroscopic Measurements 
 Absorption measurements were made with a Jasco V-550 
spectrophotometer with 1 cm path length quartz cuvettes at a protein 
concentration of 1-10 μM in 100 mM KP, pH 7.4. Intrinsic fluorescence 
emission spectra were recorded on a Jasco FP-750 spectrofluorimeter 
equipped with a thermostatically controlled cell holder by using a 1 cm 
path length quartz cuvette. Protein emission spectra were taken from 
300 to 500 nm (excitation at 280 nm) with both the excitation and the 
emission slits set to 5 nm. The protein concentration was 0.1-1 μM. 
Spectra of blanks were taken immediately before the measurements of 
samples containing protein. CD measurements were taken with a Jasco 
J-710 spectropolarimeter at a protein concentration of 5–10 μM, by 
using 1 cm path length cells. Routinely, three spectra were recorded at 
a scan speed of 50 nm/min with a bandwidth of 2 nm and averaged 
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automatically. All the spectral measurements were carried out in 100 
mM KP, pH 7.4, at 25°C.  
IV.4.10. Dynamic Light Scattering (DLS) Measurements 
DLS measurements were performed on a Zetasizer Nano S device 
from Malvern Instruments in PBS at a protein concentration of 7.5 μM 
for unconjugated and conjugated proteins and 0.5 mg/mL for the free 
polymer. The temperature of sample cell was set to 25°C by a Peltier 
temperature control system and 12.5 Å  ̴45-mm disposable cells with 
stopper were used. 
IV.4.11. Cell Culture and Conjugates Transduction 
CHO cells stably expressing GO and CHO-GO cells stably expressing 
AGT were cultured as previously reported [42]. For protein transduction 
experiments, CHO-GO cells were seeded in a 6 cm dish at 6.0 x 105 
cells/dish. After 24 hours the medium was replaced with fresh Ham’s 
F12 medium containing purified PEG-PGA-AGT-Ma, PEG-PGA-AGT-SKL, 
or PEG-PGA-AGT-SSKL conjugates at a concentration range of 0.3–5 μM. 
After 24 hours, cells were extensively rinsed with PBS, trypsinised, and 
lysed according to a previously published protocol [56]. The protein 
concentration in the cell lysate was determined by Bradford assay.  
IV.4.12. Western Blot Analyses 
Ten micrograms of cell lysate were loaded per lane on a 
MiniProtean TGXTM pre-cast gel (Biorad) along with the Precision plus 
protein KaleidoscopeTM (Bio-Rad) molecular mass markers. Proteins 
were transferred to a nitrocellulose membrane by the iBlot device 
(Invitrogen) and the membrane was blocked in 5% milk solution in TBST 
(50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.1% Tween 20) for 1 hour at 
room temperature. For AGT detection, the membrane was incubated 
with polyclonal rabbit anti-AGT serum (dilution 1:6000), washed three 
times in TBST, and then incubated with peroxidase-conjugated anti-
rabbit IgG (dilution 1:10000). 
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IV.4.13. Live Cell Imaging and Immunofluorescence Microscopy 
(IFM) 
For live cell imaging experiments, 3 x 105 cells were seeded into 
each well of a 4-well chamber slide (µ-Slides, Ibidi) with a 13-mm glass 
bottom, treated with 5 µM AGT-FITC or PEG-PGA-AGT-FITC and grown 
for 24 hours. For plasma membrane and nuclei staining, the Cell MaskTM 
Deep Red fluorescent dye and Hoechst, respectively, were added at 
1:1000 dilution in the culture media 5 minutes before the 
measurement. Before the acquisition, the medium was replaced with a 
special medium without phenol red (DMEM/F12 NoPhenolRED, 
Invitrogen). In IFM experiments, 3 x 105 cells were seeded into each well 
of a 24-well plate containing a 13-mm glass coverslip, and treated with 
unconjugated or conjugated AGT, AGT-SKL, and AGT-SSKL (5 µM) for 24 
hours. Cells were then fixed in 4% (w/v) paraformaldehyde, 
permeabilised with 0.3% Triton X-100 in PBS and blocked in 3% bovine 
serum albumin in PBS. For the immunolabeling, rabbit polyclonal anti-
human AGT and guinea-pig anti-PMP70 were used as primary antibody, 
and Alexa Fluor conjugated antibodies (AF488 and AF555, Life 
technologies) were used as secondary antibodies. Nuclei were stained 
with DAPI (Molecular Probes) and the coverslips were mounted over 
slides in AF1 medium (Dako). In both live cell imaging and IFM 
experiments, images were captured using a confocal laser-scanning 
fluorescence microscope Leica SP5 (Molecular Probes, Leica 
Microsystem, Manheim, Germany) at 63× magnification. For qualitative 
analyses, the ImageJ software was used (Rasband, W.S., ImageJ, U. S. 
National Institute of Health, Bethesda, Maryland, USA 
(http://rsb.info.nih.gov/ij/,1997–2008). Images were processed using 
Adobe Photoshop. 
IV.4.14. Glycolate Toxicity Assay 
CHO-GO-AGT or CHO-GO cells treated with PEG-PGA-AGT or PEG-
PGA-AGT-SSKL were cultured as described above. After 24 hours, 
glyoxylate production was induced by adding HEPES buffered glycolate, 
pH 7.0 at a final concentration of 0.9 mM. Cell viability was evaluated 
after a 24 hour incubation using the crystal violet staining (Sigma 
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Aldrich) as previously reported [27]. The absorbance at 595 nm, which 
is proportional to the number of viable cells, was measured with a 
TECAN plate reader. Six replicates were performed for each assay 
condition. 
IV.4.15. Stability and Biocompatibility Studies 
 Human plasma and RBC isolated from the buffy coat fractions of 
healthy volunteers were centrifuged on Ficoll-Paque PLUS gradient 
(1078 g/ml density, GE Healthcare, Little Chalfont, United Kingdom) at 
400 g for 30 min, at room temperature, at a 1:1 ratio. For stability 
studies 7.5 μM AGT and AGT-SSKL either in the unconjugated or in the 
purified conjugated forms were incubated in fresh human plasma at 
37°C. At scheduled times (0, 4, 8, 24 and 48 hours) 2 μL of the mixtures 
were withdrawn and subjected to SDS-PAGE. The gel was then blotted 
on a nitrocellulose membrane and incubated with anti-AGT antibody as 
previously described. For haemolysis studies RBC were resuspended 1:1 
in PBS and treated with purified PEG-PGA-AGT (5 μM), purified PEG-
PGA-AGT-SSKL (5 μM), NaCl (0.9% w/v) or Triton X-100 (1% v/v) at 37°C 
in a 96 well plate. After 1 h incubation, the plate was centrifuged at 3000 
g and the absorbance at 570 nm of the supernatants was measured. 
Each sample was performed in triplicate. 
IV.4.16. Statistical Analysis 
Experiments were performed at least in triplicate. Statistical 
analysis was performed with the Origin® 7.03 (Origin Lab) or GraphPad 
Prism Version 5.0 (GraphPad software, San Diego, CA, USA) software 
packages. 
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The work presented in this thesis chapter was made possible by a 
collaboration between the Polymer Therapeutics lab at the Centro de 
Investigación Príncipe Felipe, in Valencia and the School of Chemistry 
from Cardiff University in Dr. Alison Paul’s group.  
V.1. INTRODUCTION AND BACKGROUND 
V.1.1. Small Angle Scattering Techniques 
The application of new, robust, and sophisticated methodologies 
has complemented existing techniques to meet the challenge of 
studying the conformation of nanomedicines under physiological or 
near-physiological conditions [1]. Remarkable progress in the design of 
nanoscale drug delivery systems (nanoDDS) has precipitated the 
formation of developmental guidelines to be followed to achieve a 
specific therapeutic effect [2]. Therefore, the exhaustive 
physicochemical characterisation of new nanosized entities, which 
allows the control of pharmacokinetics and biodistribution, will permit 
the generation of more efficient nanomedicinal therapeutic strategies. 
Small angle scattering (SAS) techniques are included within the 
methodologies recently used to study nanoDDS solution conformation. 
In SAS, radiation is elastically scattered by the sample and analysis of 
resultant patterns are used to infer sample structure. SAS techniques 
such as small angle neutron scattering (SANS), small angle X-ray 
scattering (SAXS), and small angle light scattering (SLS) provide 
information on the size, shape, and orientation of structures [3]. The 
main difference between these methods is the nature of the radiation 
employed to obtain complementary information. Otherwise, they share 
several similarities and the same mathematical formalism can be used 
to analyse data. By using a suitable and physically rational model for the 
data, any change in solution is quantifiable. However, this analysis can 
be laborious, requires considerable prior knowledge, and the 
information obtained must often be combined with complementary 
physicochemical characterisation techniques to fully describe the 
systems under investigation. In some cases, the radius of gyration, Rg, 
and the inner structure of the nanosystems can be obtained without 
making any assumptions in a preliminary analysis of the data [4-6]. 
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SANS is a neutron-based non-destructive technique that can probe 
structural information at length scales ranging from 1 to 100 nm. SANS 
is used in a wide range of scientific fields, including the study of soft 
matter, biophysics, and biology. Importantly, SANS experiments are 
relevant for the elucidation of links between biological activity and 
solution conformation, as characterisation can be carried out under 
physiologically relevant conditions. Thanks to this technique, 
researchers analysed the physicochemical properties and 
conformational behaviour under physiological conditions of PK1, a 
clinically evaluated polymer-anticancer drug conjugate (N-(2-
hydroxypropyl)methacrylamide-doxorubicin (HPMA-DOX) conjugate) 
[7]. Subsequent complementary studies [8] demonstrated the influence 
of drug type, drug loading, and pH on sample conformation and, 
therefore, changes in properties such as conjugate biodistribution, 
potential toxicity, and pharmacological activity.  
This process also permitted the investigation of conformational 
changes in endosomolytic polymers for the intracellular delivery of 
proteins and genes as a function of pH and salt type [4, 9]. This revealed 
the potential for SANS to analyse samples under complex 
environmental conditions. Another interesting example allowed the 
correlation of the different in vitro biological outputs of tert- or block- 
diethylstilbestrol (DES)-polyacetal conjugates in two different human 
prostate cancer cell lines (PC3 hormone independent and LNCaP 
hormone dependent) with the different solution conformations [10].  
SANS has the crucial feature of differentiating the scattering length 
densities between isotopes and, more precisely, between hydrogen and 
deuterium (though they are essentially identical in X-rays and light 
analyses). In biological systems, hydrogen can be exchanged with 
deuterium producing a minimal effect on the sample. However, this has 
dramatic effects on the scattering, so allowing intriguing contrast 
variation studies [11-13] and provides the ability to independently 
characterise the different deuterium labelled domains within a drug 
delivery system structure in solution (Figure V.1). 
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Figure V.1. Example of SANS contrast variation study. 
In the case of SAXS experiments, the elastic scattering of X-rays is 
recorded using wavelengths comparable to neutrons and, therefore, 
measures similar length scales. The difference lies in the radiation 
employed and the sample behaviour in response. In SANS, the neutrons 
are scattered by the nuclei and the interaction depends on the isotope 
used, while in SAXS, the X-rays are scattered by the electrons.  
Therefore, the bigger the element, the bigger the intensity of the 
scattering, and this has a direct impact on the selection of samples and 
their observed properties.  
Examples of SAXS application in soft matter include the 
investigation of non-viral gene delivery systems [14], block copolymer 
micelles [12], and peptide amphiphile self-assembled nanovectors [15]. 
Additionally, studies also used synchrotron based X-ray radiation to 
investigate the nanostructure of PEGylated lipid nanosystems in order 
to study the protein corona effect [16]. As for SANS, SAXS is generally a 
non-destructive method, although biomaterials such as DNA or proteins 
may be susceptible to radiation damage at high intensities. Moreover, 
unlike the SANS technique, heavier elements mask the scattering from 
lighter elements in SAXS.  
In this chapter, we will report, for the first time, a rigorous and 
detailed structural investigation of polymeric nanosystems already 
classified as successful drug delivery nanocarriers: (i) the three-
dimensional (3D) structure of 3- and 4-arm star shaped polyglutamates 
including information on the size, shape, and internal structure with 
varying different parameters such as glutamic acid-units (GAU) content 
(from 100 to 250 GAU) or core composition, and (ii) the conformational 
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analysis of the first example of polymer combination therapy combining 
an endocrine disruptor (DES) and a chemotherapeutic drug (paclitaxel, 
PTX) attached to the same polyacetal backbone. 
V.1.2. Small Angle Scattering Essentials  
When incident radiation is scattered by a particle, it does so in an 
elastic fashion, experiencing a change in momentum but not energy. 
Therefore the wave vector, k, of the incident radiation will have the 
same magnitude as the wave vector of the scattered radiation, k’. Using 
vector triangles then allows a scattering vector, Q, to be derived where 
Q = k →k’ (Figure V.2) [17]. 
 
Figure V.2. Vector triangle showing how the scattering vector, Q, is derived. 
As the wave vector has the value of  
    𝑘 = 𝑘′ = 2𝜋/𝜆                                                        (Equation V.1) 
from simple trigonometry on the vector triangle 
𝑄 =
4𝜋
𝜆
 sin (
𝜃
2
)                                                           (Equation V.2) 
The magnitude Q has dimensions of reciprocal length, meaning 
that larger objects scatter at low Q values and smaller objects scatter at 
high Q values. 
In SAS experiments, the scattering intensity, I(Q), is measured as a 
function of Q and is described in terms of the relative contributions of 
the form factor, P(Q) (which describes the size and shape of the 
scattering body), the structure factor, S(Q) (which describes interactions 
between different scattering bodies), and Binc which is a flat background 
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arising from incoherent scattering, principally from hydrogenated 
material within the sample (Equation V.3).  
I(Q) = ф𝑉𝑝(𝛥𝜌)
2𝑃(𝑄)𝑆(𝑄) + 𝐵𝑖𝑛𝑐                                               (Equation V.3) 
фVp(Δρ)2 is a sample-dependent scale factor modulated by the 
polymer volume fraction ф, the volume of a single particle Vp, and the 
contrast term (Δρ)2, which describes the difference in scattering length 
density between the solvent and the polymer, Δρ=ρsolvent-ρpolymer.  
In the specific case of SANS, as hydrogen and deuterium are at 
opposite ends of the scattering length density scale, we achieved 
contrast by dissolving the different studied polymers in D2O. In the case 
of SAXS, we prepared the solutions by dissolving the different 
substances in H2O, phosphate buffer saline (PBS), or D2O, to compare 
the results obtained using both techniques, thereby complementing the 
obtained information. 
V.2. USE OF SAS TO STUDY STAR SHAPED POLYGLUTAMATES  
V.2.1. SAS from Branched Polymers  
A huge number of SAS investigations have focused on 
characterising branched polymer systems such as star polymers, 
dendrimers, and graft polymers, so demonstrating the effectiveness of 
these techniques in the characterisation of such polymeric 
nanocarriers. For example, conformational and size information, such 
as Rg, were obtained using Guinier and Kratky standard plots in dilute 
solutions of poly(ethylene oxide) star polymers ranging from 30 arms 
(G3 dendrimer) to 150 arms (G10 dendrimer) with a polyamidoamine 
(PAMAM) dendrimer core [18].  
Another example is the thermodynamic measurements made after 
mixing star branched and linear polymers [19]. The Flory-Huggins 
interaction parameters, χ, (which take account of the energy of 
interdispersing polymer and solvent molecules) were determined for a 
number of branching architectures and polymer chemistry. This study 
demonstrated that χ increases with the number of branch points and 
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with the number of chain ends. This may be understood based on chain 
topology.  
The group of Jones et al. [20] published a study focused on 
measuring the contribution of χ on chain architecture for a blend of star 
branched and linear polymers finding that χ increased upon star 
presence (number of arms). The thermodynamics of miscibility of star-
star polymers, including isotopic mixtures with different number of 
arms, has also been investigated  [21].  
Other SANS investigations involved stars with dendrimer cores and 
deuterated arms in solution [22]. The solvent scattering length density 
was matched to that of the arms (zero contrast condition) in order to 
obtain characteristic sizes (Rg) and Porod (fractal) exponents. This study 
found that such properties depend strongly on core branching 
architecture in the dilute region and inter-particle structure factors 
were obtained for semi-dilute solutions. Rathgeber et al. [23] studied 
the application of the Beaucage model on branched dendrimers in 
solution, which allowed the characterisation of the degree of branching 
and its regularity. Star polymers with a dendrimer core have also been 
investigated in the bulk state (without any solvent) with ordered 
structures resolved employing transmission electron microscopy (TEM), 
SAXS and SANS [24].  
V.2.2. Star Shaped Polyglutamates 
Star polymers are branched polymers made up of several linear 
chains attached to a central core. Their unique mechanical, rheological, 
and biomedical properties make them optimal platforms for drug 
delivery and offer improved yield compared to conventional linear 
polymers [25]. When compared to linear polymers with similar 
molecular weight (MW), star-shaped systems present a more compact 
structure, a large surface area, and an increased concentration of 
functionalised end groups. Furthermore, multi-arm stars, as well as 
hyperbranched polymers, show enhanced solubility, lower melt 
viscosity, and different thermal and physical properties. Such properties 
depend more on arm MW than on the total MW of the star polymer.  
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When compared to dendrimers, star polymers offer the 
advantages of feature accelerated and tuneable methods of synthesis. 
However, the most appealing feature is their self-assembly behaviour. 
Recent studies suggest that macromolecular architecture is a key 
parameter for the tuning of micellar behaviour and properties. 
Therefore both potential biological applications as well as architecture 
must be taken into consideration when designing new materials such as 
nanoDDS. 
A recent study described the synthesis, physicochemical 
characterisation, preliminary in vitro evaluation, and exhaustive in vivo 
biodistribution and pharmacokinetics of a new star shaped 
polyglutamate family (St-PGA) [25]. This study highlighted the 
advantages of such branched systems when compared with their linear 
counterparts in terms of cell uptake enhancement and prolonged 
plasma half-life. In order to understand even better the prospective in 
aqueous solution of these nanoDDS systems in particular, and any other 
in general, revealing their inner structure and the detailed delivery 
mechanisms, more sophisticated methods are needed. Surprisingly, 
there is a lack of such studies for clinically relevant systems except for 
recent works by Paul et al. [7, 13]. 
In this section, we will present the 3D structure of 3- and 4-arm star 
shaped polyglutamates including information on the size, shape, and 
internal structure. 
V.2.3. Results and Discussion  
The strategy and tactics generally followed during the SAS data 
analysis to obtain the desired structural information are schematically 
shown in Figure V.3.  
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Figure V.3. Schematic for SAS data collection, evaluation, analysis, modelling, 
and interpretation. Adapted from [26]. 
Conceptually the SAS experiment can be divided into four major 
steps: data collection, data evaluation, data analyses, and solution 
structure modelling, each of which will be detailed below. 
V.2.3.1. 3- and 4-Arm Star Shaped Polyglutamates 
3- and 4-arm star shaped polyglutamates were previously 
synthesised by Duro-Castaño and colleagues using a recently published 
versatile methodology yielding well-defined carriers with tunable MW 
and low polydispersities [25]. The schematic structure of the 3-arm 
shaped polyglutamates is presented in Figure V.4.  
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Figure V.4. Schematic structure of 3-arm star shaped polyglutamates. R: -NH- 
in ethyl based polymers; -CH2CH2CH2CH2NH- in hexyl based polymers; and -
OCH2CH2OCH2CH2NH- in 3,6-dioxa-octanediamine (DOOA) based polymers. 
Five different sets of polymers were synthesised for study by SANS 
and SAXS. The first polymer set (Set 1) comprised 3-arm star polymers 
with the same multifunctional core coupled with three different amines 
(R: -NH- in ethyl based polymers; -CH2CH2CH2CH2NH- in hexyl based 
polymers; and -OCH2CH2OCH2CH2NH- in 3,6-dioxa-octanediamine, 
DOOA, based polymers) and different number of GAU. We studied 
these compounds by SANS on the D11 instrument at the Institute Laue-
Langevin (ILL), Grenoble and the physicochemical characteristics 
studied are listed in Table V.1.  
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Table V.1. Physicochemical characteristics of the 3-arm star shaped 
polyglutamates, Set 1, studied by SANS. Adapted from [25]. 
Star 
Polymer 
Amine 
(R) 
DPtheo 
Mna 
(kDa) 
Mnb 
(kDa) 
DPa DPb Ða 
SE1 Ethyl  100 21.3 21.0 97 96 1.26 
SE3 Ethyl 250 50.3 51.5 229 235 1.09 
SD2 DOOA 100 22.2 24.1 101 110 1.23 
SD4 DOOA 200 40.5 41.6 185 190 1.12 
SH3 Hexyl 250 51.5 52.6 235 240 1.17 
a Determined by SEC in DMF; b Estimated by 1H NMR. DP= degree of 
polymerisation. DPtheo= monomer concentration/initiator concentration. Mn= 
number average MW. Ð= polydispersity= MW/Mn. S= 3-arm star polymer. E= 
ethyl; D= DOOA; H= hexyl. 
A second set of polymers (Set 2) consisted of 3-arm star shaped 
polyglutamates with ethyl as a coupled amine certain GAU 
functionalised with propargylamine or ethylene glycol azide amine. The 
presence of these functionalities allows site-specific conjugation of 
relevant molecules such as antibodies, proteins, or imaging probes 
enabling the design of advanced theranostics or polymer-based 
combination nanopharmaceutics [27]. Set 2 polymers also include the 
physical mixture of both compounds as well as their covalent 
attachments. We studied these compounds by SANS on the SANS2d 
diffractometer at the ISIS Spallation Neutron Source, Rutherford 
Appleton Laboratory, Didcot, UK. Their physicochemical characteristics 
are listed in Table V.2.  
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Table V.2. Physicochemical characteristics of the functionalised ethyl 
derivatives 3-arm star shaped polyglutamates, Set 2, studied by SANS.  
Star Polymer 
Amine 
(R) 
DPtheo 
Mna 
(kDa) 
Ð 
SP Ethyl  150 22.9 1.23 
SN Ethyl 150 24.0 1.23 
SP+SN Ethyl 150+150 - - 
SP-SN Ethyl 150+150 - - 
a Estimated after 1H NMR. SP= 3-arm star polymer 
functionalised with 10 mol% propargylamine. SN= 3-arm star 
polymer functionalised with 5 mol% ethylene glycol azide 
amine. SP+SN= physical mixture. SP-SN= covalent capture. 
 
In order to probe the regions occupied by the core vs. the 
corresponding amine, R, we performed contrast variation experiments 
with a third set of 3-arm star shaped polyglutamates (Set 3). Set 3 
polymers contained star polymers with ethyl as a substituent and 
certain GAU functionalised with propargylamine or ethylene glycol 
azide amine as in the previous case. However, Set 3 polymers contained 
a deuterated core. We studied these compounds by SANS on the time-
of-flight LOQ diffractometer at the ISIS Spallation Neutron Source, 
Rutherford Appleton Laboratory, Didcot, UK. Their physicochemical 
characteristics are listed in Table V.3.  
Table V.3. Physicochemical characteristics of deuterated 3-arm star shaped 
polyglutamates, Set 3, studied by SANS. 
Star Polymer 
Amine 
(R) 
DPtheo 
Mna 
(kDa) 
Ð 
SDP Ethyl 120 18.3 1.19 
SDN Ethyl 120 19.4 1.19 
a Estimated after 1H NMR. SDP= 3-arm star polymer with 
deuterated core and functionalised with 12 mol% 
propargylamine. SDN= 3-arm star polymer with deuterated 
core and functionalised with 5mol% ethylene glycol azide 
amine. 
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The fourth set of polymers (Set 4) is composed of all previously 
studied 3-arm star shaped polyglutamates with ethyl as substituent. 
However, we studied these polymers by SAXS at the beamline NCD11 at 
ALBA Synchrotron Light Facility, Barcelona, Spain. Set 4 and their 
physicochemical characteristics are listed Table V.4.  
Table V.4. Physicochemical characteristics of the ethyl derivatives 3-arm star 
shaped polyglutamates studied by SAXS. 
Star Polymer 
Amine 
(R) 
DPtheo 
Mna 
(kDa) 
Mnb 
(kDa) 
Ð 
S Ethyl  150 23.1 - 1.23 
SD Ethyl 120 18.1 - 1.19 
SDP Ethyl 120 - 18.3 1.19 
SDN Ethyl 120 - 19.4 1.19 
a Data obtained by SEC in DMF. b Estimated after 1H NMR. S= 3-arm star 
polymer. SD= 3-arm star polymer with deuterated core. SDP= 3-arm 
star polymer with deuterated core and functionalised with 12 mol% 
propargylamine. SDN= 3-arm star polymer with deuterated core and 
functionalized with 5 mol% ethylene glycol azide amine. 
The final set (Set 5) comprised star polyglutamates with 4 arms (4S) 
with certain GAU functionalised with bisdemethoxycurcumin (BDMC) to 
assess how polymer shape and size change as function of this pendant 
moiety. BDMC was chosen instead of curcumin due to its greater 
stability in physiological conditions and its ability to inhibit inflammation 
while reducing plaque deposition in Alzheimer’s disease models [28]. 
We studied Set 5 by SANS on the SANS2d diffractometer at the ISIS 
Spallation Neutron Source, Rutherford Appleton Laboratory, Didcot, 
UK. Their physicochemical characteristics are listed in Table V.5. 
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Table V.5. Physicochemical characteristics of 4-arm star polymers studied by 
SANS. 
Star Polymer DPtheo 
Mna 
(kDa) 
Mnb 
(kDa) 
DPa DPb Ð 
4S 200 16.8 16.0 111 106 1.34 
4S(PEG-PGA) 200 - 28.8 - -- 1.34 
4SCα 200 - 18.2 - - 1.34 
4SCβ 200 - 19.7 - - 1.34 
a Data obtained by SEC in DMF; b Estimated after 1H NMR. 4S= 4-arm star 
polymer. 4SC = 4-arm star polymer functionalised with BDMC. α= 4 mol% 
modification. β= 8 mol% modification. 
V.2.3.2. SANS Data Analysis: Set 1 
We employed SANS to determine the solution conformation of the 
polymers presented in Table V.1. Scattering data for the studied 
polymers obtained before and after subtracting the solvent (D2O) are 
depicted in Figure V.5.  
 
Figure V.5. Scattered intensity obtained by SANS, I(Q), as a function of the 
scattering vector, Q, for the Set 1 before and after subtracting the solvent (D2O) 
at concentration of 1 wt% (weight percent). Error bars are shown. 
Determination of experimental parameters such as Rg, I(0), Dmax 
(maximum dimension), excluded volume, and MW usually represents 
the first step in reconstruction of the solution structure (Figure V.3). In 
some cases, Rg and I(0) can be determined from the SAS curve using the 
Guinier plot or through calculation of the pair-distribution function, P(r) 
[29, 30]. Disagreement between the values may be a sign of improper 
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assignment of Dmax for the indirect Fourier transformation or other 
problems such as heterogeneity or unfolding.  
V.2.3.2.1. Guinier Approximation 
Rg may be extracted from I(Q) by treating the compounds as 
particles of unspecified size and shape and conducting a Guinier 
analysis. Guinier demonstrated that, in dilute systems where S(Q) = 1, 
at low Q values (where large length scales are observed), the scattering 
from a single particle can be simplified to 
 ln(𝐼(𝑄)) ≈ ln (𝐼(0)) −
𝑄2𝑅𝑔
2
3
⁄                                   (Equation V.4) 
where Rg (the root-mean-square distance of all scattering elements 
from the centre of gravity) gives an idea of the overall size of the 
particle. A plot can be produced of I(Q) vs. Q2 where, from Equation V.4, 
the slope of the data at low Q (provided QRg < 1 or QRg<1.3 for globular 
substances) is -Rg2/3 [30]. Strictly speaking, Equation V.4 is an 
approximation valid only where Q<<Rg -1. However, for quasi-spherical 
particles, the upper limit of the useful Q range is extended because the 
scattering form factor of a sphere is approximated well by Equation V.4 
even for Q ≈ Rg.  
Non-linear behaviour in the Guinier plot in the range Q<1.3/Rg 
indicates the presence of aggregation or inappropriate Q range (Figure 
V.6). Scattering from aggregation influences the entire dataset and any 
further data processing should proceed with caution.  
 
Figure V.6. Different behaviours in the Guinier plot. Adapted from [26]. 
For the studied set of star polymers, there is no Guinier region in 
the range Q<1.3/Rg, indicating the presence of larger substances than 
unimers in D2O, the solvent used. This is most likely due to self-assembly 
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behaviour. When the sample is dissolved in PBS instead of D2O or H2O, 
the presence of smaller substances were observed, indicating lower 
interaction between particles due to the effect of salt concentration 
(Section V.2.3.5). These findings demonstrate the powerful influence of 
salt in the conformation of star shaped polyglutamates due to ionic 
strength as well as counterion (Duro-Castano et al., submitted). 
V.2.3.2.2. Kratky Approach 
Kratky plots emphasise deviation from the high-Q behaviour of the 
scattering intensity I(Q). The Kratky plot, Q2I(Q) vs. Q, which also can be 
calculated directly from the scattering curve, provides an excellent tool 
for evaluating the folding of samples. For folded domains, the Kratky 
plot yields a parabolic-like curve. Additionally, the position of the curve 
peak provides some information about overall size. However, this 
position is shape-dependent, like Rg, and thus cannot directly provide 
information regarding MW. In contrast, extended semi-flexible 
polymers, such as random coil peptides, follow the Porod-Kratky worm-
like chain model [31, 32]. Random coil or unstructured peptides lack the 
characteristic folded peak and are linear with respect to Q in the large 
Q-region. Therefore, SAS is sensitive to the overall shape of the 
macromolecule, and samples that are unfolded are clearly visible in the 
Kratky plot (Figure V.7). 
 
Figure V.7. Kratky plot identifies unfolded samples. Adapted from [26].  
For the polymers under study in this section, the Kratky plots 
(Figure V.8) depicts smooth growth of I(Q)Q2, suggesting that the 
compounds are folded or partially unfolded. However, more accurate 
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conclusions require further modelling of the obtained data (Section 
V.2.3.2.3). 
 
Figure V.8. Kratky representation of the SANS scattering from Set 1. 
V.2.3.2.3. FISH Data Fitting 
If a solution of macromolecules is monodisperse (or quasi-
monodisperse as in the case of the polymers under study), the 
measured scattering profiles can be used for solution structure 
determination. Comparison of multiple reconstructions is extremely 
important to verify the stability of the solution and multiple repetitions 
of the modelling process significantly decreases the risk of inferring 
erroneous shapes. Unfortunately, given incorrect symmetries, ab-initio 
programs will often find shapes that also fit the scattering profiles [26].  
If the atomic structure of the sample is known or an atomic model 
can be proposed, comparisons of theoretical SANS profiles with the 
experimental data is the first step in the structure evaluation. For this 
reason, we carried out modelling of the data to already defined precise 
form factors to gain more detailed information on the polymer 
conformation. To achieve this, we calculated the theoretical SANS 
profile with the FISH program [33], using the sum of square errors (SSE) 
to evaluate the best models.  
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We tested a multitude of form factors and fits which are presented 
in the following sections: rods, solid ellipsoids, and Gaussian coil for a 
Dozier star polymer. However, overinterpretation of the data must be 
avoided, and hence, beginning with the simplest models, such as those 
for solid geometric shapes, is most appropriate. A comprehensive 
description of all the models, including all written equations, can be 
found in the FISH manual [33].  
V.2.3.2.3.1. Rod Form Factor 
Equations V.5 and V.6 give the form factor for N randomly 
orientated rods from which a rod length, L, and cross-sectional radius, 
R, can be obtained. J1(x) is the first order Bessel function, and the 
volume, V= πR2L. 
𝑃(𝑄) = 𝑁 ∫ 𝐹2
𝜋
2⁄
0
(𝑄) sin(𝛾) 𝑑𝛾                                  (Equation V.5) 
where: 𝐹(𝑄) = (∆𝜌)𝑉
sin(1 2 ⁄ 𝑄𝐿 cos 𝛾)
1
2⁄ 𝑄𝐿 cos 𝛾
2𝐽1(𝑄𝑅 sin 𝛾)
𝑄𝑅 sin 𝛾
              (Equation V.6) 
Table V.6 shows the best fit parameters obtained for the rod form 
factor and Figure V.9 shows scattering data for the star polymers with 
best fits to the mentioned rod model.  
Table V.6. Best fit parameters and SSE for the rod model. 
Star Polymer 
Rod Model 
L (nm) R (nm) SSE 
SE1 17.6 188.4 3.94e+03 
SE3 3.4 168.7 1.90e+03 
SD2 18.3 43.3 5.39e+03 
SD4 12.2 109.9 4.52e+03 
SH3 4.8 26.0 4.50e+03 
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Figure V.9. Scattering data for the Set 1 star polymers with best fits to the rod 
form factor. 
Both the fitted curves (Figure V.9) and the obtained parameters 
(Table V.6) suggest a preferred disc shape. However, values lie out of 
range of SANS technique and SSE values are high, leading to a mismatch 
between the fit and the curve. For these reasons, we suggest that the 
rod model is not the most suitable approach for the studied compounds 
and continued analyses of other forms. 
V.2.3.2.3.2. Ellipsoid Form Factor 
Equations V.7, V.8, and V.9 are applied for solid ellipsoids from 
which radius, A, and axial ratio, X, can be obtained.  
𝐼(𝑄) = 𝐼(𝑄) + 𝑆𝐶𝐴𝐿𝐸 ∫ ф2(𝑢) sin(∝)𝑑 ∝
𝜋
2⁄
0
           (Equation V.7) 
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where             ф(𝑢) = 3(sin(𝑢) − 𝑢 · cos(𝑢))/𝑢3             (Equation V.8) 
and                 𝑢 = 𝑄𝐴(𝑠𝑖𝑛2(∝) + 𝑋2𝑐𝑜𝑠2(∝))
1
2⁄               (Equation V.9) 
Table V.7 shows the best fit parameters obtained for the ellipsoid 
model and Figure V.10 shows scattering data for the Set 1 star polymers 
with best fits to the ellipsoid form factor. 
Table V.7. Best fit parameters and SSE for the ellipsoid model. 
Star Polymer 
Ellipsoid Model 
A (nm) X (nm) SSE 
SE1 86.7 0.010 4.26e+03 
SE3 198.2 0.001 2.04e+03 
SD2 45.6 0.020 7.80e+03 
SD4 528.7 0.001 5.79e+03 
SH3 26.0 0.010 5.27e+03 
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Figure V.10. Scattering data for the star polymers with fits to the ellipsoid form 
factor. 
Both the fitted curves (Figure V.10) and the obtained parameters 
(Table V.7) suggest a preferred thin disc shape. However, values lie out 
of range of SANS technique and SSE values are high, leading to a 
mismatch between the fit and the curve. For these reasons, we suggest 
that the solid ellipsoid model is not the most suitable approach for the 
studied compounds and continued analyses of other forms. 
V.2.3.2.3.3. Gaussian Coil for a Dozier Star Polymer Form Factor 
In this case, Rg is obtained from the form factor, by fitting the data 
to the following equation: 
𝑃(𝑄) = 𝑁𝑓 (𝑒𝑥𝑝{−𝑄2𝑅𝑔
2/3} +
4𝜋𝛼
𝑄ξ(Nf)
sin(μ tan−1(𝑄ξ))
(1+𝑄2ξ2)
𝜇
2⁄
)      (Equation V.10) 
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where Nf is the scale, α/Nf is the relative scale of the fractal term, ξ is 
the exponential damping length and = 1/ (+ 1) is the Flory exponent 
(3/5 in good solvent, 1/2 in theta solvent (i.e. = 2/3 to 1)).  
In Figure V.11 the scattering data with fits are shown and Table V.8 
shows the best fit parameters obtained by using this model. 
Table V.8. Best fit parameters and SSE values obtained with the Gaussian coil 
for a Dozier star polymer mathematical model. 
Dozier 
Model 
SE1 SE3 SD2 SD4 SH3 
I(0) 11.3 8.0 2.0 16.9 12.9 
Rg (nm) 95.6 95.7 80.2 94.8 97.1 
α/Nf 0.011 0.007 0.019 0.007 0.005 
ξ (nm) 19.5 18.9 13.2 15.3 12.8 
ν 0.34 0.38 0.31 0.33 0.36 
HS S(Q) VOL 0.052 0.046 0.050 0.076 0.096 
SPH R 21.7 21.1 19.4 17.3 12.8 
BKG A 0.007 0.018 0.004 0.014 0.017 
BKG B*Q -0.007 -0.009 -0.004 -0.012 -0.009 
BKG C*Q2 0.009 0.012 0.006 0.015 0.010 
SSE 5.13e+02 4.76e+02 4.81e+02 5.58e+02 5.09e+02 
Errors on the refined parameter are Rg (±15); ξ (±5); υ (±0.05). 
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Figure V.11. Scattering data for Set 1 with fits to the Gaussian coil for a Dozier 
star polymer form factor obtained by using all the possible parameters. 
Looking at both fit curves (Figure V.11) and the obtained 
parameters (Table V.8), we note that the values obtained for all the 
parameters are acceptable and within the detection limits for SANS. 
Furthermore, SSE values have diminished considerably compared to 
those obtained in previous models indicating the selection of an 
appropriate model. Additionally, as shown in Figure V.11, the 
theoretical curves match the experimental findings. Critically, the star 
model is the only model that reproduces the inflexion point feature 
observed in the scattering curves at approximately Q= 0.006 A-1. 
Based on these results, we performed a second data adjustment in 
order to minimise the number of fit parameters by using a flat 
background (Q independent background) which will be dominated by 
Chapter V 
 
283 
 
any incoherent scattering, if present, but will also contain any 
instrument background not perfectly subtracted during data analysis. 
The obtained results are shown in Figure V.12 and Table V.9. 
 
Figure V.12. Scattering data for the star polymers with fits to the Gaussian coil 
for a Dozier star polymer form factor without backgrounds B and C 
contribution. 
The obtained results using a flat background demonstrate that the 
theoretical and experimental curves still match and SEE values remain 
low. 
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Table V.9. Best fit parameters and SSE for the Gaussian coil for a Dozier star 
polymer without backgrounds B and C contribution. 
Dozier 
Model 
SE1 SE3 SD2 SD4 SH3 
I(0) 5.77 7.61 55.2 104.4 11.9 
Rg (nm) 116.2 94.4 130.0 130.9 92.1 
α/Nf 0.012 0.009 0.014 0.007 0.006 
ξ (nm) 25.8 18.2 20.4 24.8 12.6 
ν 0.36 0.40 0.34 0.36 0.39 
HS S(Q) VOL 0.055 0.217 0.098 0.104 0.046 
SPH R 23.8 175.1 22.0 20.9 13.4 
BKG A 0.020 0.024 0.025 0.024 0.023 
BKG B*Q - - - - - 
BKG C*Q2 - - - - - 
SSE 1.58e+03 1.02e+03 1.87e+03 1.44e+03 9.32e+02 
Errors on the refined parameter are Rg (±15); ξ (±5); υ (±0.05). 
In a final attempt, we minimised the number of fitting parameters 
using a flat background and negating the S(Q) term in the model, i.e. 
assuming absence of interparticle interactions. Figure IV.13 shows the 
perfectly matched fit and Table IV.10 shows the fit parameters. 
We obtained confirmation of the global (rather than local) 
minimum in the fit by varying the initial parameters and refitting the 
data set.  We established the error in each component by determining 
when a difference in the fit could be visually determined after manual 
alteration of the chosen setting and relaxation of the coupled 
parameters.  Associated errors are indicated in Table V.10. 
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Table V.10. Best fit parameters and SSE for the Gaussian coil for a Dozier star 
polymer without both S(Q) and backgrounds B and C contribution. 
Dozier 
Model 
SE1 SE3 SD2 SD4 SH3 
I(0) 30.18 9.99 12.90 19.52 6.32 
Rg (nm) 101.2 102.0 91.0 92.5 82.1 
α/Nf 0.010 0.007 0.016 0.007 0.007 
ξ (nm) 18.8 18.9 12.8 13.4 9.6 
ν 0.35 0.40 0.32 0.34 0.38 
HS S(Q) Vol - - - - - 
SPH R (nm) 15.0 15.0 15.0 15.0 15.0 
BKG A 0.020 0.024 0.025 0.025 0.023 
 B*Q - - - - - 
 C*Q2 - - - - - 
SSE 1.94e+03 1.06e+03 2.65e+03 1.92e+03 1.12e+03 
Errors on the refined parameter are Rg (±15); ξ (±5); υ (±0.05). 
Fit parameters demonstrate that, in the absence of interparticle 
interactions (S(Q)= 1), the Rg of the analysed compounds ranged from 
80 to 100 nm.  Rg values decrease in the order Ethyl>DOOA>Hexyl but, 
surprisingly, there was no dependence on MW.  This is a key concept 
towards the elucidation of the 3D shape of the molecules.  The Flory 
component values variation was found to be small, closed to ⅓, 
indicating a relatively poor solvent and suggesting that the polymers 
studied are in a collapsed conformation (dense stars). Packing close to 
the core is influenced by the packing efficiency of the substituents (i.e. 
the polymer packs around a larger overall excluded volume for Ethyl 
than Hexyl). Moving towards the outer layers, it appears that the arms 
tend to reorganise themselves around a fixed core, hence the core is 
simply more “wrapped” as MW increases allowing Rg to remain 
relatively unchanged.  
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Figure V.13. Scattering data for the star polymers with fits to the Gaussian coil 
for a Dozier star polymer form factor without both S(Q) and backgrounds B and 
C contribution. 
The ξ parameter provides an indication of how the polymer 
swelling changes upon the distance from the core. As with the Rg values, 
the ξ parameters are clearly dependent on the substituent used, and 
vary in the same order as Rg (Ethyl>DOOA>Hexyl). When combined with 
the Flory parameter, this provides a consistent picture of how the 
conformation varies with MW: for larger Rg values the larger core area 
to cover results in more swollen outer layers and higher ξ values. 
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V.2.3.3. SANS Data Analysis: Set 2 
We also used SANS to determine the solution conformation of the 
Set 2 polymers presented in Table V.2. A summary of every compound 
tested with the different measured conditions is shown in Table V.11. 
Table V.11. Summary of the different conditions tested with the different star-
shape polymers from set 2. 
Star Polymer Arms GAU Solvent 
Concentration  
(mg/mL) 
SPc 3  150 D2O 2 
SPd 3 150 D2O 1 
SNd 3 150 D2O 1 
(SP+SN)c 3+3 150+150 D2O 2 
(SP+SN)e 3+3 150+150 D2O 0.1 
(SP-SN)c 3-3 150-150 D2O 2 
(SP-SN)e 3-3 150-150 D2O 0.1 
c= 2 mg/mL; d= 1 mg/mL; e= 0.1 mg/mL. SP= 3-arm star polymer 
functionalised with 10 mol% propargylamine. SN= 3-arm star polymer 
functionalised with 5 mol% ethylene glycol azide amine. SP+SN= physical 
mixture. SP-SN= covalent capture. 
 
We studied the SP polymer (ethyl as substituent, 150 GAU, 
functionalised with propargylamine) in D2O at two different 
concentrations, 2 and 1 mg/mL (SPc and SPd respectively), values above 
its critical aggregation concentration (CAC), 0.5 mg/mL (Duro-Castano 
et al., submitted). This CAC value not only represents the concentration 
above which aggregation processes are taking place, but also represents 
the maximum concentration of free non-aggregated polymer species 
present in the sample under specific conditions (temperature, ionic 
strength, pH). Scattering data after subtracting the solvent and scaling 
the curves for the two different concentrations are shown in Figure 
V.14.  
Chapter V 
 
288 
 
 
Figure V.14. Scattered intensity obtained by SANS, I(Q), as a function of the 
scattering vector, Q, for the studied star polymer after subtracting the solvent 
(D2O) and scaling at two different concentrations: 2 and 1 mg/mL (SPc and SPd 
respectively). Error bars are shown. 
We studied the SN polymer (ethyl as substituent, 150 GAU, 
functionalised with ethylene glycol azide amine) in D2O at 1 mg/mL 
(SNd), value above its CAC (0.5 mg/mL) (Duro-Castano et al., submitted). 
Scattering data after subtracting the solvent are shown in Figure V.15.  
 
Figure V.15. Scattered intensity obtained by SANS, I(Q), as a function of the 
scattering vector, Q, for the studied star polymer after subtracting the solvent 
(D2O) at 1 mg/mL. Error bars are shown. 
When SP and SN polymers are compared at the same 
concentration (1 mg/mL, Figure V.16) we observed similar curve shapes, 
suggesting that the propargylamine and ethylene glycol azide amine 
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used has no significant effect in the conformation of the parent star 
polymers or that the effect produced is exactly the same. 
 
Figure V.16. Comparison between SPd and SNd. Error bars are shown. 
We next measured a physical mixture of SP and SN polymers 
(SP+SN) in D2O at two different concentrations: 2 and 0.1 mg/mL 
((SP+SN)c and (SP+SN)e respectively), values above and below CAC 
respectively. Scattering data after subtracting the solvent are shown in 
Figure V.17. 
 
Figure V.17. Scattered curve for the mixture SP+SN after subtracting the 
solvent (D2O) at two different concentrations: 2 mg/mL ((SP+SN)c) and 0.1 
mg/mL ((SP+SN)e). Error bars are shown. 
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As shown in Figure V.17, the curve at 0.1 mg/mL presents with a 
poor signal/noise ratio, although, at high Q values, the shape of the 
curve is similar for both concentrations. 
When covalent attachment is carried out at the same 
concentrations as in the previous case (2 and 0.1 mg/mL), the scattered 
curve of the resulting compound (SP-SN) presents itself as shown in 
Figure V.18. 
 
 
Figure V.18. Scattered curve for the compound SP-SN after subtracting the 
solvent (D2O) and scaling the curves at two different concentrations: 2 mg/mL 
((SP-SN)c) and 0.1 mg/mL ((SP-SN)e). Error bars are shown. 
In this case, we observed that the effect of the concentration does 
not affect the shape of the obtained compound after covalent capture. 
Comparing both the physical mixture and the covalent attachment 
in the same graph at the same concentration (Figure V.19), we noted a 
small difference in the shape of the curve at low Q values, suggesting 
that both solutions could contain different substances. 
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Figure V.19. Comparison between (SP+SN)c and ((SP-SN)c. Error bars are 
shown. 
V.2.3.3.1. FISH Data Fitting 
Taking the results obtained for the Set 1 polymers as a starting 
point, we selected the Gaussian Coil for a Dozier Star Polymer model in 
order to elucidate the parameters related to size and shape for this 
second set of star polymers.  
During the fitting, we minimised the number of parameters using 
a flat background and negating the S(Q) term in the model.  
Regarding SP polymer, Figure V.20 shows the scattering data with 
fits and Table IV.12 shows the best fit parameters obtained for the two 
different concentrations: 2 mg/mL (SPc) and 1 mg/mL (SPd).  
 
Figure V.20. Scattering data for with fits to the Gaussian coil for a Dozier star 
polymer form factor without both S(Q) and backgrounds B and C contribution. 
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Comparing these parameters with those obtained for Set 1 
(obviating the functionalisation and GAU), we observed a strong 
concentration-dependence on the self-assembly process. Table V.12 
shows similar parameters for the SP compound at 2 mg/mL and at 1 
mg/mL. Therefore, when the concentration increases, the self-
assembling process increases exponentially.  
Table V.12. Best fit parameters and SSE for the Gaussian coil for a Dozier star 
polymer without both S(Q) and backgrounds B and C contribution. 
Dozier Model SPc SPd 
I(0) 5.14 1.30 
Rg (nm) 31.9 32.1 
α/Nf 0.004 0.005 
ξ (nm) 5.1 8.1 
ν 0.31 0.31 
HS S(Q) Vol - - 
SPH R (nm) 15.0 15.0 
BKG A 0.003 0.024 
 B*Q - - 
 C*Q2 - - 
SSE 5.60e+01 6.30e+01 
Errors on the refined parameter are Rg (±15); ξ 
(±5); υ (±0.05). 
In the case of the SN polymer, Figure V.21 shows the scattering 
data with fit and Table V.13 shows the best fit parameters obtained for 
1 mg/mL (SNd).  
Despite the associated error bars in the measurement, Figure V.21 
and Table V.13 demonstrate that the modification of the GAU does not 
affect the conformation of the star polymer (with these percentages of 
functionalisation). 
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Figure V.21. Scattering data for with fit to the Gaussian coil for a Dozier star 
polymer form factor without both S(Q) and backgrounds B and C contribution. 
Table V.13. Best fit parameters and SSE for the Gaussian coil for a Dozier star 
polymer without both S(Q) and backgrounds B and C contribution. 
Dozier Model SNd 
I(0) 0.31 
Rg (nm) 29.4 
α/Nf 0.034 
ξ (nm) 8.9 
ν 0.31 
HS S(Q) Vol - 
SPH R (nm) 15.0 
BKG A 0.003 
 B*Q - 
 C*Q2 - 
SSE 6.03e+01 
Errors on the refined parameter 
are Rg (±15); ξ (±5); υ (±0.05). 
Concerning to the physical mixture (SP+SN) and the covalent 
attachment (SP-SN) of the functionalised compounds, Figure V.22 
shows the scattering data with fits and Table V.14 shows the best fit 
parameters obtained at 2 mg/mL ((SP+SN)c and (SP-SN)c). Due to the 
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signal/noise ratio, we did not study 0.1 mg/mL samples ((SP+SN)e and 
(SP-SN)e) at length.  
 
Figure V.22. Scattering data for with fit to the Gaussian coil for a Dozier star 
polymer form factor without both S(Q) and backgrounds B and C contribution. 
Table V.14. Best fit parameters and SSE for the Gaussian coil for a Dozier star 
polymer without both S(Q) and backgrounds B and C contribution. 
Dozier Model (SP+SN)c (SP-SN)c 
I(0) 0.92 0.56 
Rg (nm) 33.8 29.7 
α/Nf 0.276 0.021 
ξ (nm) 24.4 11.8 
ν 0.34 0.34 
HS S(Q) Vol - - 
SPH R (nm) 15.0 15.0 
BKG A 0.005 0.004 
 B*Q - - 
 C*Q2 - - 
SSE 5.64e+01 5.70e+01 
Errors on the refined parameter are Rg (±15); 
ξ (±5); υ (±0.05). 
The fit parameters obtained demonstrate that, in the absence of 
interparticle interactions (S(Q)=1), the Rg of the analysed Set 2 polymers 
are around 30 nm, independent of the conjugate substituent. 
Comparing these findings with the previous result (Table V.13) suggests 
that the self-assembly process has decreased.  As in Set 1, the Flory 
component values vary little, and are close to ⅓, indicating a relatively 
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poor solvent. Therefore, the polymer is collapsed (dense stars) and the 
arms tend to reorganise themselves around the fixed core.  
When (SP+SN) and (SP-SN) systems are compared, the only 
difference found is the ξ value. In the case of physical mixture, this value 
is higher than for covalent attachment suggesting that this linkage gives 
rise to a more compact structure with no major influence on the final 
conformation of the star polymer. 
V.2.3.4. SANS Data Analysis: Set 3 
A crucial feature of SANS is the difference in scattering length 
densities between isotopes and, more precisely, between hydrogen and 
deuterium, -0.3741 x 10-12 cm and 0.6671 x 10-12 cm, respectively 
(though they are essentially identical in X-ray and light analyses). This 
difference allows us to change the scattering power of part of a 
molecule by substituting hydrogen for deuterium with a minimal effect 
on the sample.  
Table V.15. Summary of the different conditions tested for the different 
deuterated star polymers within Set 3.  
Star Polymer Arms GAU Solvent 
Concentration 
(mg/mL) 
SDN2a 3  120 H2O 10 
SDN3a 3 120 D2O 10 
SDN3c 3 120 D2O 2 
SDN4b 3 120 dPBS 5 
SDP3a 3 120 D2O 10 
2= H2O. 3= D2O. 4= deuterated PBS (dPBS). a= 10 mg/mL. b= 5 mg/mL. c= 2 
mg/mL. SDN= 3-arm star polymer with deuterated core and functionalised with 
6 mol%l ethylene glycol azide amine. SDP= 3-arm star polymer with deuterated 
core and functionalised with 12 mol% propargylamine. 
 
However, this change has dramatic effects on the scattering 
allowing intriguing contrast variation studies [11-13] and provides the 
ability to independently characterise the different deuterium labelled 
domains within a drug delivery system structure in solution. To this end, 
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we attempted to demonstrate the regions occupied by the core vs. the 
substituent using contrast variation experiments by analysing the 
scattering data obtained for the compounds listed in Table V.3 (Set 3). 
A summary of every compound tested with the different measured 
conditions is shown in Table V.15. 
Due to elevated experimental difficulty, the number of 
accumulations per run had to be significantly increased in order to 
minimise error bars. Unfortunately, due to beam-time allowance, the 
measured Q-range was insufficient for the elucidation of the compound 
structure (Figure V.23). To complete the data, future studies will require 
an extension of the measured Q-range, and will hopefully provide 
interesting results, as we observed a remarkable difference in the 
behaviour of the systems when comparing SDN2a and SDN3a graphs 
(Figure V.24). 
 
Figure V.23. Scattered curve for the deuterated core star polymers presented 
in Table V.15 after subtracting the solvent different. Error bars are shown. 
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Figure V.24. Comparison between SDN in H2O (SDN2a) and D2O (SDN3a) at the 
same concentration (10 mg/mL). Error bars are shown. 
V.2.3.5. SAXS Data Analysis: Set 4 
As a complement to SANS, we used SAXS to determine the solution 
conformation of the polymers presented in Table V.4. In this section, we 
will present the analysis of all studied compounds, divided by different 
issues (ionic strength and concentration). 
Table V.16 contains a summary of every compound tested with the 
different measured conditions. 
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Table V.16. Summary of the different conditions tested for Set 4 of 3-arm star 
polymers.  
Star Polymer Arms GAU Solvent 
Concentration  
(mg/mL) 
S1a 3 150 PBS 10 
S2a 3 150 H2O 10 
S2b 3 150 H2O 5 
S2c 3 150 H2O 2 
S2d 3 150 H2O 1 
SD1a 3 150 PBS 10 
SD2b 3 150 H2O 5 
SD2c 3 150 H2O 2 
SD2d 3 150 H2O 1 
SDP2a 3 150 H2O 10 
SDN2a 3 150 H2O 10 
SDN3a 3 150 D2O 10 
(SDP+SDN)1a 3+3 150+150 PBS 10 
(SDP+SDN)1b 3+3 150+150 PBS 5 
(SDP+SDN)1c 3+3 150+150 PBS 2 
(SDP+SDN)1d 3+3 150+150 PBS 1 
(SDP+SDN)2a 3+3 150+150 H2O 10 
(SDP+SDN)2b 3+3 150+150 H2O 5 
(SDP+SDN)2c 3+3 150+150 H2O 2 
(SDP+SDN)2d 3+3 150+150 H2O 1 
(SDP-SDN)2a 3+3 150-150 H2O 10 
1= PBS. 2= H2O. 3= D2O. a=10 mg/mL. b= 5 mg/mL. c= 2 mg/mL. d= 1 mg/mL. 
S= 3-arm star polymer. SD= 3-arm star polymer with deuterated core. SDP= 
3-arm star polymer with deuterated core and functionalised with 10 mol% 
propargylamine. SDN= 3-arm star polymer with deuterated core and 
functionalised with 5 mol% ethylene glycol azide amine. SDP+SDN= physical 
mixture. SDP-SDN= covalent capture. 
We studied the S polymer (ethyl as substituent, 150 GAU) in both 
PBS (S1a, at 10 mg/mL) and H2O (S2a, S2b, S2c, S2d, at concentrations 
between 10 and 1 mg/mL).  
Figure V.25 shows the scattering data, before and after subtracting 
the solvent, for these polymers and a comparison between the same 
concentration of star polymer in PBS and H2O. 
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Figure V.25. (A) Scattered curve for S1a polymer before and after subtracting 
the solvent (PBS). (B) Scattered curve for S2 polymers before and after 
subtracting the solvent (H2O) at different concentrations: 10 mg/mL (S2a), 5 
mg/mL (S2b), 2 mg/mL (S2c), 1 mg/mL (S2d). (C) Comparison between S1a and 
S2a. 
As shown in Figure V.25, ionic strength has a clear influence on the 
self-assembling behaviour. When the star polymers are dissolved in H2O 
(as in the case of polymers studied by SANS above reported), the 
observed particle size increased compared to PBS-polymer solutions 
(Figure V.25C). These findings demonstrate that salt concentration has 
a significant effect on the polymer size by decreasing the incidence of 
polymer aggregation. The superposition of scattering curves from 
different concentrations in H2O (Figure V.25B) reveals a clear 
concentration-dependent trend similar to the findings from Section 
V.2.3.1: when the polymer concentration diminishes, the structures 
become smaller.  
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To verify the effect of core deuteration and to compare with the 
information obtained in previous sections, we performed the same 
analysis for SD polymers (ethyl as substituent, deuterated core, 150 
GAU). We studied SD polymer in both PBS (SD1a, at 10 mg/mL) and H2O 
(SD2), measuring concentrations between 5 and 1 mg/mL (SD2b, SD2c, 
SD2d) in H2O. Figure V.26 shows the scattering data before and after 
subtracting the solvent for these polymers in PBS and H2O. As shown in 
Figure V.26, again, we found a clear influence of the ionic strength on 
nanostructure size. Additionally, when concentration increases, the size 
also increases. 
 
Figure V.26. (A) Scattered curve for SD1a polymer before and after subtracting 
the solvent (PBS). (B) Scattered curve for S2 polymers before and after 
subtracting the solvent (H2O) at different concentrations: 5 mg/mL (SD2b), 2 
mg/mL (SD2c) and 1 mg/mL (SD2d). 
We analysed the SDP polymer (ethyl as substituent, deuterated 
core, 10 mol% functionalised with propargylamine, 150 GAU) in H2O at 
a concentration of 10 mg/mL (SDP2a) (Figure V.27). 
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Figure V.27. Scattered curve for SDP2a polymer before and after subtracting 
the solvent (H2O).  
 
Figure V.28. (A) Scattered curve for SDN2a polymer before and after 
subtracting the solvent (H2O) at 10 mg/mL. (B) Scattered curve for SDN3a 
polymer before and after subtracting the solvent (D2O) at 10 mg/mL. (C) 
Comparison between SDN2a and SDN3a. 
We also measured the SDN polymer (ethyl as substituent, 
deuterated core, 5 mol% functionalised with ethylene glycol azide 
amine, 150 GAU) in both H2O and D2O at 10 mg/mL (SDN2a and SDN3a 
respectively). As expected (Figure V.28C), the size and shape of polymer 
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dissolved in H2O and D2O were exactly the same. These findings 
therefore suggest that the data obtained by SANS in deuterated 
solvents is perfectly valid and can be extrapolated to non-deuterated 
solvents in the same conditions. 
 
Figure V.29. (A) Scattered curve for the mixture SDP+SDN before and after 
subtracting the solvent (PBS) at different concentrations: 10 mg/mL 
[(SDP+SDN)1a], 5 mg/mL [(SDP+SDN)1b], 2 mg/mL [(SDP+SDN)1c], 1 mg/mL 
[(SDP+SDN)1d]. (B) Scattered curve for the mixture SDP+SDN before and after 
subtracting the solvent (H2O) at different concentrations: 10 mg/mL 
[(SDP+SDN)2a], 5 mg/mL [(SDP+SDN)2b], 2 mg/mL [(SDP+SDN)2c], 1 mg/mL 
[(SDP+SDN)2d]. (C) Comparison between polymers inside PBS and H2O at the 
same concentration.  
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In order to ratify the behaviour of the studied polymers in terms of 
mobility and deformability, we studied the physical mixture and 
covalent attachment of SDP and SDN polymers in both PBS and H2O.  
Firstly, we measured the physical mixture SDP+SDN at four selected 
concentrations, from 1 to 10 mg/mL (Figure V.29). Figure V.29A and 
Figure V.29B demonstrate how size increases when concentration also 
increases. However, this growth is less pronounced when PBS is used, 
demonstrating once again the influence of ionic strength on 
nanostructure size.  
When both SDP and SDN compounds are covalently attached and 
dissolved in PBS, the scattered curve changes, suggesting the presence 
of higher nanostructures compared to the physical mixture (Figure 
V.30). 
 
Figure V.30. (A) Scattered curve for the compound SDP-SDN before and after 
subtracting the solvent (H2O) at 10 mg/mL [(SDP-SDN)2a]. (B) Comparison 
between the physical mixture and the covalently attached compound at the 
same concentration (10 mg/mL).  
V.2.3.5.1. Guinier Approximation 
As stated previously, at low resolution, scattering can be described 
by the Guinier approximation (Equation V.4). The Guinier plot will give 
a straight line from which Rg and I(0) can be extracted.  
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Concerning S polymers, Table V.17 shows the results obtained 
when the Guinier approximation is applied, confirming the previous 
assumptions about the size of the polymers in different solvents and 
different concentrations. 
Table V.17. Guinier approximation applied to S polymers. 
Star Polymer Rg I(0) QRg limit QRg limit Fidelity 
S1a 2.26 ± 0.09 2.32 ± 0.0044 0.31 1.30 0.96 
S2a No data* - - - - 
S2b No data* - - - - 
S2c 2.41 ± 0.54 0.53 ± 0.01  0.79 1.11 0.60 
S2d 3.31 ± 0.26 0.31 ± 0.0055 0.54 1.30 0.78 
1= PBS. 2= H2O. 3= D2O. a=10 mg/mL. b= 5 mg/mL. c= 2 mg/mL. d= 1 mg/mL. 
S= 3-arm star polymer.* This indicates no linear Guinier region (e.g. because 
the sample is severely polydisperse) or the Guinier region is too short (because 
the sample is too big in size for the given minimum Q). 
Concerning SD polymers, Table V.18 shows the results obtained 
when the Guinier approximation is applied, again confirming the 
previous assumptions about the size of the polymers under different 
ionic strengths and different concentrations. 
Table V.18. Guinier approximation applied to SD polymers. 
Star Polymer Rg I(0) QRg limit QRg limit Fidelity 
SD1a 3.47 ± 0.06 3.78 ± 0.015 0.60 1.29 0.80 
SD2b No data* - - - - 
SD2c No data* - - - - 
SD2d 3.43 ± 0.56 0.58 ± 0.027 0.74 0.72 0.51 
1= PBS. 2= H2O. 3= D2O. a=10 mg/mL. b= 5 mg/mL. c= 2 mg/mL. d= 1 mg/mL. 
SD= 3-arm star polymer with deuterated core.* This indicates no linear Guinier 
region (e.g. because the sample is severely polydisperse) or the Guinier region 
is too short (because the sample is too big in size for the given minimum Q). 
As previously mentioned, the SDP2a, SDN2a, and SDN3a polymers 
are functionalised with propargylamine (SDP2a) and ethylene glycol 
azide amine (SDN2a and SDN3a). In all these cases, the samples proved 
to be too large in size for the given minimum Q and the Guinier plots 
did not provided any coherent results. 
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When SDP and SDN polymers are physically mixed under different 
conditions (PBS and H2O) and at different concentrations (from 1 to 10 
mg/mL), Guinier approximation provides the results shown in Table 
V.19. 
Table V.19. Guinier approximation applied to the physical mixture of SDP and 
SDN polymers at different concentrations. 
Star Polymer Rg I(0) QRg limit QRg limit Fidelity 
(SDP+SDN)1a 2.63 ± 0.05 3.25 ± 0.012 0.58 1.30 0.82 
(SDP+SDN)1b 3.45 ± 0.07 2.62 ± 0.017 0.64 1.30 0.81 
(SDP+SDN)1c 3.29 ± 0.06 1.17 ± 0.012 0.64 1.30 0.80 
(SDP+SDN)1d 4.30 ± 0.48 1.08 ± 0.015 0.46 1.29 0.89 
(SDP+SDN)2a No data* - - - - 
(SDP+SDN)2b No data* - - - - 
(SDP+SDN)2c No data* - - - - 
(SDP+SDN)2d 3.28 ± 0.32 0.70 ± 0.017 0.86 1.09 0.54 
1= PBS. 2= H2O. 3= D2O. a=10 mg/mL. b= 5 mg/mL. c= 2 mg/mL. d= 1 mg/mL. 
SDP= 3-arm star polymer with deuterated core and functionalised with 10 
mol% propargylamine. SDN= 3-arm star polymer with deuterated core and 
functionalised with 5 mol% ethylene glycol azide amine. SDP+SDN= physical 
mixture. SDP-SDN= covalent capture.* This indicates no linear Guinier region 
(e.g. because the sample is severely polydisperse) or the Guinier region is too 
short (because the sample is too big in size for the given minimum Q). 
When SDP and SDN polymers are covalently conjugated and 
dissolved in H2O, the Guinier approximation provides the results shown 
in Table V.20.  
Table V.20. Guinier approximation applied when SDP and SDN are covalently 
attached at 10 mg/mL. 
Star Polymer Rg I(0) QRg limit QRg limit Fidelity 
(SDP-SDN)2a 11.32 ± 1.20 16.19 ± 0.84 0.84 1.26 0.78 
2= H2O. a=10 mg/mL. SDP= 3-arm star polymer with deuterated core and 
functionalised with 10%mol propargylamine. SDN= 3-arm star polymer with 
deuterated core and functionalised with 5%mol ethylene glycol azide amine. 
SDP-SDN= covalent capture. 
 
To confirm that the data obtained via Guinier plots are reliable, the 
fidelity value shown in all tables should to be close to 1. Therefore, the 
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obtained data needs to be further modelled for a more accurate 
conclusion. We will performe this thorough analysis in the near future. 
V.2.3.6. SANS Data Analysis: Set 5 
We applied SANS to determine the solution conformation of the 
Set 5 polymers presented in Table V.5. Table V.21 shows a summary of 
every compound tested with the different measured conditions. 
Table IV.21. Summary of the different conditions tested for Set 5 of 4-arm 
star polymers.  
Star Polymer Arms GAU Solvent 
Concentration 
(mg/mL) 
4S3d 4 200 D2O 1 
4S(PEG-PGA)3d 4 200 D2O 1 
4SCα3c 4 200 D2O 2 
4SCβ3c 4 200 D2O 2 
4S= 4-arm star polymer. 4SC = 4-arm star polymer functionalised with 
BDMC. α= 4 mol% modification. β= 8 mol% modification . 
Figure V.31. Scattered intensity obtained by SANS, I(Q), as a function of the 
scattering vector, Q, for the studied 4-ar star polymers after subtracting the 
solvent (D2O) and scaling the curves. Error bars are shown. 
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Figure V.31 shows the scattering data for the studied 4-arm star 
polymers obtained after subtracting the solvent (D2O) and scaling the 
curves. 
We noted that all curves exhibit the similar patterns, so we expect 
similar results after mathematically analysing each polymer.  
V.2.3.6.1. FISH Data Fitting 
Following the results obtained for the Set 1 and Set 2 polymers, we 
selected the Gaussian Coil for a Dozier Star Polymer model to elucidate 
the parameters related to size and shape for this 5th set of star polymers. 
As in previous cases, during the fitting, we minimised the number of 
parameters using a flat background and negating the S(Q) term in the 
model.  
Figure V.32 shows the scattering data with fits and Table V.22 
shows the best fit parameters obtained. 
 
Figure V.32. Scattering data for the star polymers with fits to the Gaussian coil 
for a Dozier star polymer form factor without both S(Q) and backgrounds B and 
C contribution. 
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Table V.22. Best fit parameters and SSE for the Gaussian coil for a Dozier star 
polymer without both S(Q) and backgrounds B and C contribution. 
Dozier Model 4S3d 4S(PEG-PGA)3d 4SCα3c 4SCβ3c 
I(0) 0.75 3.08 4.28 4.25 
Rg (nm) 34.0 37.0 37.0 28.7 
α/Nf 0.037 0.128 0.041 0.040 
ξ (nm) 9.6 25.4 17.5 18.7 
ν 0.39 0.39 0.35 0.43 
HS S(Q) Vol - - - - 
SPH R (nm) 15.0 15.0 15.0 15.0 
BKG A 0.002 0.003 0.003 0.005 
 B*Q - - - - 
 C*Q2 - - - - 
SSE 6.20e+01 6.38e+01 6.86e+01 1.92e+03 
Errors on the refined parameter are Rg (±15); ξ (±5); υ (±0.05). 
As expected, the results obtained for all structures are similar. The 
exception is the observed variations in the ξ value, indicating that the 
presence of PEG or BDMC increased the effective volume occupied by 
the arms of the star polymer. 
V.2.4. Conclusions 
SAS techniques have proven to be suitable for the elucidation of 
the solution conformation of all studied star polymers.  
Concerning SANS experiments, we made several attempts to fit the 
data with different models commonly used for polymers. After 
extensive analysis, we found the Gaussian coil for a Dozier star polymer 
to be the most appropriate model to fit the data for both 3- and 4 arm 
star polymers. This generated information about the radius of gyration, 
as well as other conformational parameters.  
During the fitting, we made attempts to minimise the number of 
parameters using a flat background and negating the S(Q) term in the 
model (S(Q)=1).  Fit parameters (Table V.10 for Set 1; Tables V.12, V.13 
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and V.14 for the Set 3; and Table V.22 for the Set 5), together with the 
results obtained by SAXS, show that, in the absence of interparticle 
interactions (S(Q)=1), the Rg deeply depends on the polymer used and 
salt concentration. Furthermore, the Rg is directly related to both 
conditions, although there is no dependence on the MW. This 
important information allowed us to elucidate the 3D shape of the 
nanostructures. When H2O or D2O were used as a solvent (given that 
the Flory component values vary little, and are close to ⅓, indicating a 
relatively poor solvent) the polymer is relatively collapsed (dense stars) 
and the arms tend to reorganise themselves around the fixed core. 
Therefore, the core is more “wrapped” as molecular weight increases, 
allowing Rg to remain relatively unchanged. When PBS was used, the 
self-assembling behaviour diminished, resulting in much smaller 
structures due to a greater ionic strength.  
Moreover, the functionalization of GAU with minimal amounts of 
relevant biomolecules did not lead to significant changes in structure, 
allowing the opportunity of site-specific conjugation of different 
bioactive agents. This will enable the design of advance theranostics or 
polymer-based combination nanopharmaceutics. 
V.3. USE OF SANS TO STUDY POLYACETAL-BASED CONJUGATES 
V.3.1. Polyacetal-Based Conjugates 
During recent decades, great advances have been made in 
combination therapy for cancer treatment, among other diseases and 
disorders. The term “combination therapy” is used when more than one 
drug or type of therapy (i.e. chemotherapy, radiotherapy, etc.) are 
simultaneously administrated to treat a disease. One of the advantages 
of using combination therapy is the possibility of modulating more than 
one signalling pathway in diseased cells, maximising the therapeutic 
effect, and possibly overcoming mechanisms of resistance [34].  
The Combination Index (CI) is used to determine whether or not 
the combination of the drugs is effective [35,36]. CI allows the 
calculation of n chemical interactions (synergism, additive effect, 
antagonism) simultaneously, while not requiring knowledge of 
Chapter V 
 
310 
 
mechanisms of action. The toxicity of a mixture depends on the toxicity 
of the components and how the components interact with each other 
in a dose-dependent way. Chemicals in a mixture may show zero 
interaction or may provide more than an additive effect (synergism) or 
less than an additive effect (antagonism). 
Polymer drug conjugates are nanoDDS in which a drug is covalently 
bound to a polymer carrier. The main benefits compared to the parent 
free drug are: (a) the passive tumor targeting by the enhanced 
permeability and retention (EPR) effect [37], (b) decreased toxicity  [38], 
(c) increased solubility in biological fluids [39], (d) the ability to overpass 
some mechanisms of drug resistance [40], and (e) the ability to elicit 
immunostimulatory effects [41, 42]. After the success of first generation 
of polymer-drug conjugates on the market and in clinical trials, a second 
generation has been developed based on combination therapy [27]. 
Polymer-drug conjugates for combination therapy involve at least four 
types of systems, including polymer-drug conjugate plus free drugs 
(Type I), polymer-drug conjugate plus polymer-drug conjugate (Type II), 
a single polymeric carrier carrying a combination of drugs (Type III), and 
polymer-directed enzyme prodrug therapy (PDEPT) and polymer 
enzyme liposome therapy (PELT) (Type IV). In this work we chose to 
focus on Type III conjugates to permit the delivery of two different drugs 
on the same carrier to the tumor site and ensure a simultaneous action.  
The present section aims to structurally investigate a family of 
polyacetals synthesised to improve the therapeutic effect of already 
reported polyacetal-DES conjugates [10, 43, 44]. For this purpose, we 
added PTX as a second drug covalently bound to the carrier in order to 
obtain a polymer-based combination conjugate with endocrine plus 
chemotherapy looking for anticancer synergism in advanced prostate 
and breast cancer models.  
PTX is a microtubule-interfering agent and a clinically well-
established anti-neoplastic agent used for the treatment of breast and 
prostate cancers among others. However, PTX has serious drawbacks 
limiting its efficacy. Due to its lack of aqueous solubility, PTX must be 
solubilised in a formulation vehicle, Cremophor EL (CrEL) or ethanol 
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when used clinically causing additional undesirable sides effects 
(hypersensitivity) to those caused by the drug itself. Additionally, due to 
its short half-life and low selectivity, only a small amount of drug 
normally reaches the tumour sites.  
Different approaches have been developed to enhance solubility of 
PTX and improve its pharmacokinetics to overcome these problems and  
numerous anticancer conjugates are currently in advanced phase of 
clinical trials [45]. An albumin-based PTX nanoparticle, Abraxane (ABI-
007, Celgene Corporation), was approved by the Food and Drug 
Administration (FDA) in 2004 for the treatment of breast cancer [46,47]. 
The most advanced PTX-conjugated system is a PGA-PTX conjugate 
(Opaxio®) which displays a better safety profile  compared to free PTX 
in cancer treatment alone or in combination with radiotherapy or other 
small drugs such as cisplatin [48-53]. Micellar-based drugs containing 
PTX [54] or PTX-inclusive anticancer agent combinations (such as 
estramustine plus PTX [55] or docetaxel (DCX) plus PTX [56]) have been 
studied for the treatment of prostate cancer. Anti-prostate cancer 
effects can be improved by combining PTX with other drugs, such as 
DES. Indeed, combination of DES with another taxane family member, 
DCX, improves therapeutic effect of DCX in the treatment of metastatic 
androgen-independent prostate cancer [57]. 
Herein, we report the conformational analysis of the first example 
of polymer combination therapy combining endocrine (DES) and 
chemotherapeutic (PTX) drugs attached to the same polymer backbone. 
The design of a successful prodrug requires a stability in the 
bloodstream but reasonably quickly conversion into active agents at the 
site of action.  Chemical derivatisation of PTX at the C 2’ or the C 7’ 
position offered the best options in the creation of the prodrug. 
Therefore, we synthesised 2’ ester derivatives of PTX to increase 
aqueous solubility and permit PTX release under physiological 
conditions.  
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V.3.2. Results and Discussion 
The strategy and tactics followed to obtain the desired structural 
information from SANS data analysis are schematically shown in Figure 
V.3.  
V.3.2.1. Tert- and Block-Polyacetals 
A series of polyacetal-based combination conjugates were 
prepared by J. Movellan and V. Gimenez following a polyacetal synthetic 
strategy previously described (Figure V.33) [10, 43]. Both drugs, Serinol 
(Ser) and DES were incorporated in a random distribution to form tert-
polymers, or in a sequential approach to form block-co-polymers. DES 
and Ser moieties were used as co-monomers during the polymerisation 
reaction and form part of the polymer main-chain.  
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Figure V.33. Synthetic approach followed to obtain (A) tert-DES-Ser, (B) block-
DES-Ser. Adapted from [10]. 
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Ser moieties offer new anchoring positions to incorporate PTX in a 
second conjugation step (Figure V.34).  
 
Figure V.34. Synthetic approach followed to obtain tert-DES-SerPTX and block-
DES-SerPTX. 
The structures of these novel systems consisted of a diol drug, DES, 
incorporated into the polymer main-chain and a functionalised drug, 
PTX, conjugated to polymer side-chains by post-polymerisation 
modifications yielding tert-DES-SerPTX and block-DES-SerPTX 
combination conjugates. The schematic structure and characteristics of 
the studied polyacetals are presented in Figure V.35 and Table V.23, 
respectively. 
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Figure V.35. Schematic representation of some studied polyacetals. (A) 
tert/bock-DES-SerFmoc (9-fluorenylmethoxycarbonyl protected Ser); (B) 
tert/block-DES-Ser; (C) tert/block-DES-SerPTX. 
Table V.23. Characteristics of studied polyacetals. 
Conjugate Polymer 
Loadinga (wt%)  
Free contentb  
(wt% of TDL) 
DES  SerFmoc/Ser  PTX  DES PTX 
Tert-DES 3.5 - - 0.2 ± 0.1 - 
Tert-DES-SerFmoc 3.5 3.0 - 0.1 ± 0.1 - 
Tert-DES-Ser 3.5 3.0 - 0.1 ± 0.1 - 
Tert-DES-SerPTX 3.5 2.3 0.7 0.1 ± 0.1 0.2 ± 0.1 
Block-DES 3.0 - - 0.2 ± 0.1 - 
Block-DES-SerFmoc 3.0 3.0 - 0.1 ± 0.1 - 
Block-DES-Ser 3.0 3.0 - 0.1 ± 0.1 - 
Block-DES-SerPTX 3.0 2.3 0.7 0.1 ± 0.1 0.2 ± 0.1 
a Estimated by 1H NMR. b Determined by HPLC analysis. TDL: total drug 
loading. 
We studied these compounds by SANS on the D11 instrument at 
the Institute Laue-Langevin (ILL), Grenoble. 
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V.3.2.2. SANS Data Analysis 
V.3.2.2.1. Influence of SerFmoc in Polyacetal Conformation 
Previously published DES-polyacetal SANS studies [10] focused on 
the elucidation of the solution conformation of tert- and block-
copolymer conjugates containing a fixed DES content of 4 wt% using 
deuterated solvents (dPBS and methanol, MeOD). A single short rod 
represented the most appropriate model for both conjugates in 
methanol (1.5 nm diameter, 18.5 nm in length). This demonstrated that 
a loss of solvophobicity of the block-DES occurred in methanol 
compared to dPBS. Such an effect inhibited the aggregation, observed 
in the case of dPBS, of the DES-rich region of the molecule, and with it, 
the large difference in solution structures observed between the block-
DES and tert-DES conjugates. Hence, the solution behaviour in aqueous 
media was driven by the hydrophobicity of DES (Figure V.36).  
 
Figure V.36. Graphic representation of previously obtained results [10]. 
In the light of these results, we first used SANS to study possible 
changes in polyacetal conformation derived from the addition of 
another pendent hydrophobic moiety, SerFmoc (9-
fluorenylmethoxycarbonyl protected Ser). We then compared the 
findings of this study with previously published results. As mentioned 
previously, all compounds were prepared in dPBS and MeOD using 
deuterated solvents to provide contrast. 
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Figure V.37. SANS data from 1 wt% conjugate solutions. (A) tert-DES and tert-
DES-SerFmoc in dPBS and MeOD. (B) block-DES and block-DES-SerFmoc in dPBS 
and MeOD. Representative error bars are shown. 
Figure V.37 shows critical comparisons of the scattering obtained 
from tert- (Figure V.37A) and block- (Figure V.37B) conjugates in dPBS 
and MeOD. This includes previously presented data for tert-DES and 
block-DES conjugates for clarity and comparison purposes. The addition 
of SerFmoc moiety produces a clear change in solution conformation 
for tert- and block- polymers both in dPBS and in MeOD. In MeOD, 
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scattering plots are identical for tert- and block- systems indicating that 
in dPBS there is a small influence of the tert- or block- nature of the 
polymer on the solution conformation. Figure V.36 shows the 
comparison scattering from the tert- and block- polymers containing 
SerFmoc in MeOD and dPBS. This figure demonstrates that the 
scattering curves for tert- and block- conjugates become similar in 
shape following the introduction of SerFmoc.   There still remains a 
difference in the curvature of the two profiles, although this is less 
pronounced when compared with polyacetals in dPBS.  
 
Figure V.38. SANS data from 1 wt% conjugate solutions. In dPBS: tert-DES-
SerFmoc, block-DES-SerFmoc. In MeOD: tert-DES-SerFmoc, block-DES-
SerFmoc. Red lines are best fits to the data. Representative error bars are 
shown. 
However, the difference between tert- and block- polymers is 
much smaller with the SerFmoc than without, indicating that SerFmoc 
induced a more dominant effect on solution conformation with the 
block- distribution. Thus, the addition of SerFmoc dramatically changed 
the scattering shape and the differences seen between tert-DES and 
block-DES polymers were significantly reduced. 
For the tert-DES-SerFmoc polymer in dPBS, the modelling analysis 
indicates the presence of two different co-existing disks in solution. The 
biggest disk is approximately 30 nm in diameter and 6 nm in length, and 
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the other disk is 10 nm in diameter and 3 nm in length. In the case of 
block-DES-SerFmoc polymer, the modelling also indicates the presence 
of two sets of disks, one approximately 15 nm in diameter and 6 nm in 
length, the other larger than can be accurately quantified by SANS over 
this Q range.  
V.3.2.2.2. Influence of PTX in Polyacetal Conformation 
Continuing this study, we compared combination polymers 
containing DES and PTX moieties to their single parent drug. In Figure 
V.39, tert-DES-SerPTX and both parent single conjugates, one conjugate 
without PTX (tert-DES-Ser), one conjugate without DES (tert-SerPTX), 
and tert-DES for comparison, have been represented in order to resolve 
any effect on solution conformation following incorporation of each 
component.  
 
Figure V.39. SANS data from 1 wt% tert-polymer solutions in dPBS: tert-DES, 
tert-DES-Ser, tert-DES-SerPTX, and tert-SerPTX. Error bars are shown. 
We made the same comparisons for the block- family of polymers 
in Figure V.40. 
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Figure V.40. SANS data from 1 wt% block-polymer solutions in dPBS: block-DES, 
block-DES-Ser, block-DES-SerPTX. Error bars are shown. 
We observed significant scattering profile differences after 
comparing tert-DES with the synthesised polyacetals containing PTX, 
tert-DES-SerPTX and tert-SerPTX, both with profiles similar in shape but 
different with regards to intensity. This fact clearly demonstrated that 
the incorporation of PTX is the major driving force behind solution 
conformation.  This is confirmed by studying the block-polymer series, 
as the shape of the scattering profiles changes substantially following 
the addition of PTX. Block-polymers take on the same characteristics at 
that shown by the tert-DES-SerPTX and tert-SerPTX polymers. 
 Scattering from the tert-SerPTX sample was best fit to a thin rod 
of radius 1 nm, length 30 nm with a Q-n term with n= 3.5.  For tert-DES-
SerPTX the scattering was dominated by a Q-4 term, possibly indicating 
the presence of an extremely large structure out with the resolution of 
SANS experiments.  We also observed similar findings for the block-DES-
SerPTX. This experiment clearly confirmed that PTX drives solution 
conformation of the polyacetals due to high hydrophobicity inducing 
significant differences in aggregation parameters. Overall, this drives 
polymers to form larger structures in solution. 
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V.3.3. Conclusions 
We developed polyacetal-based combination conjugates through 
the modification of DES-polyacetals with Ser-co-monomers, thus 
allowing the conjugation of PTX. SANS studies confirmed that following 
fmoc-protected Ser and PTX incorporation the hydrophobic pendant 
chain exerted a dominant effect on the polymer conformation. 
V.4. MATERIALS AND METHODS 
V.4.1. Materials 
All 3- and 4-arm star shaped polyglutamates studied in this chapter 
were synthesised by Duro-Castaño and colleges using a recently 
published methodology [25]. Polyacetal-based combination conjugates 
were prepared by J. Movellan and V. Gimenez following a polyacetal 
synthetic strategy previously reported [10, 43]. D2O, deuterated 
methanol, and deuterated PBS were purchased form Deuter GmbH. Any 
water used was of Millipore grade. Polymer solutions were prepared by 
simply dissolving the desired material in its respective solvent. 
V.4.2. SANS Data Acquisition 
SANS experiments were performed using the D11 diffractometer 
at the Institute Laue-Langevin (ILL, Grenoble), and diffractometers 
SANS2d and LOQ at ISIS Spallation Neutron Source (Didcot, UC). All 
solutions were prepared in D2O at a concentration of 1 wt% and were 
placed in 2-mm path length, UV-spectrophotometer grade, quartz 
cuvettes (Hellma UK) and mounted in aluminium holders on top of an 
enclosed, computer-controlled, sample chamber. Sample volumes were 
approximately 0.6 cm3. Temperature control was achieved using a 
thermostatted circulating bath pumping fluid through the base of the 
sample chamber, achieving a temperature stability of ±2 ºC.  Data were 
collected and corrected for the scattering and transmission of the 
solvent and cell and were placed on an absolute intensity scale with 
reference to a flat scatterer. Scattering data are expressed in terms of 
the scattering vector Q which is given by Q = 4nπ/λ sin (θ/2) in which n 
is the refractive index for neutrons (n≈1), λ is the wavelength, and θ is 
the scattering angle. 
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V.4.3. SAXS Data Acquisition 
SAXS spectra of 1 mg/mL to 10 mg/mL filtered star polymer 
solutions were collected at the beamline NCD11 at ALBA Synchrotron 
Light Facility (Barcelona, Spain). The energy of the incident beam was 
12.6 KeV (λ= 0.995 Å). Samples were placed in a thermostated liquid cell 
using 150 µL of sample per measurement. The scattered X-ray was 
recorded in a two-dimensional CCD detector Quantum 210r (4096 x 
4096 pixels highest achievable resolution - pixel size 51 microns), 
converted to one-dimensional scattering by radial averaging, and 
represented as a function of the momentum transfer vector 
Q=4πsinθ/λ, in which θis half the scattering angle and λ is the 
wavelength of the incident X-ray beam. The sample-to-detector 
distance was maintained at 1.4 m. Measurements of each sample were 
collected over 0.1 to 1 s each. Solutions were prepared using deionised 
water, deionised water buffered with PBS at pH = 7.4, or deuterated 
water at 20˚C. The comparison of the successive exposures of an 
acquisition experiment indicated no changes in the scattering patterns 
(i.e. no measurable radiation damage to the samples).  Data were 
normalised to the intensity of the transmitted beam, and the scattering 
data from the background solvent, tested before and after each 
corresponding sample measure, were averaged and used to subtract 
the background. 
V.4.4. FISH Modelling 
The FISH data fitting program [33] was used to predict size and 
shape of the different species in solution through the obtained SANS 
data. This program uses an iterative, linear least-squares process to fit 
data to models which contain the equations describing the scattering 
expected for different form factors, structure factors, contrast steps, 
polydispersities, and background scattering. Known model parameters, 
such as volume fraction and polydispersities, can be fixed manually and 
the program is then allowed to optimise the fit by refining the remaining 
parameters. 
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V.4.5. ATSAS Programs 
The SAXS data were processed using standard procedures for 
ATSAS programs [58]. The forward scattering I(0) and the radius of 
gyration, Rg, were computed using the Guinier approximation for QRg < 
1.3.  
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Many nanosized drug delivery systems aim to deliver bioactive 
agents to a specific intracellular compartment, such as the cytosol, and 
may represent a powerful tool for the treatment and/or prevention of 
several currently relevant human diseases. However, while we have 
made great advances in biomacromolecules, such as oligonucleotides 
or proteins, this strategy still requires improvements to the approaches 
employed to transport therapeutic molecules into specific cell types. 
While the last 20 years has seen the emergence of a range of promising 
methods, shortcomings such as low/variable delivery efficiency, high 
cytotoxicity, and perhaps most importantly, ineffective 
endosomal/lysosomal escape still exist. A potential solution to these 
problems lies in the field of Polymer Therapeutics (PT) [1]: well-defined 
polypeptide-based therapeutics with suitable biodegradability, 
predictable structure and conformation, high homogeneity, and high 
drug loading capacity  [2-4].  
Within the field of PT, the use of advanced physicochemical 
techniques has generated efficient therapeutic strategies by controlling 
pharmacokinetics and biodistribution. Small angle neutron scattering 
(SANS) or small angle X-ray scattering (SAXS) offer means to gather 
information on the size, shape, and orientation of structures of samples 
at length scales ranging from 1 to 100 nm, even under physiological 
conditions [5]. By using suitable and physically rational models for data 
analysis, we can quantify changes in solution; however, this analysis can 
be laborious and requires considerable prior knowledge. 
With this in mind, the objective of this thesis dissertation focused 
on two key topics: 
i) The design, development, and validation of nanosized 
polypeptide-based carriers to facilitate the cytosolic 
delivery of bioactive agents that display an impaired 
capability to cross biological membranes by themselves or 
exhibit low lysosomal stability. This includes plasmid DNA 
(pDNA), small interfering RNA (siRNA), and proteins. 
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ii) The exhaustive physicochemical characterisation of 
polymeric drug delivery systems to determine their 
solution conformation.  
Initial efforts addressed the fundamental question of whether 
negatively charged well-defined polyglutamic acid (PGA) polymers 
functionalised with positively charged oligomer domains could be used 
as oligonucleotide delivery systems. To this end, we designed different 
conjugates of PGA with succinyl tetraethylene pentamine (Stp) 
oligoaminoamides (Table II.3). Optionally, we included histidines for 
modulation of endosomal buffer capacity and cysteines for pDNA or 
siRNA complex stabilisation, followed by the characterisation of 
biophysical properties and gene transfer efficiency in N2a 
neuroblastoma or 4T1 breast cancer cells. 
The first three developed systems were based on PGA polymers 
(homopolymers or block-co-polymers) modified with a monodisperse 
Stp-based oligoaminoamide. In System 1, we orthogonally modified 
PGA side-chains with oligomer S by means of amide bond formation 
using the S terminal amine (Figure II.3) and DMTMM·Cl (4-(4,6-
Dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride) coupling 
chemistry [6]. In System 2, we modified PGA side-chains analogously 
with SH (additionally containing histidines to improve the 
endosomolytic effect) [7], SC (containing cysteine to stabilise the pDNA 
complex via disulphide formation) [8, 9], or SHC (containing both 
histidines and cysteine). To generate System 3, we performed the 
conjugation via bioreducible disulphide bonds using the terminal 
cysteine of SHC to avoid possible side-chain crosslinking reactions. For 
this purpose, we employed a pyridyl disulphide modified PGA (PGA-PD) 
as the starting material (Figure II.25) [6]. Due to the similar behaviour 
of SHC and PCSH polyplexes, we designed an alternative system (System 
4) hoping to improve the activity of SHC by promoting complex stability. 
First, we generated a polyplex between pDNA and oligoaminoamide 
SHC and subsequently coated the positively charged pDNA complex 
with a negatively charged PGA-polymer in an attempt to improve the 
biocompatibility of SHC. We employed two different lengths of PGA and 
diblock PEG-PGA as coating agents [10]. 
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Unfortunately, our studies suggested that the systems assessed 
were not suitable for siRNA delivery. We propose the poor stability of 
complexes as the major factor contributing to a lack of transfection 
ability. Nanoparticle formulations with siRNA present important 
differences to plasmid formulation. Although both self-assemble 
through electrostatic forces, plasmids are several hundred-fold larger 
than siRNA, suggesting that different kinds of polycations may be 
optimal. This again demonstrates that pDNA and siRNA differ 
considerably in their properties and suitable delivery vectors must be 
tailored individually [11]. 
 Concerning pDNA, the conjugation of Stp derivatives to the PGA 
chain through amide bond formation (System 1 and System 2) resulted 
in stable non-toxic nanosystems with the ability to efficiently transfer 
pDNA. This improved the efficiency of both PGA and Stp-based 
compounds as transfection agents, with a more pronounced effect for 
Stp derivatives bearing histidine moieties. Moreover, the complexation 
capacity depended on the content of the oligoaminoamide. 
Complexation of pDNA with System 1 or 2 polymers exceeded the 
effectiveness of PEI in gene delivery. Thus, the presence of PGA 
promoted the enhanced transfection capacity of the Stp5 family.  
In the case of System 3, SHC conjugated to PGA by disulphide bonds 
improved cell viability, even given the relatively high amount of PGA-
based polymer required. Upon coating (System 4), we did not observe 
significant improvements in gene transfer efficiency, mainly as SHC 
itself already demonstrated a high gene transfer capability. However, 
coating did permit a slight enhancement in cell viability. We also 
expected that a coating strategy would provide advantages when 
compared with SHC in vivo due to the enhanced permeability and 
retention (EPR) effect and possible alterations to pharmacokinetics. 
Further experiments are ongoing to explore this hypothesis. 
The obtained results permitted the generation of guidelines for the 
synthesis and physicochemical characterisation of new multifunctional 
polymeric platforms for effective gene delivery. These new systems 
were composed of natural or synthetic polyaminoacids (and their 
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derivatives) with low polydispersity (Ɖ  ̴ 1.2) and, therefore, precise and 
well-defined structures, allowing reproducibility and the determination 
of structure-activity relationships. 
As a first step, we designed, synthesised, and evaluated PGA-based 
systems modified with different endosomolytic moieties containing 
secondary and tertiary amines as possible gene delivery carriers. 
However, the proposed systems did not form complexes with the 
desired oligonucleotide. With these results in mind, we designed a 
second set of PGA-based polymers containing pyridyl disulphide (PD) to 
form a conjugate via a disulphide bond between the polymer and the 
oligonucleotide. However, these conjugates were not stable in plasma 
or cell culture media even at short incubation times. 
Using the same rational as for PGA, we explored the potential of 
polyarginine (PArg) in oligonucleotide complexation. We designed 
different systems aiming to avoid negative charges in the PGA chain and 
to employ non-modified polymers. However, these compounds did not 
display cell transfection capabilities. 
Continuing the exploration of alternatives within the field of 
polypeptides, we next developed a strategy based on positively charged 
synthetic polyornithine (P(Orn)). As in the case of PArg, we expected 
ornithine to enhance gene delivery due to the cationic charge of its 
pendant amino groups at physiological pH. These can contribute to the 
binding and condensation of the oligonucleotide and, in parallel with 
lysine, form parts of cell penetrating peptides. We chemically modified 
P(Orn) derivatives and complexed the resulting structures (POP1, POP2, 
POPF, and POPD) to siRNA at an optimised N/P ratio. We demonstrated 
their nanosized appearance and positive surface charge to be 
favourable for in vitro applications (non-cytotoxic and non-haemolytic). 
More importantly, the polyplexes successfully transfected a luciferase-
transfected melanoma cell model (B16F10-luc-G5), evidencing the 
potential of this polypeptidic platform. We are currently carrying out 
further analyses to validate this system. 
Continuing the design of systems for cytosolic drug delivery, we 
reported a strategy to conjugate alanine:glyoxylate aminotransferase 
General Discussion 
335 
 
(AGT) to PEG-PGA diblock-co-polymers through the formation of 
disulphide bonds [12]. Furthermore, we successful applied the obtained 
conjugates to restore glyoxylate detoxification in eukaryotic cells 
mimicking a primary hyperoxaluria type I (PH1) phenotype. Our 
protocol permitted high conjugation yields without significantly 
affecting the functional properties of the enzyme. CHO-GO cells, a well-
accepted cellular model of PH1, internalised the obtained conjugates, 
which located to discrete compartments in the cytosol. Furthermore, 
conjugate-treated cells efficiently detoxified endogenously produced 
glyoxylate. By applying a protein engineering approach, we then 
generated a mutated form of AGT bearing the substitution of Cys387-
to-Ser and of Lys390-to-Ser (AGT-SSKL) to favour the interaction with 
the peroxisomal targeting machinery. These modified conjugates 
displayed peroxisomal import in CHO-GO cells and more effectively 
detoxified glyoxylate when compared to PEG-PGA-AGT conjugates. In 
vitro data confirmed high plasma stability and hemocompatibility of 
conjugated AGT, thus suggesting that the developed conjugates are 
suitable for intravenous administration. Overall, our data supports the 
exploitation of this system to replenish PH1 patients with a catalytically 
active and correctly localised enzyme with the ability to counteract the 
deficit responsible for oxalate accumulation. As polymer-based 
nanoconjugates have been widely employed for the delivery of 
therapeutic proteins, mainly due to their versatility and 
biocompatibility [13-15], these results, using a biodegradable carrier, 
constitute a fundamental step towards the future development of a 
safer enzyme administration therapy effective for all PH1 patients 
independent of the type of mutation.  
The correct targeting of a protein represents an important issue, 
particularly in the case of disorders involving peroxisomal enzymes 
whose functionality is strongly influenced by subcellular localisation 
[16]. Previous reports on the administration of catalase to peroxisomes 
to rescue reactive oxygen species (ROS)-induced damage employed an 
enzyme derivative endowed with a non-covalently bound cell-
penetrating peptide [17-19]. To the best of our knowledge, our strategy 
represents the first report of a PGA-based conjugate designed to 
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efficiently deliver a catalytically active therapeutic protein to the 
peroxisome. Thus, our work also represents an example to implement 
in other diseases caused by peroxisomal enzyme deficiency. 
Finally, we have demonstrated the successful application of 
powerful physicochemical techniques (SANS and SAXS) to better 
understand the behaviour of polymer-based therapeutics. These 
techniques permitted the elucidation of the solution conformation of 
polymers with the possibility of changing several experimental 
parameters to allow measurements close to physiological conditions.  
In the first project, we analysed 3- and 4 arm star-shaped 
polyglutamates by SANS. All 3-arm systems comprised the same 
multifunctional core coupled with three different amines and a 
different number of polyglutamate units (GAU). We made several 
attempts to fit the data with different models commonly used for 
polymers. After extensive analysis, we found the Gaussian coil for a 
Dozier star polymer to be the most appropriate model for both 3- and 
4 arm star polymers. This generated information regarding the radius of 
gyration and other conformational parameters.  
During data fitting, we attempted to minimise the number of 
parameters using a flat background and negating the S(Q) term in the 
model (S(Q)=1). Fit parameters, together with the results obtained by 
SAXS, show that, in the absence of interparticle interactions (S(Q)=1), Rg 
deeply depended on the polymer used and the salt concentration. 
Furthermore, Rg is directly related to both conditions, although there is 
no dependence on MW. This important information allowed us to 
elucidate the 3D shape of the nanostructure. When H2O or D2O were 
used as a solvent (given that the Flory component values vary little, and 
are close to ⅓, indicating a relatively poor solvent), the analysed 
polymer was relatively collapsed (dense star) and the arms tended to 
reorganise themselves around the fixed core. Therefore, the core is 
more “wrapped” as molecular weight increases, allowing Rg to remain 
relatively unchanged. When we employed PBS as a solvent, self-
assembly behaviour diminished, resulting in much smaller structures 
due to a greater ionic strength.  
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Moreover, the functionalization of GAU with minimal amounts of 
relevant biomolecules did not significantly alter the structure, allowing 
the opportunity of site-specific conjugation of different bioactive 
agents. This will enable the design of advance theranostics or polymer-
based combination nanopharmaceuticals. 
In the last project, we developed polyacetal-based combination 
conjugates through the modification of DES-polyacetals with Ser-co-
monomers, thus allowing the conjugation of paclitaxel (PTX). SANS 
studies confirmed that following fmoc-protected serinol (Ser) and PTX 
incorporation the hydrophobic pendant chain exerted a dominant 
effect on the polymer conformation.  
These results demonstrate the potency of these techniques in the 
field of PT by using relevant physiological conditions. 
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• Non-viral vectors based on poly-L-glutamic acid (PGA)-derivatives 
modified with pentameric succinyl tetraethylene pentamine (Stp5) were 
designed, developed, and in vitro validated. Histidines for modulation 
of endosomal buffer capacity and cysteines for pDNA or siRNA complex 
stabilisation were included. Vectors were characterised for biophysical 
properties and gene transfer efficiency in N2a neuroblastoma or 4T1 
breast cancer cells. 
• The conjugation of Stp derivatives to the PGA chain through 
amide bond formation resulted in stable non-toxic nanosystems with 
the ability to efficiently transfer pDNA. This improved the efficiency of 
both PGA and Stp-based compounds as transfection agents, with a 
more pronounced effect for Stp derivatives bearing histidine moieties. 
Thus, the presence of PGA enhanced transfection capacity of the Stp5 
family. 
• PGA conjugation of Stp derivatives through post-polymerisation 
modification via disulphide bonds significantly improved Stp cell 
viability.  
• Multifunctional polymeric platforms based on PGA, poly-L-
arginine (PArg), poly-L-ornithine (P(Orn)), and their derivatives, were 
also obtained through post-polymerisation modifications. Polymeric 
carriers were fully characterised and biologically evaluated as non-viral 
vectors for siRNA delivery in cell models.  
•P(Orn)-based nanosystems with a net positive surface charge 
demonstrated the most promising cell silencing results. Furthermore, 
these nanosystems displayed acceptable cytotoxic and haemolytic 
profiles using the concentrations tested previously in B16F10-luc-G5 
melanoma cells. 
• The conjugation of poly(ethylene glycol)-co-poly(L-glutamic acid) 
(PEG-PGA) block-co-polymer to alanine:glyoxylate aminotransferase 
(AGT) via the formation of disulfide bonds between the polymer and 
cysteine residues of the enzyme was performed as a novel treatment 
for Primary Hyperoxaluria type I (PH1). PEG-PGA conjugation did not 
affect AGT structural/functional properties and allowed internalisation 
Final Conclusions 
344 
 
of the enzyme in a cellular model of PH1 and the restoration of 
glyoxylate-detoxification. The insertion of the C387S/K390S amino acid 
substitutions reduced conjugation efficiency but endowed conjugates 
with the ability to reach the peroxisomal compartment. These results, 
along with the finding that conjugates are hemocompatible, stable in 
plasma, and non-immunogenic, hold promise for the development of 
polypeptide-based AGT conjugates as a therapeutic option for PH1 
patients. Furthermore, these findings lay the groundwork for 
applications in other diseases related to deficits in peroxisomal 
proteins. 
• SAS techniques elucidated of the solution conformation of all 
studied polymers. A Gaussian coil for a Dozier star polymer was the 
most appropriate model to fit the data for both 3- and 4 arm star-
shaped PGA polymers. These assessments also generated information 
about the radius of gyration as well as other conformational 
parameters.  
• SANS studies in polyacetal-based combination conjugates 
confirmed that, following fmoc-protected serinol (SerFmoc) and 
paclitaxel (PTX) incorporation, the hydrophobic pendant chain exerted 
a dominant effect on the polymer conformation. 
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1. INTRODUCCIÓN Y MARCO TEMÁTICO DE LA TESIS 
Un transporte citosólico adecuado puede ser utilizado como una 
poderosa herramienta para el tratamiento y/o prevención tanto de 
cáncer como de otras muchas enfermedades que nos afectan hoy en 
día. Junto con los avances recientes dentro de las tecnologías 
terapéuticas basadas en biomacromoléculas, tales como genes, 
oligonucleótidos y proteínas,  se requiere un desarrollo tecnológico 
enfocado a la mejora en la eficiencia del trasporte celular de esas 
moléculas terapéuticas [1]. Una gran variedad de métodos 
prometedores han salido a la luz en los últimos 20 años. Por ejemplo el 
uso de péptidos de penetración celular (cell-penetrating peptides, 
CPPs), liposomas o polímeros. Sin embargo, a pesar de este progreso 
tan significativo, estos métodos presentan serios inconvenientes como 
baja/variable eficiencia en el transporte, alta citotoxicidad y, quizá más 
importante, escape endosomal/lisosomal inefectivo. En este contexto, 
los llamados Polímeros Terapéuticos (PT) [2] emergen como una 
potente y prometedora alternativa para superar dichas limitaciones. 
Específicamente, los PT basados en polipéptidos bien definidos son 
unos excelentes candidatos para el transporte de fármacos debido a su 
adecuada biodegradabilidad, conformación y estructuras predecibles, 
alta homogeneidad así como alta capacidad de carga de fármaco [3-5]. 
La aparición de técnicas de caracterización novedosas, potentes y 
sofisticadas ha complementado la tarea realizada por las técnicas ya 
existentes a la hora de afrontar el reto de trabajar en condiciones 
fisiológicas. El notable desarrollo en el diseño de sistemas de 
administración de fármacos ha obligado a establecer unas pautas que 
seguir en dicho diseño con el fin de lograr el efecto terapéutico 
deseado. Por lo tanto, la importancia de una exhaustiva caracterización 
fisicoquímica de estructuras complejas ha quedado patente, dando 
lugar a estrategias terapéuticas más eficientes controlando tanto la 
biodistribución como la farmacocinética de dichas nanomedicinas [6]. 
Partiendo de estas bases, el objetivo de la tesis  doctoral se ha 
centrado en dos temas principales.  
Appendix 
348 
 
i) Diseño y desarrollo de portadores polipeptídicos de 
tamaño nanométrico, capaces de facilitar el transporte 
citosólico de agentes bioactivos que no son capaces de 
traspasar las membranas biológicas por sí solos o que 
exhiben baja estabilidad lisosomal, tales como DNA 
plasmídico (plasmid DNA, pDNA), pequeño RNA de 
interferencia (small interfering RNA, siRNA) o proteínas.  
ii) Caracterización fisicoquímica exhaustiva de diferentes 
moléculas con una base polimérica similar a los 
compuestos anteriores. Para cumplir este último propósito 
se utilizaron técnicas altamente avanzadas intentando 
simular las condiciones fisiológicas.  
2. OBJETIVOS DE LA INVESTIGACIÓN 
El objetivo global de la presente tesis se centra tanto en el 
transporte citosólico de biomacromoléculas a través de portadores 
polipeptídicos de tamaño nanométrico como en la exhaustiva 
caracterización fisicoquímica en disolución de sistemas poliméricos 
similares. Estos objetivos principales pueden desglosarse en cuatro 
objetivos específicos: 
(i) Diseño de complejos basados en ácido poli-L-glutámico (PGA) 
para terapia génica. Esto engloba el diseño, la síntesis, la caracterización 
fisicoquímica y evaluación biológica in vitro de sistemas basados en 
cadenas de PGA funcionalizadas con diferentes poliamidoaminas 
sintéticas lineales que serán utilizados como sistemas para el transporte 
de oligonucleótidos. 
(ii) Desarrollo de portadores polipeptídicos no virales para el 
transporte de siRNA. Dentro de este punto se encuentra tanto el 
desarrollo como la evaluación biológica de una metodología versátil en 
la que diferentes poliaminoácidos, tanto sintéticos como naturales, 
serán modificados con el fin de obtener vehículos adecuados para el 
transporte de siRNA. 
(iii) Desarrollo de conjugados basados en PGA para el transporte 
intraperoxisomal de  alanina:glioxilato aminotransferasa (AGT). En este 
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punto se estudiará la factibilidad del transporte de AGT mediante la 
conjugación de la encima a un portador polimérico compuesto por 
polietilenglicol y PGA (PEG-PGA). 
(iv) Uso se Dispersión de Neutrones de Ángulo Pequeño (Small 
Angle Neutron Scattering, SANS) y Dispersión de Rayos X de Ángulo 
Pequeño (Small Angle X-ray Scattering, SAXS) para estudiar la 
estructura en disolución de sistemas de transporte de fármacos. Este 
último objetivo se centra en la exhaustiva caracterización fisicoquímica 
de diferentes nanosistemas en disolución a través de complejas y 
avanzadas técnicas como SANS o SAXS, intentando mimetizar las 
condiciones fisiológicas. 
3. METODOLOGÍA 
3.1. Materiales e Instrumentación 
3.1.1. Materiales 
Todos los reactivos y disolventes utilizados durante el desarrollo de 
la tesis fueron de grado analítico o superior y se usaron sin purificación 
adicional, a no ser que se indique lo contrario. De manera general, las 
reacciones llevadas a cabo en disolventes orgánicos se realizaron bajo 
atmósfera inerte de nitrógeno. El agua utilizada fue desionizada con una 
conductancia por debajo de 0.06 µS (agua milliQ). 
Los métodos más utilizados de purificación de los conjugados 
poliméricos se basaron en el uso de diálisis o cromatografías por 
exclusión de tamaño. Para las diálisis se utilizaron Vivaspin®, Float-A-
Lyzer® o membranas moleculares. En el caso de purificación por 
cromatografía, se utilizaron resinas Sephadex o columnas comerciales 
pre-empaquetadas PD10. 
3.1.2. Instrumentación 
Espectroscopía de Resonancia Magnética Nuclear (NMR). Los 
espectros 1H NMR y DOSY NMR se llevaron a cabo en un sistema Bruker 
Advance AC 300 (300 MHz) o AV500 (500 MHz) utilizando para ello al 
menos 5 mg de compuesto, temperatura ambiente y disolventes 
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deuterados. Los datos obtenidos se analizaron mediante la utilización 
del software MestreNova 6.2. 
Dispersión de Luz Dinámica (DLS). Las medidas tanto de tamaño 
de partícula como de potencial ζ se realizaron a 25˚C en un dispositivo 
Malvern Zetasizer Nano ZS equipado con un láser (532 nm) a un ángulo 
de dispersión fijo de 90˚. La celda utilizada fue DTS 1070. Para las 
medidas de tamaño, el tiempo de equilibrado fue de 0 min con 
atenuación automática. El índice de refracción del disolvente, en este 
caso agua, fue 1,330 y, por lo tanto, la viscosidad fue 0,8872. Para el 
análisis de los diferentes polímeros se utilizó el índice de refracción del 
látex de poliestireno (1,590). Cada muestra se midió tres veces con 10 
submedidas. El potencial ζ se calculó a través del modelo Smoluchowski. 
Se utilizaron entre 10 y 30 medidas de 10 s cada una a 25˚C (n=3). 
Espectroscopía Ultravioleta-Visible (UV-Vis). Los espectros se 
tomaron en un espectrofotómetro Jasco V-630 UV/Vis a 25˚C con celdas 
de plástico o cuarzo (en su caso) de 1 cm y ancho de banda de 0.5 nm. 
Microscopía Electrónica de Transmisión (TEM). Las imágenes se 
adquirieron en un microscopio de transmisión electrónica FEI Tecnai G2 
Spirit (FEI Europe, Eindhoven, Netherlands) usando una cámara digital 
Morada (Olympus Soft Image Solutions GmbH, Münster, Germany). 
Para su preparación, las muestras se adsorbieron en rejillas de cobre 
recubiertas por una película de carbón de 200 mallas. Tras ello, se 
realizó una tinción de contraste negativo con una disolución de acetato 
de uranilo al 2%. 
Microscopía de Fluorescencia Confocal. Las imágenes fueron 
adquiridas con un microscopio (invertido) láser confocal Leica, modelo 
TCS SP8 AOBS (Leica Microsystems Heidelberg and MBH, Germany). 
Todas las imágenes se adquirieron bajo las mismas condiciones y se 
analizaron mediante el software de Leica LAS AF Lite (Leica 
Microsystems Heidelberg and MBH, Germany). 
Dispersión de Neutrones de Ángulo Pequeño (SANS). Los 
experimentos de SANS se llevaron a cabo utilizando el difractómetro 
D11 del Instituto Laue-Langevin (ILL, Grenoble) y los difractómetros 
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SANS2d y LOQ en ISIS Spallation Neutron Source (Didcot, UK). Todas las 
disoluciones fueron preparadas en disolventes deuterados a la 
concentración máxima de 1 wt% y se colocaron en celdas de cuarzo de 
2 mm de camino óptico. Los volúmenes de muestra fueron 
aproximadamente de 0,6 cm3. Los datos fueron recogidos y corregidos 
de la transmisión y dispersión de la celda y del disolvente y se pusieron 
en una escala de intensidad absoluta. Los datos de dispersión fueron 
expresados en función del vector de dispersión Q, el cual viene dado por 
Q = 4nπ/λ sin (θ/2) en el que n es el índice de refracción para los 
neutrones (n≈1), λ es la longitud de onda, y θ es el ángulo de dispersión.  
Dispersión de Rayos X de Ángulo Pequeño (SAXS). Los espectros 
de SAXS de disoluciones filtradas de concentraciones entre 1 mg/mL y 
10 mg/mL, fueron obtenidos en la línea de luz NCD11 del Sincrotrón 
ALBA (Barcelona, España). La energía del haz incidente fue 12,6 KeV (λ= 
0.995 Å). Las muestras se colocaron en una celda termostatada  
utilizando aproximadamente 150 µL por medida. Los rayos X 
dispersados fueron recogidos en un detector bidimensional CCD 
Quantum 210r, convertidos a monodimensionales y representados 
como función del vector Q=4πsinθ/λ, en el que θ es la mitad del ángulo 
de dispersión y λ es la longitud de onda del haz de rayos X incidente. La 
distancia entre la muestra y el detector se mantuvo constante a 1,4 m. 
Las medidas de cada muestra se hicieron durante tiempos entre 0,1 y 1 
s cada una. Las disoluciones fueron preparadas utilizando agua 
desionizada, agua tamponada con PBS a pH = 7,4 o agua deuterada a 
20˚C. La comparación de las exposiciones sucesivas de un experimento 
de adquisición no indicó cambios en los patrones de dispersión (es 
decir, ningún daño de radiación medible a las muestras). Los datos 
fueron normalizados con respecto a la intensidad del haz transmitido, y 
los datos de dispersión por el fondo del disolvente, medido antes y 
después de la correspondiente muestra, haciendo la media y 
utilizándolo para eliminar el fondo. 
Modelado con FISH. El programa FISH [7] fue la herramienta 
utilizada para predecir tanto el tamaño como la conformación de las 
distintas especies en disolución a través los datos obtenidos en los 
diferentes experimentos de SANS. Dicho programa  emplea un proceso 
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lineal de mínimos cuadrados iterativo para ajustar los datos a modelos 
que contienen las ecuaciones que describen la dispersión esperada para 
diferentes factores de forma, factores de estructura, pasos de 
contraste, polidispersidades y dispersión de fondo. Parámetros de 
modelo conocidos, tales como fracción de volumen y polidispersidades, 
se pueden fijar manualmente y se permite al programa optimizar el 
ajuste refinando los parámetros restantes. 
Programas ATSAS. Los datos obtenidos de los experimentos de 
SAXS fueron procesados utilizando procedimientos estándar de los 
programas ATSAS [8]. 
Ensayos Celulares. Todos los procesos relacionados con el cultivo 
celular se llevaron a cabo en una cabina de flujo laminar recirculante 
vertical con seguridad biológica clase II (Telsar). En todo momento se 
utilizó material estéril. 
Medidas de absorbancia o luminiscencia de ensayos in vitro.   
Estas medidas se realizaron en un equipo Victor2 Wallac 1420 Multilabel 
HTS counter Perkin Elmer (Northwolk, CT, EEUU) utilizando placas de 96 
pocillos y las correspondientes longitudes de onda propias de cada 
compuesto. 
3.2. Métodos más Relevantes 
3.2.1. Protocolos de Síntesis 
Síntesis de Fmoc-Stp(boc)3-OH. La síntesis de Fmoc-Stp(boc)3-OH 
se reprodujo básicamente de la referencia [9] realizando algunas 
modificaciones. 
Carga de la Resina 2-Chlorotrityl Chloride con Fmoc-L-Trp(boc)-
OH. Todas las síntesis en fase sólida fueron realizadas utilizando una 
resina 2-chlorotrityl chloride (CTC-resin, 200-400 mesh). La resina (1,56 
mmol chloride/g) fue pre-hinchada en diclorometano (DCM) anhidro (1 
mL/100 mg resina) durante 20 min. 0,45 equivalentes (eq.)/g (150% de 
la carga deseada) del aminoácido protegido con 9-
fluorenilmetiloxicarbonil (Fmoc-L-Trp(boc)-OH) por gramo de resina y 
N,N-diisopropiletilamina (DIPEA, 0,9 eq./g) fueron disueltos en DCM 
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anhidro, añadidos a la resina y mezclados durante 1 h. Después del 
acoplamiento, una mezcla de DCM/metanol (MeOH)/DIPEA (80/15/5; 
v/v/v) fue añadida durante 30 min para capturar los cloruros residuales. 
Para determinar la carga de resina, una pequeña cantidad de ésta 
(~10 mg) fue lavada dos veces con DCM y dos veces más con n-hexano 
y secada a vacío. 1 mg de la resina seca (por triplicado) se mezcló con 1 
mL de piperidina 20% (v/v) en N,N-dimetilformamida (DMF) y se incubó 
durante 1 h. La cantidad de grupo protector Fmoc fue cuantificada 
midiendo la absorción a 301 nm. La carga fue calculada usando la 
siguiente ecuación: 
𝑐𝑎𝑟𝑔𝑎 [𝑚𝑚𝑜𝑙 𝑔⁄ ] =  
1000 × 𝐴301
𝑚 [𝑚𝑔] × 7800 × 𝐷
 
Donde D es el factor de dilución. Después de la determinación de la 
carga, la resina fue incubada cuatro veces durante 10 min con piperidina 
20% (v/v) en DMF, lavada tres veces con DMF, tres veces con DCM, tres 
veces con n-hexano y secada a vacío. 
Procedimiento General de Síntesis de Péptidos en Fase Sólida. Las 
poliamidoaminas fueron sintetizadas en una resina 2-chlorotrityl 
chloride cargada previamente con Fmoc-L-Trp(boc)-OH utilizando un 
tamaño de lote de 25 μmol. La resina fue pre-hinchada durante 20 min 
con DCM antes del primer paso de desprotección. El grupo fmoc fue 
eliminado durante tres tratamientos secuenciales con piperidina (20% 
piperidina en DMF, 5 min, 10 min, 10 min) seguidos de un exhaustivo 
lavado con DCM (3 veces) y DMF (3 veces). Los acoplamientos de 
succinil tetraetilen pentamina (Stp) fueron hechos disolviendo el Fmoc-
building block amino ácido (4 eq.) y DIPEA (8 eq.) en la mínima cantidad 
de DCM, PyBOP® (4 eq.) y 1-hidroxibenzotriazol (HOBt, 4 eq.) en la 
mínima cantidad de DMF, y seguidamente transferidas al reactor. 
Después de 120 minutos, la resina fue lavada con DMF seguida de DCM. 
Para comprobar que el acoplamiento había terminado se utilizó en test 
de Kaiser [10]. Si el test de Kaiser muestra que el acoplamiento no ha 
acabado se repite el ciclo. Después del paso final de desprotección del 
grupo Fmoc, la resina fue lavada con DMF (3 veces) seguida de DCM (3 
veces) y secada a vacío en un desecador. 
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Escisión del Enlace Péptido-Resina. La escisión de la resina se 
realizó mediante el tratamiento con una disolución que contenía ácido 
trifluoroacético (TFA)/triisopropilsilano (TIS)/H2O (95/2,5/2,5) durante 
1,5 h. Después de lavar la resina dos veces con TFA y dos veces con DCM, 
todas las disoluciones se juntaron, concentraron y precipitaron. Para 
ello la disolución concentrada se añadió gota a gota sobre una mezcla 
de n-hexano y tert-butilmetileter (MTBE; 1:1) previamente enfriada a -
20˚C. El producto obtenido después de centrifugar fue secado bajo 
nitrógeno y disuelto en un tampón de exclusión por tamaño 
conteniendo 10 mM HCl y 30% acetonitrilo (ACN). Tras la purificación 
por exclusión por tamaño en una columna G-10, se juntaron las 
fracciones adecuadas, se congeló en nitrógeno líquido y se liofilizó. 
Método General de Modificación de PGA utilizando DMTMM·Cl. 
1 eq. de PGA sal de sodio (MW 151 por unidad, 50 unidades) fue disuelto 
en la mínima cantidad de agua milliQ. Seguidamente, la 
correspondiente cantidad de 4-(4,6-dimetoxi-1,3,5-triazin-2-il)-4-
metilmorfolina (DMTMM·Cl) para el % de modificación deseado (para 
el 50%, 1 eq.) fue disuelta también en agua milliQ. 10 min después, la 
mitad de cantidad de la correspondiente amina a introducir fue disuelta 
en agua milliQ y añadida a la mezcla de reacción. El pH se ajustó a 8 
añadiendo algunas gotas de disolución 1M NaHCO3. Se dejó reaccionar 
agitando a temperatura ambiente durante 16 h. Transcurrido ese 
tiempo, se paró la reacción y se purificó a través de Vivaspin® o Float-A-
Lyzer® del correspondiente MWCO. 
Método General de modificación de PGA-PD a través de la 
Formación de un Enlace Disulfuro. 1 eq. de PGA-PD (sintetizado 
utilizando una modificación del método recientemente publicado [11]) 
y la correspondiente cantidad del compuesto portador del grupo tiol 
fueron disueltos por separado en PBS a pH 7.4. Seguidamente, ambas 
disoluciones se mezclaron y se dejó reaccionar a con agitación continua 
y a temperatura ambiente durante 5 h. Transcurrido ese tiempo, una 
diálisis mediante Vivaspin® o Float-A-Lyzer® del correspondiente 
MWCO. 
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Método General de Formación de Poliplejos. Las formulaciones de 
poliplejos que fueron utilizadas tanto para transfecciones como para 
electroforesis fueron preparadas del siguiente modo: 200 ng de pDNA 
o 500 ng de siRNA y la cantidad adecuada de polímero al ratio +/- o N/P 
indicado, fueron diluidos individualmente en tubos separados en 10 µL 
de tampón 20 mM HEPES a pH 7.4. Solamente los nitrógenos 
protonables, fueron considerados en los cálculos de +/- o N/P. El ácido 
nucleico correspondiente y la disolución de polímero fueron mezclados 
a través de un pipeteo rápido (arriba-abajo, al menos 5 veces) e 
incubados durante 30-40 min a temperatura ambiente. 
3.2.2. Caracterización 
Ensayos de Unión de pDNA y siRNA mediante Electroforesis. Para 
pDNA, el gel 1% agarosa fue preparado disolviendo la agarosa en 
tampón TAE y calentando hasta ebullición por encima de los 100°C. Una 
vez enfriado más o menos a 50°C y añadido el EtBr, el gel de agarosa se 
introdujo dentro de la unidad de electroforesis. Los poliplejos 
conteniendo 200 ng de pDNA en 20 µL de 20 mM HEPES y tampón de 
carga, fueron introducidos dentro de los pocillos. La electroforesis se 
llevó a cabo a 80 V durante 80 min. Para siRNA, el gel 2,5% agarosa fue 
preparado de la misma manera que antes. Los poliplejos conteniendo 
500 ng de siRNA en 20 µL de HEPES y tampón de carga fueron 
introducidos en los pocillos. La electroforesis se llevó a cabo a 80 V 
durante 40 min. 
3.2.3. Evaluación Biológica 
Ensayo de Transfección con pCMVluc. Células N2a  o 4T1 fueron 
sembradas en placas de 96 pocillos con 100 μL de medio (10000 o 5000 
células por pocillo respectivamente). Pasadas 24 h, el medio fue 
reemplazado por 80 μL de medio fresco. Los poliplejos formados 
conteniendo 200 ng de pCMVluc en cada pocillo fueron añadidos en un 
volumen de 20 μL e incubados a 37˚C. LPEI a un N/P óptimo no tóxico 
fue utilizado como patrón positivo. Todos los experimentos se 
realizaron por quintuplicado. 24 h después de la transfección, las células 
fueron tratadas con 20 µL del reactivo Bright-Glo™. La actividad de la 
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luciferasa fue medida espectroscópicamente con el equipo Victor2 
WallacTM. 
Ensayo de Silenciamiento con siRNA. Los experimentos de 
silenciamiento se realizaron utilizando células N2a/EGFPluc o B16F10 
luc en placas de 96 pocillos libres de RNasa (5000 o 7500 células por 
pocillo respectivamente, por triplicado). Las células fueron sembradas 
24 h antes del tratamiento, después el medio fue reemplazado por 80 
µL de medio fresco. 20 µL de disolución de poliplejo a su 
correspondiente +/-, conteniendo 500 ng de siRNA se añadieron a cada 
pocillo y se incubaron a 37°C. 48 h después de la transfección, las células 
fueron tratadas con 20 µL del reactivo Bright-Glo™. La actividad de la 
luciferasa fue medida espectroscópicamente con el equipo Victor2 
WallacTM. 
Ensayo de Viabilidad Celular (MTS). Células N2a, 4T1 o B16F10 luc 
fueron sembradas en placas de 96 pocillos a una densidad de 10000, 
5000 o 7500 células por pocillo respectivamente. Pasadas 24 h, el medio 
fue reemplazado por 80 μL de medio fresco y 20 μL de disolución de 
poliplejo a su correspondiente +/- fueron añadidos. Todos los estudios 
se realizaron por quintuplicado. 24 h después de la transfección, 20 μL 
de una disolución MTS/PMS (20:1) se añadió a cada pocillo, y la placa se 
incubó durante 2 h más. La densidad óptica de cada pocillo fue medida 
espectrofotométricamente a 490 nm utilizando el equipo Victor2 
WallacTM. Los valores de absorbancia fueron representados como 
porcentaje de viabilidad celular tomando como 100% de viabilidad 
celular células control sin tratar. 
4. RESULTADOS 
4.1. Diseño de Poliplejos como Vectores No Virales para Terapia 
Génica Basados en PGA (Capítulo II) 
Debido a la naturaleza polianiónica tanto del DNA como del RNA, 
normalmente formulaciones catiónicas o neutras han sido utilizadas 
para el transporte de dichos oligonucleótidos. Dando un nuevo enfoque 
a esta cuestión, nuestro estudio se centró en el diseño, desarrollo y 
validación de vectores zwiteriónicos no virales con base polipeptídica. 
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Con este fin, se diseñaron derivados de PGA modificados con diferentes 
pentamino succinil tetraetilen pentaminas (Stp5) [12]. Opcionalmente, 
se incluyeron histidinas para la modulación de la capacidad tampón 
endosomal y cisteínas para la estabilización del complejo de pDNA o 
siRNA, seguido por la caracterización de las propiedades biofísicas y la 
eficiencia de transferencia de oligonucleótidos en células de 
neuroblastoma N2a o células de cáncer de mama 4T1. 
Los tres primeros sistemas desarrollados se basaron en polímeros 
de PGA (homopolímeros o copolímeros en bloque) modificados con una 
oligoaminoamida monodispersa basada en Stp. En el Sistema 1, las 
cadenas laterales del PGA fueron ortogonalmente modificadas con el 
oligómero S mediante la formación de enlace amida con la amina  
terminal de S (Figura II.3). En el Sistema 2, las cadenas laterales del PGA 
fueron modificadas análogamente con SH (portando histidinas para 
mejorar el efecto endosomolítico) [13], SC (que contiene cisteína para 
estabilizar el complejo pDNA a través de la formación de enlaces 
disulfuro) [9, 14], o SHC (conteniendo histidinas y cisteínas). Para 
generar el Sistema 3, realizamos la conjugación mediante enlaces 
disulfuro biorreducibles utilizando la cisteína terminal de SHC. El 
Sistema 4 difiere de los sistemas anteriores en varias maneras. En 
primer lugar, se generó un poliplejo entre pDNA y oligoaminoamide 
SHC, y posteriormente se recubrió el complejo cargado positivamente 
con PGA (cargado negativamente) en un intento de mejorar la 
biocompatibilidad de SHC. Se emplearon dos longitudes diferentes de 
PGA y dibloque PEG-PGA como agentes de recubrimiento. 
Lamentablemente, nuestros estudios sugirieron que los sistemas 
evaluados no son adecuados para el transporte de siRNA. Este hecho 
puede ser debido a la baja estabilidad de los complejos que contribuye 
a la falta de capacidad de transfección. La formulación de 
nanopartículas con siRNA presenta algunas diferencias importantes con 
respecto a la de pDNA. Aunque ambos se auto-ensamblan por fuerzas 
electrostáticas, los plásmidos son varios cientos de veces más grandes 
que el siRNA, sugiriendo que diferentes tipos de policationes pueden 
ser válidos. Esto demuestra nuevamente que pDNA y siRNA difieren 
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considerablemente en sus propiedades y el diseño de vectores debe de 
ser llevado a cabo de manera individual para cada uno de ellos [15]. 
 En cuanto al pDNA, la conjugación de los derivados de Stp a la 
cadena lateral de PGA mediante reacciones de postpolimerización 
(enlace amida, Sistema 1 y Sistema 2) dio como resultado nanosistemas 
no tóxicos, estables, con la capacidad de transferir eficientemente 
pDNA. Los conjugados PGA-Stp presentaron una mayor eficacia como 
vectores no virales de transfección comparados con los compuestos de 
partida (PGA y Stp) observando un efecto más pronunciado para los 
derivados de Stp que portaban restos de histidina, superando incluso a 
los resultados obtenidos con PEI (control positivo). Además, se encontró 
que la capacidad de complejación depende del contenido de la 
oligoaminoamida.  
En el caso de los Sistemas 3-4, la conjugación de SHC a la cadena 
de PGA mediante enlaces disulfuro mejoró significativamente la 
viabilidad celular de sistemas anteriores aunque no fue capaz de 
mejorar la capacidad de transfección de la oligoamina de partida (SHC), 
incluso tras el revestimiento (Sistema 4). Cabe resaltar que una 
estrategia de revestimiento además de conjugación polimérica, podría 
proporcionar ventajas cuando se compara con SHC libre in vivo debido 
al efecto EPR, que proporciona una mayor acumulación de tales 
macromoléculas en el tumor. Otros experimentos están en curso para 
demostrar este punto. 
4.2. Desarrollo de Vectores Polipeptídicos No Virales para el 
Transporte de siRNA (Capítulo III) 
El RNA interferente (iRNA) inducido por siRNA es una estrategia 
prometedora para el tratamiento de diversas enfermedades mediante 
la regulación de dianas previamente “undruggable”. Sin embargo, el 
proceso de transporte sigue siendo la limitación más crucial, lo que 
dificulta el desarrollo terapéutico/clínico. En este proyecto, diferentes 
plataformas poliméricas multifuncionales fueron sintetizadas y físico-
químicamente caracterizadas utilizando poliaminoácidos naturales o 
sintéticos y sus derivados con el fin de encontrar un vector no viral para 
un transporte génico eficaz. Todos los sistemas se sintetizaron a partir 
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compuestos poliméricos con baja polidispersidad (Ɖ  ̴ 1.2) y, por lo 
tanto, estructuras precisas y bien definidas, lo que permite la 
reproducibilidad y la determinación de una clara relación estructura-
actividad. 
En primer lugar, se diseñaron y sintetizaron sistemas basados en 
PGA modificados con éxito con diferentes residuos endosomolíticos que 
contenían aminas secundarias y terciarias, evaluándose como posibles 
poliplejos de administración génica. Sin embargo, los sistemas 
propuestos no dieron lugar a la formación complejos con el 
oligonucleótido deseado. Con estos resultados en mente,  se diseñó un 
segundo set de polímeros basados en PGA conteniendo además piridil 
disulfuro (PD) para formar un conjugado a través de un enlace disulfuro 
entre el polímero y el oligonucleótido. Sin embargo, estos conjugados 
no fueron estables ni en plasma ni en medio de cultivo celular incluso a 
tiempos de incubación cortos. 
Utilizando los mismos conceptos pero con polipéptidos 
intrínsecamente catiónicos a pH fisiológico, se seleccionó poli-L-
arginina (PArg) y su precursor poli-L-ornitina (P(Orn)) para explorar su 
potencial como vectores no virales después de la complejación de 
siRNA. Ningún resultado positivo fue encontrado con la PArg, sin 
embargo la derivatización química de P(Orn) ofreció estrategias muy 
prometedoras. Los derivados de P (Orn) fueron químicamente 
modificados, complejando las estructuras resultantes (POP1, POP2, 
POPF y POPD) al siRNA a una relación N/P optimizada. Su tamaño 
nanométrico y su carga superficial positiva resultaron favorables para la 
aplicación in vitro (no citotóxica y no hemolítica). Más importante aún, 
los polipéptidos transfectaron con éxito un modelo de células de 
melanoma transfectadas con luciferasa (B16F10-luc-G5), evidenciando 
el potencial de esta plataforma polipéptidica. Se están realizando más 
análisis para validar este sistema tanto in vitro como in vivo. 
4.3. Desarrollo de Conjugados Basados en PGA para el Transporte 
Intraperoxisomal de Alanina Glioxilato Aminotransferasa (Capítulo IV) 
En este trabajo, se presentó una estrategia para conjugar la enzima 
Alanina Glioxilato Aminotransferasa (AGT) a copolímeros dibloque de 
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PEG-PGA a través de la formación de enlaces disulfuro, así como el uso 
exitoso de los conjugados obtenidos para restablecer la destoxificación 
de glioxilato en células eucarióticas imitando un fenotipo hiperoxaluria 
primaria tipo I (PH1), considerada una enfermedad rara letal. Un 
transporte eficiente de AGT a peroxisomas es requerido para obtener 
una actividad terapéutica adecuada [16]. 
El protocolo utilizado permitió conseguir un alto rendimiento de 
conjugación sin efectos significativos sobre las propiedades funcionales 
de la enzima. Los conjugados polímero-proteína obtenidos 
demostraron una internalización adecuada en células CHO-GO, un 
modelo celular bien aceptado de PH1, encontrándose principalmente 
en compartimentos discretos del citosol. Además, desintoxican 
eficientemente el glioxilato producido endógenamente. Mediante la 
aplicación de un enfoque de ingeniería de proteínas, se generó una 
forma mutada de AGT con la sustitución de Cys387-a-Ser y de Lys390-a-
Ser (AGT-SSKL), para favorecer la interacción con la maquinaria de 
focalización peroxisomal. Los conjugados de PEG-PGA-AGT-SSKL 
internalizados en células CHO-GO se importan a peroxisomas y son más 
eficaces en la destoxificación de glioxilato con respecto a los conjugados 
de PEG-PGA-AGT. Los datos in vitro confirmaron una alta estabilidad en 
plasma y una excelente hemocompatibilidad del conjugado proteico, lo 
que sugiere que los conjugados son adecuados para inyección 
intravenosa. En general, estos datos respaldan la utilización de este 
sistema para reponer a los pacientes  de PH1 con una enzima 
catalíticamente activa y correctamente localizada capaz de 
contrarrestar el déficit responsable de la acumulación de oxalato. 
Debido a que los nanoconjugados con base polimérica han sido 
ampliamente utilizados para el transporte de proteínas terapéuticas, 
principalmente por su versatilidad y biocompatibilidad  [17-19], estos 
resultados constituyen un paso fundamental en el futuro desarrollo de 
una terapia efectiva de administración de enzimas más seguras para 
todos los pacientes PH1, independientemente del tipo de mutación. 
La correcta focalización de un fármaco proteico es un tema 
importante, particularmente en el caso de trastornos que involucran 
enzimas peroxisomales cuya funcionalidad está fuertemente 
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influenciada por la localización subcelular [20]. Los informes anteriores 
sobre la administración de catalasa en el interior de peroxisomas para 
solventar el daño inducido por la especie reactiva de oxígeno (ROS) se 
basaron en el uso de un derivado enzimático dotado de un péptido de 
penetración celular unido de manera no covalente [21-23]. Hasta donde 
sabemos, la estrategia esbozada en este capítulo es el primer reporte 
de un conjugado basado en PGA, diseñado para el suministro eficiente 
de una proteína terapéutica catalíticamente activa al peroxisoma. Por 
lo tanto, representa un ejemplo a implementar para otras 
enfermedades causadas por deficiencias de enzimas peroxisomales. 
4.4. Uso de SANS y SAXS para el Estudio Conformacional en 
Disolución de Sistemas de Transporte de Fármacos (Capítulo V) 
Las técnicas SAS han demostrado ser adecuadas para la elucidación 
conformacional en solución de todos los polímeros estudiados en esta 
tesis. 
En un primer lugar y tras varios intentos de ajustar los datos de 
SANS a los modelos comúnmente utilizados, se encontró que el modelo 
de Dozier para polímeros en forma de estrella era el modelo más 
apropiado para los poliglutamatos en forma de estrella de 3 y 4 brazos. 
Esto permitió obtener información sobre el radio de giro, así como otros 
parámetros conformacionales. Durante el ajuste, se intentó minimizar 
el número de parámetros utilizando un fondo plano y negando el 
término S (Q) en el modelo (S (Q) = 1). Los parámetros de ajuste (Tabla 
V.10 para el Set 1; Tablas V.12, V.13 y V.14 para el Set 3; y Tabla V.22 
para el Set5), junto con los resultados obtenidos por SAXS, muestran 
que, en ausencia de interacciones entre partículas (S (Q) = 1), el radio 
de giro (Rg) depende en gran medida del polímero utilizado y de la 
concentración de sal. Además, el Rg está directamente relacionado con 
ambas condiciones, aunque no hay dependencia del peso molecular. 
Esta importante información permitió elucidar la estructura 3D de los 
sistemas estudiados. Cuando se utilizó H2O o D2O como disolvente 
(dado que los valores de los componentes de Flory varían poco, y están 
próximos a ⅓, lo que indica un disolvente relativamente pobre) el 
polímero se colapsa relativamente (estrellas densas) y los brazos 
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tienden a reorganizarse alrededor del núcleo. Por lo tanto, el núcleo 
está más "envuelto" a medida que aumenta el peso molecular, 
permitiendo que Rg permanezca relativamente sin cambios. Cuando se 
utilizó el mismo sistema en un medio iónico como PBS, el 
comportamiento de autoensamblaje disminuyó, dando lugar a 
estructuras mucho más pequeñas debido a una mayor fuerza iónica. 
Además, la funcionalización de las cadenas de ácido glutámico con 
cantidades mínimas de biomoléculas relevantes no condujo a cambios 
significativos en la estructura, permitiendo la conjugación específica de 
diferentes agentes bioactivos, como es el caso de anticuerpos o 
proteínas, o de agentes de imagen.  
Por último, los estudios de SANS en conjugados de combinación 
basados en poliacetales confirmaron que después de la incorporación 
de residuos o fármacos hidrofóbicos, tales como serinol protegido con 
fmoc (SerFmoc) y paclitaxel (PTX ), la cadena lateral hidrófoba ejercía 
un efecto dominante sobre la conformación del polímero de partida. 
5. CONCLUSIONES 
La novedad y relevancia del presente trabajo radica en haber 
logrado los siguientes objetivos: 
- El diseño y validación in vitro de derivados de PGA modificados 
con Stp5 para su utilización como vehículos no virales para el transporte 
de oligonucleótidos. Opcionalmente, se incluyeron histidinas para la 
modulación de la capacidad tampón endosomal y cisteínas para la 
estabilización del complejo de pDNA o siRNA, seguido por la 
caracterización de las propiedades biofísicas y la eficiencia de 
transferencia génica en células de neuroblastoma N2a o de cáncer de 
mama 4T1. 
- La conjugación de los derivados de Stp a la cadena de PGA a través 
de la formación del enlace amida dio lugar a nanosistemas no tóxicos, 
estables y con la capacidad de transfectar eficazmente pDNA en 
modelos celulares. Dicho efecto fue más pronunciado para los 
derivados de Stp que portaban restos de histidina. La conjugación de 
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derivados de Stp a la cadena de PGA a través de enlaces disulfuro 
mejoró la viabilidad celular. 
- Se obtuvieron plataformas poliméricas multifuncionales basadas 
en PGA, PArg, P (Orn) y sus derivados mediante modificaciones post-
polimerización y se caracterizaron fisicoquímicamente para encontrar 
un vehículo para el transporte de siRNA. Se obtuvieron varios 
conjugados y complejos de oligonucleótidos y se realizaron estudios 
preliminares in vitro. Comparando los resultados obtenidos del 
silenciamiento de los sistemas P(Orn), fueron los que ofrecieron los 
resultados más prometedores. 
- Los derivados de P(Orn) modificados químicamente, se 
complejaron al siRNA a una relación N/P optimizada. Su tamaño 
nanométrico y su carga superficial positiva resultaron favorables para la 
aplicación in vitro (no citotóxica y no hemolítica). Más importante aún, 
los polipéptidos transfectaron con éxito un modelo de células de 
melanoma transfectadas con luciferasa (B16F10-luc-G5), evidenciando 
el potencial de esta plataforma polipéptida. Se están realizando más 
análisis para validar este sistema. 
- Se evaluó la viabilidad del transporte de la enzima AGT mediante 
su conjugación al copolímero PEG-PGA. AGT es la enzima responsable 
de la desintoxicación de glioxilato intraperoxisomal, su fallo 
desencadena la enfermedad de Hiperoxaluria Tipo I (PH1). Tal 
conjugación no produjo cambios significativos en las propiedades 
funcionales de AGT, dando a la proteína la capacidad de atravesar la 
membrana plasmática. Cabe destacar que la conjugación permitió una 
localización intracellular adecuada, ya que AGT fue localizada en los 
peroxisomas de un modelo cellular validado de PH1. La modificación de 
AGT mediante la inserción de una secuencia de focalización peroxisomal 
más fuerte (PTS) y la mutación de uno de los puntos de anclaje del 
polímero situados en el "PTS1 extendido", permitió un mayor 
direccionamiento peroxisomal, clave en la eficiencia del sistema. 
- Las técnicas SAS han demostrado ser adecuadas para la 
elucidación de la conformación en disolución de todos los polímeros 
estudiados. El modelo de Dozier para poliglutamatos estrella de 3 y 4 
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brazos fue el más apropiado para ajustar los datos obtenidos. Esto 
generó información sobre el radio de giro, así como otros parámetros 
conformacionales. 
- Los estudios de SANS en conjugados de combinación basados en 
poliacetales confirmaron que después de la incorporación de fármacos 
hidrofóbicos en polímeros hidrofílicos mediante conjugación química, 
ejercen un efecto dominante sobre la conformación del polímero. 
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